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PEF peak expiratory flow
RAST radio-allergosorbent test
RDR response dose ratio
RNA ribonucleic acid
SABA short acting β2-agonist
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Asthma is a serious health problem throughout the world, with an estimated 300 million 
affected individuals worldwide.1 In the Netherlands it has an estimated prevalence of 
4-11% among children aged < 12 years2 and a reported lifetime prevalence of 12.9% 
among children aged 12-14 years.3 Childhood asthma exerts a substantial burden on 
a child, its family and healthcare services. It accounts for a large number of lost school 
days and can affect a child’s physical and social development, sleep pattern and aca-
demic achievements.4
Asthma is a chronic disorder of the lower airways, with two key pathophysiologic 
features: airway inflammation and bronchial hyperresponsiveness (BHR).1 Asthma char-
acteristically leads to recurrent episodes (‘exacerbations’) of wheezing, dyspnoea, chest 
tightness and coughing.
The pathogenesis of asthma is complex and not yet fully understood. In the asthmatic 
airway wall and lumen, a chronic inflammatory substrate is present, containing Th2-
lymphocytes, eosinophils, mast cells and their mediators. These cells and mediators 
stimulate throphic changes of the airway, i.e. hypertrophy/hyperplasia of airway smooth 
muscle, increased numbers and hyperplasia of goblet cells, enlargement of submucous 
glands, subepithelial fibrosis, and basement membrane thickening. Furthermore, 
chronic inflammation leads to vasodilatation, microvascular leakage, hypertrophy and 
hypervascularity of the vascular bed and epithelial disruption. Eventually, more perma-
nent structural alterations to the airway occur, commonly known as ‘airway remodeling’.
BHR is the tendency of asthmatic bronchial airways to narrow excessively (compared 
to healthy individuals) in response to various specific (e.g. allergens) and nonspecific 
(e.g. exercise and viral infections) stimuli. In response to these stimuli, the inflammatory 
cells present in the asthmatic airway wall are activated and release a variety of media-
tors causing severe airflow obstruction by bronchial smooth muscle contraction, mucus 
hypersecretion and mucosal swelling (Fig. 1).
Although the clinical symptoms of asthma are well known, it can cause a variable 
pattern of symptoms in different patients. As asthma is an episodic and heterogeneous 
disease a thorough diagnostic approach is essential. Close monitoring is necessary to 
achieve and maintain clinical control. A tool that can assess the presence or resolution of 
the two key pathophysiologic features of asthma, BHR and airway inflammation, would 
improve diagnosing, monitoring and treatment of childhood asthma.
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Exercise induced bronchoconstriction
Exercise induced symptoms are not always a sign of asthma, but can also result from a 
lack of cardiovascular fitness, hyperventilation, dysfunctional breathing, vocal cord dys-
function and other lung diseases. However, exercise induced bronchoconstriction (EIB) 
is highly specific for asthma in children.6 EIB is defined as an acute, reversible bronchial 
obstruction occurring immediately after and occasionally during physical exercise.7 It 
commonly presents with wheeze, chest tightness, shortness of breath and cough 5-10 
min after exercise. EIB affects 80-90% of asthmatic children8 and is a disabling entity, 
associated with an impaired quality of life.9
The exact pathophysiologic mechanisms that cause EIB are not completely unraveled, 
but there are two current theories.7,10 The osmotic hypothesis7,10 states that exercise 
causes EIB by osmotic effects on the airway surface (Fig. 2). When breathing dry air at 
a moderate ventilation rate (60 L/min) about 25-30% of the water needed to condition 
the inspired air comes from the intrathoracic airways.7 This percentage increases when 
the air gets drier and/or colder, when the ventilation rate increases and when the depth 
of the airway surface liquid (ASL) decreases. The volume of the ASL was calculated to 
be so small (< 1 mL in the first 12 generations of airways) that the evaporative water 
loss during hyperpnoea could lead to an increase in ASL osmolarity. The increase in 
fig. 1. Differences between normal and asthmatic airway.
Pathological changes of the bronchi (‘remodeling’) are present in the airways. Inflammation and BHR are 
triggered by a variety of factors, leading to airway obstruction.
Figure adopted from International consensus on pediatric asthma 20125, with permission.
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osmolarity stimulates water to move from the mucosal cells to the lumen. Volume loss 
and regulatory restoration in cells in the airway wall lead to fast shifts in intracellular 
osmolarity, provoking intracellular events resulting in the release of mediators. These 
mediators include histamine, leukotrienes, prostaglandins, neurokinin A and chemotac-
tic factors. Histamine appears to be released first, but leukotrienes and prostaglandins 
are considered to be more important for determining the degree of bronchoconstric-
tion and the time it is sustained.11,12 The bronchial smooth muscle contracts in response 
to these mediators. Mucus secretion increases both in response to these mediators13 
and directly in response to the increase in osmolarity.14 Hyperosmolarity also increases 
the bronchial blood flow and is known to cause vasodilation and microvascular leakage 
in animals.15 First, this amplifies the airway narrowing due to edema of the airway wall. 
Later, the increase in blood flow reduces dehydration and enhances clearance of media-






























fig. 2. Osmotic hypothesis of EIB pathogenesis.
The osmotic effect on the airway surface liquid, caused by exercise induced hyperpnoea, results in airway 
narrowing, mainly through the effects of mast cell mediators.
ASL = airway surface liquid.
14 Chapter 1
The thermal hypothesis16 proposes that exercise initiates EIB by thermal effects on the 
airways. Chronic inflammation of the airway wall leads to hypervascularity and a hyper-
plastic vascular bed. Exercise induced hyperpnoea leads to cooling of the airway surface, 
causing vasoconstriction of the bronchial circulation. After exercise, a rapid rewarming 
occurs, causing hyperemia and fluid exudation from the vascular bed; subsequently 
leading to edema of the airway wall.
This hypothesis does not explain why EIB in some asthmatic adults and the majority 
of asthmatic children already starts during exercise (breakthrough EIB)17 and why it is 
diminished when exercise is performed in humid air.18 The pathophysiology of EIB is 
probably a combination of osmotic and thermal effects on the airway.
In adolescents and adults, EIB sometimes occurs without asthma, as a consequence of 
repetitive thermal, osmotic and mechanical stresses that caused injury to the airway epi-
thelium and triggered an injury-repair cascade.10,19 In genetically susceptible individuals 
this injury-repair process promotes persistent inflammation and airway remodeling, 
leading to EIB development and progression.10
In children, EIB is highly specific for asthma.6 When underlying inflammation of the 
airways is severe, this amplifies EIB, because more inflammatory cells reside in the asth-
matic airway wall and a hyperplastic vascular bed is present. EIB therefore reflects active 
inflammation of the airways and the presence of EIB indicates that the patient’s asthma 
is not well controlled.1
dIaGnosInG and monITorInG asThma
history and physical examination
A diagnosis of asthma is usually based on the presence of characteristic symptoms of 
episodic breathlessness, wheezing and cough. If symptoms are (seasonally) variable, 
tend to worsen at night or are provoked by exercise, allergen exposure or non-specific 
stimuli (e.g. smoke, fumes), a diagnosis of asthma is likely. A positive family history of 
asthma and atopic disease can support the diagnosis.
However, the symptoms of asthma in children are not always straightforward, and 
many children have a poor perception of symptom severity. Children’s health beliefs and 
coping strategies influence their perception of symptoms.20
Because asthma is an episodic disease, most clinical signs are only present during an 
exacerbation. Wheezing, tachypnoea and a prolonged expiratory phase on auscultation 
of the lungs are the most common findings. Manifestations of atopic disease, such as 




Measurement of lung function provides additional information on the severity, revers-
ibility and variability of airflow obstruction. Forced expiratory flow-volume loops are 
obtained by instructing children to perform a maximal expiratory effort from inspira-
tory vital capacity to residual volume. FVC (Forced Vital Capacity) is the total volume of 
expired air and FEV1 (Forced Expiratory Volume in 1 s) is the volume of air expired in the 
first second.
A reduction in FEV1 is not specific for asthma, but can also be caused by other lung 
diseases. A useful assessment of airflow obstruction is the FEV1/FVC ratio, which is usu-
ally greater than 0.75 – 0.80 and possibly even greater than 0.90 in children.1
Reversibility is defined as a rapid improvement in FEV1 after the inhalation of a 
short-acting β2-agonist (SABA). A reversibility ≥ 12% indicates a diagnosis of asthma. 
Variability, an improvement or deterioration of lung function over time, also supports a 
clinical diagnosis of asthma.
Spirometry is reproducible, but dependent on how the forced expiratory maneuver 
is performed. It is therefore not suitable for young children that cannot be properly in-
structed. As a majority of children have normal lung function during the asymptomatic 
intervals, spirometry at rest alone is often not enough to diagnose or monitor asthma. 
Findings on physical examination and lung function measurement are more sensitive 
when a patient has an asthma exacerbation.1,21
Bronchial Provocation Tests
Standardized bronchial provocation tests (BPTs) are used to assess BHR through the 
administration of bronchoconstrictor stimuli. BPTs are usually performed according to 
a ‘challenge-rescue’ model to evaluate both the bronchoconstrictive dose-response to 
a stimulus and the bronchodilator response to a rescue SABA. Stimuli used in BPTs are 
classified into two categories: ‘direct’ and ‘indirect’. Direct stimuli include pharmacologi-
cal agents such as histamine. Indirect stimuli include physical stimuli, such as exercise, 
and pharmacological stimuli, such as adenosine monophosphate (AMP) (Fig. 3, Table 1).
Direct stimuli induce airflow obstruction through a direct action on the effector cells 
(including smooth muscle cells, bronchial vascular endothelial cells and mucus produc-
ing cells).22 Histamine binds to histamine H1-receptors and metacholine to muscarinic 
M3-receptors. These receptors initiate an intracellular process, which provokes smooth 
muscle contraction and bronchoconstriction.
In contrast, indirect stimuli induce airflow obstruction by acting on intermediate cells, 
such as mast cells, epithelial cells and neuronal cells. Pro-inflammatory mediators and/
or neurotransmitters released by these intermediate cells act on receptors on the effec-
tor cells to cause airflow obstruction.22 (Fig. 3)
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BHR to direct stimuli can be considered to have a ‘variable’ and ‘fixed’ component. The 
variable component reflects the present inflammation and the fixed component reflects 
chronic structural changes in the airway, airway smooth muscle function and airway 
caliber.23 BHR to a direct stimulus is therefore a reflection of chronic inflammation leading 
to functional and anatomic airway remodeling and only partly relates to current airway 
inflammation.22,23 BHR to direct stimuli can persist despite high dose anti-inflammatory 
treatment for years.24 As direct BPTs reflect chronic inflammation they respond slowly to 
anti-inflammatory treatment and are less suitable to monitor short term effects.
Direct BPTs have a low specificity; children with other pulmonary diseases and even 
healthy children demonstrated BHR to these stimuli.25,26 Direct tests are considered to have 
a high sensitivity for the diagnosis of asthma, and are therefore useful in the diagnostic 
process to rule out asthma. However, the sensitivity of direct tests differs significantly in 
different patients groups. For example, in asthmatic children aged 7-9 years, the diag-































fig. 3. The difference in pathways by which two indirect stimuli (osmotic stimulus and allergen) and two 
direct stimuli (histamine and methacholine) cause airflow obstruction.
ECT = exercise challenge test.
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The response to an indirect stimulus is more closely associated with current airway 
inflammation, as it reflects the presence and active state of inflammatory cells in the 
airway.31 Indirect BPTs can therefore be used to monitor the early response to anti-
inflammatory treatment.32-34 Indirect BPTs are more specific for diagnosing asthma.25,35 
However, the sensitivity of indirect BPTs is variable; depending on the population that 
is tested and the type of indirect BPT performed. Indirect BPTs, especially allergen and 
exercise challenges, are clinically relevant ‘real life tests’, as asthma exacerbations in daily 
life are caused by indirect stimuli.
In this thesis, exercise challenge tests (ECT) and mannitol provocation tests, both indi-
rect BPTs, are used  to monitor short-term treatment responses to anti-inflammatory 
treatment.
Table 1. Differences between direct and indirect bronchial provocation tests










Adenosine, Tachykinin, Bradykinin, 
Metabisulphite, SO2, Propranolol
Osmotic Stimuli
Exercise, EVH, Hypertonic saline, Distilled water, 
Mannitol
Other Stimuli
Allergen, Ozone, Aspirin, Endotoxin 
(lipopolysaccharides), NSAID
Mechanism Direct effect on ‘effector cells’ such as 
smooth muscle cells
Effect on intermediary and inflammatory cells 











Sensitivity High in asthmatic population, lower 
in general population




Low-moderate, depending on pre-
test probability
High28





Monitoring value -Responds slowly to anti-
inflammatory treatment
-Monitoring in children results in 
higher FEV1, but similar symptom 
scores, exacerbation rates and BHR, at 
the cost of a higher ICS dose29
-Responds rapidly to anti-inflammatory treatment
-Monitoring in adults results in reduced symptom 
scores, mild exacerbation rates and BHR, but 
similar FEV1 and severe exacerbation rates, at the 
cost of a higher ICS dose30
ASM = airway smooth muscle, BPT = bronchial provocation test, EIB = exercise induced bronchoconstriction, EVH 
= eucapnic voluntary hyperpnoea, ICS = inhaled corticosteroid, NSAID = non-steroidal anti-inflammatory drug.
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Exercise challenge test
An ECT is used as an indirect BPT to diagnose and monitor EIB and performed using a 
standardized protocol.36 Optimally, the test is performed in cold and dry air. The presence 
of EIB is defined by calculating the maximum percentage fall in FEV1 from pre-exercise 
baseline FEV1 within 30 min after exercise. A ≥ 10% fall is generally considered abnormal. 
Some laboratories use a criterion of ≥ 15% fall because of the greater specificity.
Bronchoconstriction typically begins 2-4 min post-exercise and reaches its nadir 5-10 
min post-exercise (Fig. 4). The time to maximal post-exercise bronchoconstriction is age-
dependent, occurring faster in younger children.17,37,38 Bronchoconstriction can already 
start during exercise in ‘breaktrough EIB’, which is associated with more severe EIB and a 
sign of uncontrolled asthma.38
Recovery to pre-exercise FEV1 usually takes about 30 min, but can last up to 60 min. 
Younger children usually recover faster.39 Recovery can be measured as time to recover 
to within 95% of baseline FEV1. A SABA should be administered to reverse the bron-
choconstriction if the patient experiences severe bronchoconstriction, or if FEV1 has 
not recovered to within 95% of baseline after 30 min. The Area Under the Curve (AUC) 
reflects the duration of sustained bronchoconstriction and is a measure for severity of 
EIB.
Exercise induced 






















Exercise Post-exercise Maximum Fall in FEV
1
fig. 4. ‘Challenge-rescue-recovery’ model for exercise challenge test demonstrating fall in FEV1 after exer-
cise and recovery to ≥95% of baseline.
AUC = area under the FEV1 curve, SABA = short-acting β2-agonist, FEV1 = forced expiratory volume in 1s.
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1An ECT simulates the ‘real life’ circumstances of an acute episode of airflow obstruc-tion, as it challenges the inflamed airway mucosa physiologically. An ECT can be used 
to differentiate between EIB and other causes of exercise induced symptoms and has a 
high positive predictive value for the presence of asthma.
Exercise testing also has some disadvantages. As it reflects current airway inflamma-
tion, the sensitivity decreases during asymptomatic periods; for example during the 
summer months.40 The test requires expensive equipment, the inspired air needs to be 
dry and preferably cool and the intensity of exercise needs to be strenuous (85-95% of 
maximum heart rate for ≥ 6 min). Insufficient attention to temperature and water content 
of the inspired air, and duration and intensity of exercise may produce false negative 
outcomes.41 Exercise may cause a severe, potentially dangerous, bronchoconstriction. 
To overcome these problems, alternative tests that mimic the dehydrating effect on the 
airways were developed.
Mannitol test
Mannitol can mimic the airway drying provoked by exercise by dehydrating the airway 
surface. Mannitol was selected as the osmotic agent because it was considered safe 
for use in both adults and children, and had suitable properties for encapsulation and 
delivery.
A mannitol test is performed according to a standard protocol, using the mannitol test 
kit (Aridol™ or Osmohale™; Fig. 5).8,42 The dose protocol consists of 0, 5, 10, 20, 40, 80, 160, 
160 and 160 mg mannitol and FEV1 is measured 60s after each dose. The test ends when 
a ≥ 15% fall in FEV1 from baseline or a ≥ 10% fall between subsequent doses occurs, or 
the cumulative dose of 635 mg mannitol has been administered. Patients then receive a 
SABA and FEV1 is measured until lung function has recovered to within 95% of baseline. 
Sensitivity to mannitol is expressed as the provoking dose to cause a 15% fall in FEV1, PD15 
0 mg
60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s 60s
Spirometry
40 mg 80 mg20 mg10 mg5 mg 160 mg 160 mg 160 mg
≥ 15% fall in FEV1 
from baseline





PD15 = provoking dose to cause a 15% fall in FEV1
RDR = the final % fall in FEV1 divided by the total cumulative dose of mannitol
Outcome:
fig. 5. Mannitol test dose protocol.
FEV1 = forced expiratory volume in 1s, RDR = response dose ratio.
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(mg). Reactivity to mannitol is measured by the response dose ratio (RDR); the final % 
fall in FEV1 divided by the total cumulative dose of mannitol to induce such a fall in FEV1.
Mannitol is effective in identifying asthmatic adults responsive to an ECT.43,44 In steroid-
naïve asthmatic adults and children compared to healthy subjects, the specificity and 
sensitivity of mannitol for diagnosing asthma were 88.7% and 95%.45 Responses to man-
nitol can be used to monitor anti-inflammatory therapy with corticosteroids in adults.46 
Mannitol tests are safe45 and reproducible47 in children. The most common side effect of 
mannitol is a dry cough, which almost all patients experience after its inhalation.
Other osmotic BPTs
Eucapnic Voluntary Hyperpnoea (EVH) mimics the airway drying provoked by exercise 
by voluntary hyperpnoea of dry air at a high ventilation rate. It is technically a difficult 
test to conduct properly in children and has the potential to provoke severe broncho-
constriction.
Nebulized hypertonic saline (NaCl 4.5%) acts by increasing ASL osmolarity. In young 
children, hypertonic saline may be easier to administer than EVH or exercise. Hypertonic 
saline can be used to collect sputum for analysis. A disadvantage of the challenge is that 
many factors can alter the output of the aerosol, such as the temperature, the volume 
of fluid in the nebulizer, the tidal volume of the subject and the size of the valves and 
tubing.
Adenosine Monophosphate (AMP) challenge is a non-osmotic indirect BPT. Dry crys-
talline AMP powder dissolved in 0.9% saline is administered in progressively doubling 
doses via a nebulizer. After inhalation, AMP dephosphorylates into adenosine, which 
stimulates release of inflammatory mediators. AMP challenge is widely used in research, 
but is not routinely used as a BPT in clinical practice.
Biomarkers of inflammation
Bronchoscopies with biopsies and bronchoalveolar lavage (BAL) are the gold standard 
to assess airway inflammation, but are too invasive for application in clinical practice. 
Tests to measure inflammatory cells and markers in sputum, saliva, exhaled air, urine and 
peripheral blood are currently researched.48
For example, airway inflammation can be evaluated by examining sputum for eosino-
phils. However, invasive techniques are necessary to collect sputum for analysis, mak-
ing it less suitable for use in childhood asthma. Furthermore, children’s inflammatory 
phenotype may change over time.
Airway inflammation can also be assessed by measuring the fractional concentration 
of exhaled nitric oxide (FeNO). The presence of nitric oxide in exhaled breath of animals 
and humans was first described in the 1990s, followed by the observation that FeNO is 
elevated in asthmatic patients.
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1There are several ways to measure FeNO. In this thesis, the single-breath online measure-ment method is used.49 Measurement of FeNO is non-invasive and relatively easy, making 
it suitable for children. The measurement of FeNO is highly reproducible and responsive 
to changes in the underlying disease state. The level of FeNO correlates significantly with 
eosinophilic airway inflammation and decreases in response to anti-inflammatory treat-
ment.50 It is however not specific to asthma and can be elevated in children with e.g. 
atopy, AR, viral respiratory tract infections, and eosinophilic bronchitis without asthma.50
allergy
The presence of allergies increases the probability of asthma in undiagnosed children 
with respiratory symptoms and helps to identify risk factors that can cause symptoms 
in individual patients.1 Allergy can be measured by a skin prick test or a Radioallergo-
sorbent (RAST). In a skin prick test a microscopic amount of an allergen is pricked in 
the skin surface, usually the forearm. If a response is seen in the form of a rash, urticaria 
or anaphylaxis it can be concluded that the patient has a hypersensitivity to that al-
lergen. The RAST test is a radioimmunoassay test to measure specific IgE antibodies to 
suspected allergens. The use of testing allergic status in asthma is limited, as a positive 
test does not necessarily mean that the patient is allergic. A high total IgE has a high 
probability of allergic sensitization, but a low total IgE cannot rule out sensitization to 
commonly inhaled allergens.
Co-morBIdITy of asThma and allErGIC rhInITIs
allergic rhinitis
AR is the most common chronic disorder in children, with a prevalence of 10-20% in 
western countries.51 Rhinitis is defined as an inflammatory disorder of the upper airways, 
characterized by nasal pruritus, sneezing, rhinorrhoea and congestion. It is frequently 
accompanied by symptoms involving the eyes, ears, and throat. AR is induced by an 
IgE-mediated inflammatory response to specific allergens. After exposure to an allergen, 
inflammatory cells release mediators that increase vascular permeability, stimulate sen-
sory nerves to initiate a sneeze reflex and increase mucus secretion. Cytokines secreted 
by inflammatory cells attract more mast cells and eosinophils, stimulate their growth 
and survival and promote IgE production, maintaining an inflammatory substrate.
Previously, AR was subdivided into seasonal, perennial and occupational, depending 
on sensitization to cyclic pollens, year round allergens or occupational exposure. This 
subdivision was not entirely satisfactory. The majority of patients are sensitized to many 
different allergens and therefore exposed throughout the year, experiencing perennial 
symptoms and seasonal exacerbations.
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Currently, AR is subdivided based on the duration of symptoms, in intermittent AR and 
persistent AR.51 AR is classified as mild or moderate/severe depending on the severity of 
the symptoms and their impact on social life and daily living (Table 2).
AR is often undiagnosed and undertreated. Surveys in western countries have shown 
that only about 12% of adult patients sought medical treatment for AR52 and about 
one-third was undiagnosed.53 In children, this percentage may be even higher. The clini-
cal presentation of AR in children is more diverse, and children rarely complain about 
specific symptoms of AR.54 In childhood, AR can present with sleeping problems, fatigue, 
nocturnal cough, behavioral problems, decreased appetite, and poor growth. Children 
with these symptoms are often misdiagnosed and treated inappropriately.
When AR is undiagnosed or inadequately treated, symptoms can have a substantial 
impact on a patient’s quality of life and daily functioning. Furthermore, the risk for 
co-morbid conditions, including asthma, otitis media and obstructive sleep apnea, is 
increased.54
The relationship between asthma and allergic rhinitis
Asthma and AR often occur together, and are sometimes called “the united airways 
syndrome” (Fig.  6).51 Patients with moderate/severe persistent AR more often have 
asthma than patients with mild and/or intermittent AR.55 AR is present in up to 80% of 
adults and children with asthma56, but often unrecognized, as chronic inflammation of 
the nasal mucosa is present without symptoms of acute AR. Asthmatic children with AR 
experience more asthma attacks, have more visits to their physician and the emergency 
room and more hospitalizations than asthmatic children without AR.57,58 In other words, 
uncontrolled AR leads to uncontrolled asthma.
AR and asthma are mediated by similar allergic inflammatory mechanisms.56 The nasal 
and bronchial mucosa present similarities; both are lined by a pseudo-stratified epithe-
Table 2. Classification of allergic rhinitis according to ARIA guidelines
Intermittent Symptoms present
< 4 days / week
< 4 consecutive weeks
Persistent Symptoms present
> 4 days / week
> 4 consecutive weeks
mild Symptoms present but not troublesome
No impairment of daily activities, sleep, school or work
moderate/severe One or more of the following:
-sleep disturbance
-impairment of daily activities, leisure and/or sport
-impairment of school or work
-troublesome symptoms
ARIA = Allergic Rhinitis and its Impact on Asthma
Introduction 23
1
lium with columnar, ciliated cells. Vessels, mucus glands and inflammatory cells (includ-
ing eosinophils, Th2-lymphocytes and mast cells) are present in the submucosa. There 
are however some major anatomic differences between the upper and lower airways. 
The vasculature of the nasal mucosa is embedded in a rigid structure and consists of a 
large number of subepithelial capillaries and venous sinusoids. Therefore, in the upper 
airways, obstruction results mostly from mucosal swelling due to vascular engorgement 
and increased mucus secretion. In the lower airways, bronchial obstruction is mostly 
elicited by smooth muscle contraction.
AR usually precedes the development of asthma, but it is unclear whether AR repre-
sents an earlier clinical manifestation of allergic airway disease or whether the nasal dis-
ease itself is causative for asthma. In non-asthmatic adults with AR, increased numbers 
of eosinophils are present in the bronchial mucosa and thickening of the bronchial base-
ment membrane has been demonstrated.59 Many children and adults with AR, with and 
without concomitant asthma, have an increased BHR to direct BPTs, especially during 
the pollen season.60 In non-asthmatic adults with AR, nasal provocation with allergen 
induces bronchial symptoms and bronchial inflammation61 and conversely, bronchial 
provocation induces nasal symptoms and nasal inflammation.62
Intranasal corticosteroids (INCS) provide a safe and effective treatment for AR.51 
Treatment of AR with INCS tends to improve asthma symptom scores and measures of 
lung function in adults and children.63,64 However, the effect of INCS on symptoms of 




population, definition of 
AR and interpretation of 
25-40%
Asthma 
without AR AR and Asthma
80%20%
symptoms 
fig. 6. The prevalence and co-existence of allergic rhinitis and asthma.
AR = allergic rhinitis. Percentages from a population of adults and children; Bousquet et al.51
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The effect of treatment with INCS on measures of BHR and lower airway inflammation 
is controversial, as conclusions from individual studies have been conflicting.63,64 A 2004 
meta-analysis concluded that there was no effect of INCS on BHR to methacholine in 
adults.64 The effect of INCS on BHR to indirect stimuli, such as exercise, has been studied 
in only one study, which was inconclusive.65 A similar inconclusive pattern of results has 
been shown by studies investigating the effect of INCS on other measures of airway 
inflammation.66,67 The 2010 Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines 
recommended treatment of AR with INCS, but concluded there was no clear benefit 
from the use of INCS for asthma.68
asThma TrEaTmEnT
The goal of asthma treatment is to achieve and maintain clinical control, normal activity 
levels and lung function, and to reduce the risk of future exacerbations.1 Asthma control 
can be classified as well controlled, partly controlled or uncontrolled (Table 3)1 and mea-
sured by several standardized instruments, such as the Asthma Control Questionnaire 
(ACQ)69 and the Asthma Control Test (ACT)70. Both are used to measure asthma control 
in this thesis.
Treatment of asthma requires proper education of children and their caregivers, 
restriction of exposure to triggers of asthma exacerbations (such as smoking) and low-
threshold treatment of co-morbid conditions. Medicinal treatment should be adjusted 
according to asthma control in a stepwise protocol (Table 4).1
At each treatment step, a reliever SABA should be provided for quick relief of symp-
toms. For patients who need controller treatment, a low dose ICS is recommended as the 
first choice.1 For symptomatic children (> 6 years) on low dose ICS, 3 different step-up 
options are available. However, children show a considerable variability in response to 
these step-up treatments71 and there is currently a lack of evidence to guide clinicians 
Table 3. Clinical characteristics of well-, partly- and uncontrolled asthma.
level of control Controlled Partly controlled uncontrolled
Daytime symptoms ≤ 2 days / week > 2 days / week ≥ 3 signs of partly 
controlled asthma per 
week
Nocturnal symptoms / nighttime 
awakenings
None > 2 days / month
Activity limitation None Any
Need for rescue β2-agonists ≤ 2 days / week > 2 days / week
Lung function (FEV1 or PEF) normal < 80% of predicted or 
personal best value
Table adapted from GINA guidelines.1
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to the most effective one. There is also little evidence available on the optimal timing, 
sequence and degree of stepping down medications.
In this thesis, we studied the effects of stepping up and down treatment on BHR to 
indirect BPTs. In the next paragraphs we discuss the three groups of medications that 
we studied.
β2-agonists
β2-Agonists are used as bronchodilators for the acute relief of symptoms and for 
their bronchoprotective effect against BHR. SABAs have an onset of action on the β2-
adrenoreceptor (β2AR) within minutes, with a duration of 4-6h73 and are the first choice 
as rescue medications during acute bronchoconstriction. Long-acting β2-agonists 
(LABAs) have a prolonged effect on the β2AR, leading to persistent bronchodilation for 
12-24h.73
β2-Agonists stimulate the β2AR, a G-protein coupled receptor, present on smooth 
muscle cells, mast cells, epithelial and endothelial cells.74 The receptor density is highest 
on airway smooth muscle cells. Stimulation of the β2AR on smooth muscle cells induces 
a signal transduction pathway, resulting in smooth muscle relaxation (Fig. 7). Stimulation 
of the β2AR on mast cells inhibits the release of pre-stored histamine and synthesis of 
new mediators, leading to mast cell stabilization.75 Stimulation of the β2AR on epithelial 
cells leads to an increased beat frequency of cilia and may therefore facilitate mucocili-
ary clearance.76 Furthermore, β2-agonists inhibit extravasation of plasma proteins in the 
airways, thereby reducing the pulmonary edema that contributes to airway obstruction 
in asthma.75
β2-Agonists can have cardiovascular side effects, as measured by changes in heart 
rate and blood pressure. Other side effects include oral and pharyngeal irritation, 
Table 4. Available options to step-up or -down asthma treatment
step 1 step 2 step 3 step 4 step 5
Education and prevention, check inhaler technique, adherence, co-morbidity, exposures
As needed SABA
Select one Select one Select one or more Difficult to treat 
asthma††
Controller options Low dose ICS Double dose ICS Low dose ICS + 
LABA + LTRA
Quadruple dose ICS 
+ LABA + LTRA
(LTRA *) Low dose ICS + 
LABA†








*Only when inhaler technique is insufficient. †In children aged > 4 years. ††Treatment only by expert.
LABA = long-acting β2-agonist, ICS = inhaled corticosteroid, LTRA = leukotriene receptor antagonist. Table 
adapted from Dutch guideline for treatment of asthma in children.72
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nausea, tremor of hands and fingers, headache, restlessness, increased sweating and 
dizziness. Most of these side effects are consequences of the widespread distribution of 
the β2AR. Side effects are less severe when β2-agonists are administered by inhalation, 
which only gives a low systemic plasma concentration, compared to oral or intravenous 
administration.
Concerns regarding the adverse effects and safety of regular treatment with LABAs 
have emerged since their introduction in the 1990s. In the past decade, several 
meta-analyses investigating the adverse events of LABAs were published, providing 
an equivocal picture.77-83 Some of these meta analyses demonstrated an increased risk 
of serious adverse events, such as hospitalizations, life-threatening exacerbations and 
asthma-related death in both adults and children regularly taking LABAs.77-79 An advi-
sory panel of the United States Food and Drug Administration (FDA) recommends the 
use of LABAs only as add-on therapy in combination with ICSs.84
Single doses of both SABAs and LABAs provide a significant protection against EIB85 
and BHR provoked by other BPTs.86 However, longer treatment is less effective, as drug 
tolerance to the effects of β2-agonists develops.85 Exposure to an agonist leads to ho-
mologous desensitization of the β2AR within minutes, through phosphorylation of the 
receptor.74 After more prolonged exposure, an internalization of receptors occurs and 
the total transit time for the recycling of receptors increases.74 There is a net loss of re-
ceptors on the cell membrane, called downregulation.74 Eventually there is a breakdown 
of receptors, which can only be restored by transcription of the β2AR-gene.
β2AR desensitization and downregulation lead to tolerance to the effects of β2-
agonists, which can be demonstrated in a ‘challenge-rescue’ model with a BPT.87 Toler-
ance to the bronchodilator effect results in a reduced effect of rescue SABAs, a prolonged 
recovery time and the need for extra doses of rescue medication.88,89 Tolerance to the 
bronchoprotective effect results in a reduced duration and degree of protection.89-91
The process of desensitization differs in different types of cells. Lymphocytes and 
mast cells desensitize rapidly and smooth muscle cells more slowly. Therefore, toler-
ance might be more pronounced when an indirect BPT is used in the challenge-rescue 
model.86,92,93 In this thesis, we therefore studied the effects of tolerance on BHR to man-
nitol and exercise.
In vitro, β2-agonists appear to have both anti-inflammatory as well as pro-inflamma-
tory effects. They stabilize mast cells and reduce the adhesion of neutrophils and eosino-
phils to endothelial cells75 and they potentiate some of the anti-inflammatory effects 
of ICSs.94 However, they paradoxically also have pro-inflammatory effects.95-97 Clinically, 
these observations do not appear to be relevant, as a meta-analysis investigating the 
effect of LABAs on inflammation in adults and children concluded that LABAs did not 




ICSs are recommended as the first choice of controller treatment for asthma in patients 
of all ages.1 ICSs reduce symptoms, BHR, frequency and severity of asthma exacerba-
tions and asthma related mortality. Furthermore, ICSs improve lung function and quality 
of life.99
ICSs bind to glucocorticoid receptors that are located in the cytoplasm of target cells. 
They are present in both inflammatory cells, as well as structural cells, with the greatest 
level of expression in airway epithelial cells and bronchial vascular endothelial cells.100 
ICSs activate the glucocorticoid receptor to regulate the transcription of genes. A small 
number of genes are directly regulated by the glucocorticoid receptor. Many other genes 
are indirectly regulated through interaction of the receptor with other transcription fac-
tors.100 By increasing the transcription of anti-inflammatory genes and decreasing the 
transcription of pro-inflammatory genes, corticosteroids control airway inflammation.101
Corticosteroids inhibit the synthesis and release of inflammatory mediators and 
cytokines (Fig. 7). They reduce the production and survival of eosinophils and inhibit 
the expression of eosinophil chemo-attractants on airway epithelial cells. They thereby 
decrease the circulating number of eosinophils in plasma and sputum.100 The numbers 
of mast cells and dendritic cells are also reduced. Furthermore, ICSs have an inhibitory 
effect on airway microvascular leakage and mucus secretion by submucosal glands.100 
ICSs may attenuate airway remodeling by reducing the thickness of the basement mem-
brane, airway wall vascularity and airway smooth muscle hyperplasia and by restoring 
epithelial injury.102 However, even after long-term treatment with ICSs airway remodel-
ing is not completely reversed.102
The most reported local side effects of ICSs are dysphonia, hoarseness and oropha-
ryngeal candidiasis. The severity of systemic side effects depends on the duration of 
use, dosage, and specific drug used, along with individual patient variability. High 
doses can give an increased risk of infection, adrenal suppression, dermal thinning and 
bruising, decreased bone mineral density and osteoporosis.101,103 However, conventional 
doses appear to be safe in the long-term management of childhood asthma.103 A recent 
Cochrane analysis on the effect of inhaled corticosteroids on growth, showed a dose-
related reduced growth velocity over 12 months in pre-pubertal children.104 The effect 
on final attained adult height remains unclear.
Treatment with ICSs for 2 weeks or longer significantly attenuates EIB105 and BHR 
provoked by direct stimuli.106 However, the extent of improvement in BHR varies consid-
erably among patients and a subgroup of patients respond poorly to ICSs. 107
leukotriene receptor antagonists
Leukotriene receptor antagonists (LTRAs) are mostly used as step-up therapy in patients 





























































fig. 7. Effects of β2-agonists, corticosteroids and leukotriene receptor antagonists in the airways.
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1function, symptom scores and asthma control in asthmatic adults.
108 However, LTRA/
ICS combination does not reduce the need for rescue oral corticosteroids or hospital 
admission compared to the same dose of ICSs in children and adolescents with mild to 
moderate asthma.109
CysLT are a group of lipid mediators synthesized from nuclear membrane phospholip-
ids. CysLT are produced in both inflammatory cells as well as structural cells, and exert 
their effect through interaction with CysLT receptors 1 and 2. Binding to the CysLT1 
receptor stimulates airway smooth muscle contraction and mucus secretion, increases 
pulmonary vascular permeability and promotes eosinophilic inflammation.110 The 
CysLT2 receptor has a less specified role in the pathophysiology of asthma.111
CysLT are released in asthmatic airways after allergen and exercise challenges and are 
closely associated to airway inflammation.110 Exhaled breath condensate, BAL fluids and in-
duced sputum show increased concentrations of CysLT in asthmatic subjects. CysLT promote 
recruitment, activation and survival of eosinophils, activation of macrophages, migration 
and maturation of dendritic cells and survival of mast cells and basophils. CysLT promote the 
generation of Th2 cytokines and stimulate the release of pro-inflammatory mediators. Many 
of these mediators augment CysLT production, creating a positive feedback loop.110
The effects of CysLT can be influenced by inhibiting their formation (using a 5-lipoxy-
genase inhibitor) or preventing their binding to the CysLT1 receptor, such as montelukast.
Clinical studies have shown that treatment with LTRAs reduces measures of airway 
inflammation, including FeNO and eosinophils in sputum, peripheral blood and BAL 
fluid.110,111 CysLT also play a role in the process of airway remodeling by stimulating col-
lagen synthesis, proliferation and migration of fibroblasts and hyperplasia of smooth 
muscle and goblet cells.110,111 There is some evidence that this remodeling process is 
suppressed by LTRA.111
LTRAs are generally well tolerated. Adverse effects such as headache, gastro-intestinal 
disturbances and dizziness have been reported, but the frequency of these side effects 
is similar in patients treated with placebo.112
LTRAs provide significant protection against BHR to both direct and indirect BPTs113, 
which lasts from 1h after dosing until the end of the dosing interval.114,115 Treatment with 
LTRAs does not affect the bronchodilator response to rescue SABAs89 and tolerance to 
their bronchoprotective effects does not develop.116,117 Four weeks daily treatment with 
montelukast attenuates EIB at the end of the dosing interval (i.e., 20-24h after dosing) 
in children on low dose ICSs.116,118 As CysLT are considered to have a prolonged effect 
on smooth muscle contraction, montelukast mainly attenuates the duration of bron-
choconstriction after exercise, measured by the AUC and recovery time.117,118 However, 
montelukast doesn’t protect against EIB in all children. The extent of improvement in 
BHR varies considerably among patients and it was suggested that 20-40% of patients 
are non-responders both after a single dose114,115 and regular daily treatment.116,118
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oBjECTIvEs
Asthma is a chronic disorder of the lower airways, characterized by airway inflammation 
and BHR. Asthma is a complex, heterogeneous and variable disease and there is no gold 
standard to monitor disease activity and the response to treatment. To improve asthma 
control, there is a need for an alternative approach to monitoring asthma, via the use 
of objective markers that can assess airway inflammation and BHR. In this thesis, we 
used indirect BPTs to monitor asthmatic children and to follow-up and predict treat-
ment responses. Indirect BPTs are clinically relevant ‘real life tests’, and BHR to an indirect 
stimulus reflects current airway inflammation, as the presence and active state of inflam-
matory cells are required to provoke a bronchoconstrictive response.
First we studied the clinical utility of a relatively new indirect BPT, a mannitol test, to 
identify asthmatic children with EIB, as described in chapter 2. In chapter 3 and 4, we 
used exercise and mannitol tests to study the effect of stepping down LABA/ICS combi-
nation therapy to mono-therapy with an ICS. Because regular treatment with LABAs can 
lead to drug tolerance, we hypothesized that stepping down from combination therapy 
to ICS mono-therapy could have beneficial effects on airway inflammation and BHR to 
indirect BPTs. In chapter 5 we review the clinical consequences of tolerance and adverse 
effects of β2-agonists in childhood asthma in the light of current literature.
Furthermore, we used BHR to exercise to study the effect of intranasal anti-inflam-
matory treatment on lower airway inflammation. Although allergic asthma and AR are 
considered manifestations of a single ‘united airways’ syndrome, current guidelines on 
asthma treatment do not include anti-inflammatory treatment of the upper airways.1 









SABA Single dose +++ +++ ±
Longer treatment − − − ++ +++
LABA Single dose +++ +++ ±
Longer treatment ± ± ± ++ ++
ICS Single high dose ± + +
Longer treatment ++ +++ +++ n/a ++
LTRA Single dose ± ++ +
Longer treatment + ++ + n/a ±
− = negative effect, ± = neutral effect, + = positive effect
BHR = bronchial hyperresponsiveness, ICS = inhaled corticosteroid, LABA = long-acting β2-agonist, LTRA = leu-
kotriene receptor antagonist, n/a = not applicable, SABA = short-acting β2-agonist.
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1Chapter 6 focuses on the effect of intranasal corticosteroids on BHR to exercise and FeNO.
We also studied the effects of LTRAs on BHR and inflammation. Children on ICSs show a 
considerable variability in response to different step-up options, such as adding a LTRA. 
However, there is a lack of evidence to guide clinicians to the most effective option. In 
chapter 7 we aim to predict the individual responsiveness to treatment with montelu-
kast by testing the effect of a single dose on EIB. We thereby hope to pharmacologically 
phenotype patients as responders or non-responders to montelukast.
Finally, the results presented in the following chapters are summarized and discussed 
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Bronchial hyperresponsiveness (BHR), a characteristic feature of asthma, can be assessed 
through standardized bronchial provocation tests (BPTs). Exercise as a BPT is used in di-
agnosing and monitoring exercise induced bronchoconstriction (EIB). Recently a novel 
osmotic BPT has been developed, using dry powder mannitol. The aim of this study was 
to investigate the clinical utility of the mannitol challenge to identify asthmatic children 
with EIB.
materials and methods
Thirty-three clinically stable children, aged 9-18 years, with a history of EIB, performed 
both mannitol and exercise provocation challenges. Data were composed of a cross 
tabulation comparing the reaction on exercise provocation challenge to mannitol chal-
lenge. Correlations between post-exercise fall in FEV1 and response-dose ratio (RDR) and 
PD15 of mannitol were calculated.
results
Twenty-five children completed both tests. Pearson’s correlation between log-trans-
formed RDR for mannitol and post-exercise fall in FEV1 was rp = 0.666 (P < 0.001). There 
was no significant relationship between the log PD15 of mannitol and post-exercise fall 
in FEV1. Children on long-acting β2-agonists (LABAs) were significantly (P < 0.05) more 
likely to have a positive response on the mannitol challenge. Positive and negative 
predictive values of the mannitol challenge for EIB were 69% and 92%.
Conclusion
Mannitol challenge appears to be a suitable alternative for an exercise provocation 
test to assess EIB in asthmatic children. Given the negative predictive value of 92%, it is 
especially useful to exclude EIB.
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InTroduCTIon
Asthma is considered a chronic disease of the airways, characterized by inflammation, 
obstruction and hyperresponsiveness. Bronchial hyper-responsiveness (BHR) is the tran-
sient increase in airflow limitation in response to the exposure to a bronchoconstrictor 
stimulus. BHR leads to recurrent episodes of wheezing, chest tightness, breathlessness, 
and coughing.1 BHR can be assessed through the administration of bronchoconstrictor 
stimuli in standardized bronchial provocation tests (BPTs).2,3 BPTs are classified into two 
categories: ‘direct’ and ‘indirect’. Direct stimuli induce airflow limitation through a direct 
action on the effector cells, such as smooth muscle cells, bronchial vascular endothelial 
cells and mucus producing cells. Direct stimuli include pharmacological agents such 
as histamine and methacholine. Although these tests are sensitive for identifying BHR, 
they are not specific for asthma. Subjects with other pulmonary diseases and even 
healthy subjects demonstrated BHR to these agents.4-7 Indirect stimuli act on inflamma-
tory cells that interact with the effector cells, such as mast cells and neuronal cells. Pro-
inflammatory mediators and/or neurotransmitters released by these inflammatory cells 
act on the effector cells to cause airflow limitation.3 Indirect stimuli are more specific for 
identifying asthma, as they employ inflammatory cells resident in the asthmatic airway 
wall.4,7,8
Exercise is used as a BPT to diagnose and monitor exercise induced bronchocon-
striction (EIB) in children. EIB is defined as an acute, reversible bronchial obstruction 
occurring immediately after and occasionally during physical exercise. EIB is a highly 
prevalent symptom in adults and children with clinical asthma.9
Drying of the airway wall during exercise is now considered an essential determinant 
to provoke EIB. The osmolarity of the airway surface liquid increases as water is lost by 
evaporation, which causes a shift of water from the epithelial cells to the airway surface. 
This osmotic gradient induces the release of mediators that cause bronchoconstriction 
from inflammatory cells resident in the airway wall.10
The lack of sensitivity and specificity of self-reported symptoms necessitates the use 
of objective measures of lung function to confirm a diagnosis of EIB.11 Since exercise 
per se is not essential to induce the aforementioned osmotic gradient, other BPTs influ-
encing the osmolarity of the airway surface liquid have been developed. These include 
eucapnic hyperpnoea of dry air and aerosols of hypertonic saline.11 An osmotic BPT us-
ing dry powder mannitol was developed and studied during the past decade.12 Mannitol 
is effective in identifying asthmatic adults who are responsive to hypertonic saline and 
exercise13,14 and children who are responsive to methacholine.15 Responses to mannitol 
are reproducible and can be used to monitor asthma therapy with corticosteroids.16,17 
The aim of this study was to investigate the clinical utility of the mannitol challenge to 
identify asthmatic children responsive to an exercise challenge.
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Inhaled corticosteroids (ICSs) can reduce responsiveness to mannitol13,17,18 and exer-
cise.19 Regular use of long-acting β2-agonists (LABAs) can increase the airway response 
to BPTs20-22, possibly due to a desensitization of β2-adrenoreceptors on the cell mem-
brane of mast cells.23 Therefore, we compared the responses to mannitol and exercise 




Thirty-three children with a history of allergic asthma and EIB, aged 9-18 years were re-
cruited from the outpatient clinic of the pediatric department of the Medisch Spectrum 
Twente. Clinically stable, otherwise healthy children, with a forced expiratory volume in 
one second (FEV1) of at least 70% of predicted normal value, were included. Children had 
to be able to run on a treadmill and perform reproducible spirometry (i.e., coefficient of 
the predicted value variation in three of five consecutive measurements < 5%). Children 
were required to withhold the use of intranasal or systemic corticosteroids for 4 weeks; 
antihistamines, cromoglycates and anticholinergics for 2 weeks; LABAs and ICSs for 24h 
and short-acting β2-agonists for 8h before the tests. No vigorous exercise was permitted 
for 4h before the exercise challenge. All children and their parents or legal guardian 
signed an informed consent.
study design
The study is of an observational prospective cohort design. All children first performed 
an exercise challenge in cold air, with pulmonary function tests before and after the 
challenge, at the local ice rink, Euregio Kunstijsbaan, Enschede. Standard pulmonary 
function test in this study consisted of a duplicated full flow-volume loop. The second 
visit was scheduled in the local pulmonary function laboratory within 4 weeks after the 
exercise challenge. During the second visit children performed a mannitol challenge 
with pulmonary function tests before the challenge and after each subsequent dose of 
mannitol. The protocol was approved by the Medical Ethics Committee of the Medisch 
Spectrum Twente.
Pulmonary function test
A Masterscope® Jaeger®, (IBM PS 235X) was used to measure pulmonary volumes and 
flow-volume loops. This spirometer was calibrated before testing. The expiratory flow-
volume loop was recorded by instructing the children to perform a maximal expiratory 
effort from inspiratory vital capacity to residual volume. All measurements were per-
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formed in duplicate. Pulmonary function was calculated from the best curve. FEV1 was 
used as an index of BHR.
Exercise challenge
Exercise challenge testing was performed by running with nose clipped on a treadmill 
(Reebok®, TR1 premium run) using a standardized protocol.24 Baseline spirometry was 
performed and the pre-challenge FEV1 documented as the best FEV1 of two measure-
ments. During the test, heart rate was continuously monitored by a radiographic device 
(Polar Sport Tester). Cold, dry air was obtained by testing in the local ice rink with a 
constant temperature of 1°C. The test started with running at low speed on the treadmill 
with an incline of 10%. The running speed of the treadmill was increased, raising the 
heart rate to approximately 90% of the predicted maximum ((220-age) x 0.9). This speed 
was maintained for a maximum of 6 min. After the exercise challenge, flow-volumes 
were measured at t = 1, 3, 6, 9, 12, 15 and 20 min. A fall of > 15% in FEV1 from baseline 
was considered a positive response.
mannitol challenge
Baseline spirometry was performed and the prechallenge FEV1 documented as the best 
FEV1 of two measurements. The dose protocol consisted of 0 (empty capsule acting as a 
placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol. Dry powdered mannitol was 
supplied in capsules of 0, 5, 10, 20, and 40 mg. Doses of 80 and 160 mg were obtained by 
inhaling two or four capsules of 40 mg. The dry powder device used for inhalation was 
an Osmohaler® inhaler device.
The challenge started with a capsule of 0 mg mannitol. Children were asked to inhale 
from the device from near to functional residual capacity to near to total lung capac-
ity and to subsequently hold their breath for 5 sec. Children had a nose clip on during 
inhalation and were asked to exhale through their mouth to minimize deposition in the 
nasopharynx. Sixty seconds after inhalation flow-volumes were measured in duplicate 
and the best FEV1 values were retained for analysis. After flow-volume measurement 
children were given the subsequent dose within 60 sec. The procedure was repeated for 
each dose step. At each dose step the presence of cough was recorded.
Baseline FEV1 was calculated from pre-test flow-volume loops. A fall of >15% in FEV1 
from baseline was considered a positive response. The test ended when a >15% fall in 
FEV1 occurred or the cumulative dose of 635 mg mannitol had been administered. The 
lowest dose of mannitol that provoked a cough response was documented.
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statistical analysis
Best values of spirometric measurements of FEV1 were used for statistical calculations. 
Baseline % predicted FEV1 before both challenges were expressed as mean ± SD and 
compared using Student’s paired t-test.
For children positive on the mannitol challenge, the provoking dose required to cause 
a 15% fall in FEV1 (PD15; measuring airway sensivitity) was calculated by linear interpo-
lation. The response-dose ratio (RDR; measuring airway reactivity) was calculated by 
taking the final percent fall in FEV1 recorded and dividing it by the cumulative dose of 
mannitol administered to induce that percent fall.
Geometric means (Gmean) ± 95% confidence intervals (CI) were calculated using 
the log-transformed values of PD15 and RDR. Pearson’s correlation (rp) and significance 
values were used to investigate the relationship between log RDR and log PD15 and post-
exercise fall in FEV1.
Positive and negative predictive values for mannitol challenge to predict EIB were cal-
culated. Responses of children receiving treatment with LABAs or ICSs were compared 
to those of children not using these medications using a χ2-test.
The relationship between the lowest dose of mannitol that provoked a cough response 
and log RDR and log PD15 was investigated using Pearson’s correlation and significance 
values.
rEsulTs
Research population consisted of 33 children. Two children did not perform both 
tests: one child had a baseline FEV1 of < 70% predicted value and one was not able 
to perform reproducible spirometry. During mannitol challenge, three children (9.7%) 
experienced a cough persistent enough to terminate the challenge. Of the 28 children 
who completed both challenges, three children had a change in medication between 
the challenges and were excluded. Data from 25 children were used for comparison of 
the tests (Table 1). Among them were 17 boys and 8 girls. Mean age (±SD) was 12.4 ± 2.0 
years. Baseline FEV1 before mannitol had a normal distribution with a mean (±SD) of 97.4 
± 16.6% predicted value, which was not significantly different from baseline FEV1 before 
exercise (99.3 ± 20.1% predicted value).
Thirteen children (52%) had a positive response on the mannitol challenge. Their 
dose-response curves are shown in Fig. 1. Mean (±SD) difference between FEV1 at base-
line and FEV1 after 0 mg mannitol was 0.024 (±0.096) L/sec, which was not significant 
using Students’ paired t-test.
Geometric mean [95% CI] for the RDR for mannitol was 0.0086 [CI: 0.0031-0.0248]. 
Pearson’s correlation between log-transformed RDR for mannitol and fall in FEV1 after 
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exercise was rp = 0.666 (P < 0.001) (Fig. 2). Geometric mean [95% CI] for the PD15 for chil-
dren positive on the mannitol challenge was 84 mg [CI: 26-266]. There was no significant 
relationship between the log PD15 of mannitol and the percent fall in FEV1 after exercise 
(rp = -0.29, P = 0.34) (Fig. 3).
No significant correlation was found between the lowest dose of mannitol that pro-
voked a cough response and log PD15 and log RDR to mannitol. Of the three children that 
terminated the mannitol challenge due to coughing, two were unresponsive to exercise, 
suggesting that the severity of the cough was not related to the presence of EIB.
Table 1. Research population: Baseline characteristics and responses to challenges












1 M 14.7 + + 90 149 15.6 32.2
2 V 10.2 + + 132 > 635 4.2 4.9
3 M 10.3 - - 97 > 635 2.2 7.3
4 M 11.2 + + 117 258 18.3 42.5
5 V 16.1 - - 96 > 635 5.2 13.4
6 M 12.6 - + 105 11 21.1 28.9
7 M 12.5 + - 80 > 635 10.5 17.5
8 M 14.3 + + 119 247 19.1 30.3
9 V 11.5 + - 117 > 635 11.2 12.4
10 M 12.1 - + 109 400 17.8 10.4
11 V 10.2 - - 104 43 26.3 4.8
12 M 13.7 - + 90 > 635 -3.6 12.5
13 M 11.7 + + 65 256 18.5 4.8
14 M 11.3 - + 97 61 18.5 13.0
15 M 12.2 + - 128 > 635 8.8 6.2
16 M 14.6 + - 101 > 635 14.6 5.4
17 M 15.2 - - 96 > 635 2.6 12.8
18 M 10.3 - - 93 109 21.3 26.6
19 V 11.2 + + 92 > 635 7.1 3.7
20 M 9.8 + - 90 29 18.1 28.6
21 M 17.1 - - 82 > 635 13.5 9.2
22 M 14.3 + - 86 > 635 9.4 5.6
23 V 11.2 + + 96 53 21.2 32.4
24 V 13.1 + + 67 14 15.8 61.2
25 V 10.3 + + 85 151 15.3 45.4
†As measured before the mannitol challenge. FEV1 = forced expiratory volume in 1 s, ICS = inhaled corticosteroid, 































Cumulative dose mannitol (mg)
fig. 1. Individual dose-response curves relating % fall in FEV1 after mannitol to the cumulative dose of man-
nitol inhaled in children responsive to mannitol.

























fig. 2. Relationship between log-transformed response-dose ratio to mannitol and % fall in FEV1 after exer-
cise. Pearsons correlation coefficient, rp = 0.666, P < 0.001.
FEV1 = forced expiratory volume in 1s, RDR = response dose ratio, % fall in FEV1 / cumulative dose.
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Ten children (40%) had a positive response on the exercise challenge. Nine (36%) were 
positive on both challenges and 11 (44%) negative on both challenges (Table 2). Positive 
predictive value of the mannitol challenge for EIB was 69%. Negative predictive value 
was 92%.
Using χ2-test children on LABAs were significantly (P < 0.05) more likely to have a 
positive response on the mannitol challenge. Using Students’ independent samples 
t-test, there was no significant difference (P = 0.258) in mean fall in FEV1 after mannitol 
for children on LABAs. There was no difference in response to mannitol or exercise for 
children on ICSs.
Median time to perform a mannitol challenge was 24 min (range 6-30). Median time 
for children who were responsive to mannitol was 16 min (range 6-24). Mean maximum 
percent fall in FEV1 after mannitol was 13.3 ± 7.3%. None of the children had a fall of 
>30% in FEV1. FEV1 recovered spontaneously in eight children (62%) and after the ad-































fig. 3. Relationship between mannitol PD15 and % fall in FEV1 after exercise. (I) Children negative to both 
challenges. (II) Children positive to mannitol but negative to exercise. (III) Children positive to both chal-
lenges. (IV) Children negative to mannitol but positive to exercise.
FEV1 = forced expiratory volume in 1s, PD15 = provoking dose to cause a 15% fall in FEV1.
Table 2. Responses to mannitol and exercise provocation challenges
Exercise positive Exercise negative Total
mannitol positive 9 4 13
mannitol negative 1 11 12
Total 10 15 25
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Median time for an exercise challenge was 40 min (range 30-70). In children positive 
on the exercise challenge, maximum percent fall in FEV1 occurred 2.9 ± 2.0 min post-
exercise. Mean maximum fall in FEV1 was 18.9 ± 15.3%, and six children had a fall of 
>30% in FEV1.
dIsCussIon
The mannitol challenge can be used in children as a screening tool to assess EIB. There 
was a significant relationship between reactivity to inhaled mannitol, measured by log 
RDR, and fall in FEV1 after exercise. Sensitivity to inhaled mannitol, measured by log PD15, 
was not related to fall in FEV1 after exercise. There were three children (9.7%) who experi-
enced a cough severe enough to terminate the challenge. Positive and negative predic-
tive values of the mannitol challenge for EIB were 69% and 92%. All subjects positive on 
the exercise challenge had a positive response to mannitol, except for one subject, who 
had only a borderline (17.5% fall in FEV1) response to exercise. This indicates that the 
mannitol challenge can be useful as a diagnostic test to exclude EIB.
This study was the first to demonstrate that the mannitol challenge is valuable in 
identifying EIB in children. Similar results have been observed in adults. In a study by 
Brannan et al.14,24 among 23 asthmatic adults responsive to exercise, all but one were 
responsive to mannitol (sensitivity 95.7%).
Especially in children, it is important to identify and treat EIB. Physical exercise not only 
has physical benefits for asthmatic children, but also plays a key role in their social and 
neuromotor development. The mannitol challenge was already recognized as a useful 
test in identifying children with currently active asthma and those who are responsive to 
methacholine.15 It showed good repeatability in asthmatic children16 and its safety was 
demonstrated in 592 asthmatic and non-asthmatic subjects, including 126 children.13
This study demonstrated a significant relationship between the log RDR to mannitol 
and fall in FEV1 after exercise. The RDR data and calculations were previously described 
in a phase 3 study by Brannan et al.13 and Koskela et al.17 found that log RDR to mannitol 
correlated with log RDR to histamine provocation challenge and that it was reduced by 
treatment with budesonide. The log RDR to mannitol could therefore be used to assess 
the effect of treatment.
The mannitol challenge is a progressive dose-response test that is terminated when 
FEV1 falls >15% from baseline. This prevents a vigorous fall in FEV1 (>30%), which is an 
important safety feature. In this study, six children experienced a fall in FEV1 of >30% after 
the exercise challenge, while none had such a fall in FEV1 after the mannitol challenge.
The mannitol challenge was faster to perform than the exercise challenge. Median 
time for a mannitol challenge was 24 min (range 6-30). Median time for children re-
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sponsive to mannitol was 16 min, which is similar to challenge time reported in other 
studies.15,16 Median time for an exercise challenge was 40 min (range 30-70). This was 
mostly attributable to a prolonged recovery time (> 10 min after the administration of 
a β2-agonist) in nine children. Most of them (eight) were on long-term treatment with a 
LABA, which could have caused the prolonged recovery. Storms et al.25 found that after 
4 weeks of treatment with salmeterol approximately 20% of patients failed to return to 
their baseline status 30 min after rescue β2-agonist administration.
The protocol used for the exercise challenge slightly deviates from that suggested by 
the ATS.24 A different measurement of reproducibility was used, that appears more suit-
able for children: a <5% difference between the two highest FEV1 measurements.26,27 
The criterion for a positive response to exercise is controversial. A fall of 10% or more is 
considered abnormal; a fall of 15% appears to be more diagnostic of EIB, particularly if 
exercise has been performed in the field. Haby et al.28 when testing 8-11 year old healthy 
children in the field, found that the fall in FEV1 for 1.96 SD above the mean in this ‘normal’ 
group was 15.3%. Godfrey et al.5 suggested an optimal cut-off point of 13% for children 
and adolescents. Because the environmental circumstances in which the test was per-
formed were more similar to outdoor circumstances than to laboratory settings, a cut-
off value of 15% was used. A cut-off value of 10% would change the results. Six children 
that were considered negative on the exercise challenge are then considered positive. 
This would lead to a reduction in false positive subjects on the mannitol challenge from 
4 to 2 children, raising the positive predictive value to 85%. The number of false negative 
subjects would increase, reducing the negative predictive value to 58%.
In this study we used the FEV1 value at baseline prior to the mannitol challenge to 
calculate the percent fall in FEV1 and PD15 values. The standardized procedure is to use 
the FEV1 value measured after the 0 mg capsule. There was no significant difference be-
tween FEV1 measured at baseline and after 0 mg mannitol. Therefore, using FEV1 values 
measured after the 0 mg capsules would not have changed the results of this study.
Mannitol challenge was performed within 4 weeks after the exercise provocation 
challenge. The length of this interval could have influenced the results of this study. 
During these 4 weeks, two children had a change in medications and were excluded 
from the study. None of the other children had an asthma exacerbation or a respiratory 
tract infection during this period. Baseline FEV1 measured before both challenges was 
not significantly different.
Mannitol was generally well tolerated and there were no serious adverse events re-
ported. However, all children experienced a cough. This was usually a mild cough, but 
in three children it was a reason to terminate the challenge. These three children were 
excluded because their coughing was persistent enough to interfere with the fixed 
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time schedule of the mannitol challenge protocol. Coughing can be a limitation of the 
challenge when it prolongs the time between inhalation and spirometry. The mannitol 
challenge should be performed quickly, as the rate of change in osmolarity is suggested 
to be the determinant of BHR.15 Prolonging the time could therefore lead to a milder 
osmotic stimulus and give falsely negative results.
Mannitol provoked coughing was described previously and can be divided in an im-
mediate cough and one occurring after a time lag. In the three children excluded from 
the study coughing occurred immediately after inhalation, suggesting it was due to the 
impaction of powder on the oropharynx.14,15 The Osmohaler® is a low-resistance inhaler, 
permitting inhalation at high flow rates, which increases the rate of impaction on the 
oropharynx. Coughing occurring after a time lag can be attributed to the deposition 
of powder in the lower respiratory tract. Nerve fibers can be stimulated by hyperosmo-
latity29,30, which may lead to coughing. Koskela et al.31 found coughing to be related to 
the increased sensitivity of the asthmatic airways, making it useful in the diagnosis of 
asthma.
Out of the three children that were excluded, two were unresponsive to exercise, sug-
gesting that the severity of the cough was not related to the extent of EIB. Furthermore, 
we recorded the lowest dose that provoked a cough response in all children and found 
no correlation between the dose that first provoked a cough response and log PD15 and 
log RDR to mannitol.
The development of the mannitol provocation challenge was based on the theory that 
EIB is provoked by an increase in airway osmolarity. Water is lost by the humidifying of 
large quantities of dry air during exercise, causing a shift of water from the epithelial 
cells to the airway surface. Loss in cell volume leads to intracellular events that cause the 
release of inflammatory mediators from mast cells and eosinophils.10 The intracellular 
events that occur are the same whether the hyperosmolarity is caused by evaporation or 
by adding a hyperosmolar stimulus like mannitol. An essential difference however is the 
rate of change in osmolarity. Mannitol might be a more potent dehydrating stimulus to 
the airway than exercise. This could explain why some children with a positive response 
on the mannitol challenge were negative on the exercise challenge. Another possible 
explanation for this is that exercise induces a variety of other physiologic changes, such 
as the release of adrenal hormones (steroids and catecholamines), protecting the airway 
from narrowing.
Children on LABAs were significantly (P < 0.05) more likely to have a positive response 
on the mannitol challenge. These children did not have a more sensitive response to 
exercise. An increased airway response to BPTs after regular use of β2-agonists has been 
reported in other studies.20-22 Although single doses of LABAs can inhibit mediator release 
from mast cells, it was proposed that regular use desensitizes β2-adrenoreceptors on 
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mast cells and thereby decreases cell membrane stability. This hypothesis is supported 
by the finding of a significant increase in mast cell mediator tryptase following an al-
lergen challenge after treatment with salbutamol compared to placebo.23 A decreased 
stability of mast cells could explain the more sensitive response to mannitol.
In this study, half of the children using ICSs were still positive on either one or both 
of the challenges, although ICSs have been shown to reduce responsiveness to man-
nitol13,17,18 and exercise.19 These children might need an adjustment in their medication 
or dosage.
Mannitol challenge appears to be a suitable alternative for an exercise provocation test 
to assess EIB in asthmatic children. Given the negative predictive value of 92%, it is espe-
cially useful to exclude EIB. It is a practical option for use as an office-based test and has 
the potential to appeal to the wider health-care community, because of the simplicity 
and inexpensive nature of the equipment used. It is faster and easier to perform than an 
exercise provocation test, and does not require specifically trained personnel or special-
ized equipment such as treadmills and/or a dry air source. It does not require strenuous 
exercise or specific motor skills from the patient, and is therefore useful to asses EIB in 
disabled children. Furthermore, it has a built-in safety feature of a progressive dose-
response challenge; the test can be stopped before severe falls in FEV1 occur. Further 
research is required to assess the clinical utility of the mannitol challenge in monitoring 
asthma therapy in children and to define the sensitivity and specificity of the mannitol 
challenge in a larger study population of asthmatic children.
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Pilot Study: The Effect of Reducing 










Asthma therapy should be stepped up or stepped down in response to changes in 
asthma control. However, there is little evidence available on the optimal timing, se-
quence and degree of medication reductions. In this study we analyzed clinically stable 
asthmatic children who underwent a medication reduction from a combination prepa-
ration consisting of an inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) to 
monotherapy with the same dose of the ICS. We hypothesized that the extent of exercise 
induced bronchoconstriction (EIB) would not increase after the cessation of the LABA.
methods
Nineteen children, aged 8-16 years, with clinically stable asthma, receiving LABA/ICS 
combination therapy, were analyzed in this open-label pilot study. Children performed 
an exercise challenge at baseline and 3 weeks after the medication reduction. Best 
values of spirometric measurements of the forced expiratory volume in 1 sec (FEV1) were 
used for statistical calculations.
results
Maximum percent fall in FEV1 was significantly lower after 3 weeks of ICS monotherapy 
(P = 0.03). Eight of 19 children had a ≥ 15% fall in FEV1 after exercise at the initial ex-
ercise challenge. In this subgroup, maximum percent fall in FEV1 after the medication 
reduction was significantly lower (P < 0.01), and in six children it decreased to < 15%, 
indicating they no longer had EIB.
Conclusion
In clinically stable asthmatic children on LABA/ICS combination therapy, the cessation of 
the LABA can reduce and in most cases abolish EIB.
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InTroduCTIon
According to international guidelines, asthma therapy should be stepped up or stepped 
down in response to changes in asthma control.1,2 Combination therapy with an inhaled 
corticosteroid (ICS) and long-acting β2-agonist (LABA) is often prescribed as the third step 
in treatment regimens.1,2 There are many arguments in favor of this combination.3 A meta-
analysis reviewing LABA treatment for childhood asthma concluded that the addition 
of a LABA to an ICS improved pulmonary function measures, reduced the use of rescue 
medications and improved quality of life measures.4 LABAs are also effectively used as 
prophylaxis for exercise induced bronchoconstriction (EIB).5-7 EIB occurs in the majority of 
asthmatic children and is an index of airway hyperresponsiveness (AHR). However, regular 
use of LABAs can lead to downregulation of the β2-adrenoreceptor (β2AR), resulting in 
the development of tolerance.8 This implies that the duration of the bronchoprotective 
effect of a LABA against EIB is reduced.6,7,9,10 Furthermore, the recovery time from EIB to 
pre-exercise lung function after rescue therapy with a short-acting β2-agonist (SABA) is 
prolonged.11,12 Regular treatment with SABAs can even enhance the severity of EIB.11,13
By reviewing the medical records of asthmatic adults, Yawn et al. found that only 
13% of medication changes were step-down changes.14 Reductions of the dosage were 
about twice as common as steps down in the class of medication prescribed. There 
is little evidence available on the optimal timing, sequence and degree of treatment 
reductions. When asthma is controlled with LABA/ICS combination therapy, the sug-
gested step-down approach for adult asthmatics is to reduce the dose of the ICS.15-17 An 
alternative that is recommended by the FDA18 is to discontinue the LABA and continue 
ICS monotherapy at the same dose.1,2 The effect of stepping down treatment from LABA/
ICS combination therapy to ICS monotherapy on EIB has not yet been studied.
In this study, we analyzed this medication reduction in clinically stable asthmatic 
children. Because the development of tolerance has an impact on the severity of EIB, we 
hypothesized that the extent of EIB would not increase after the cessation of the LABA.
maTErIals and mEThods
subjects
Children were recruited from the outpatient clinic of the Medisch Spectrum Twente 
in Enschede. Fifty-two children with clinically stable asthma for > 3 months receiving 
treatment with LABA/ICS combination therapy, who underwent a medication reduction 
according to treatment guidelines,1,2 were selected. Twenty-four otherwise healthy 
children, aged 8-16 years, with a history of allergy (confirmed by a positive RAST test on 
≥ 1 allergen) and EIB (confirmed by a previous exercise challenge) were asked to partici-
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pate in this study. Twenty children signed an informed consent form and were included 
in the study. Children had to be able to run on a treadmill and perform reproducible 
spirometry (i.e., variation of percentage of the predicted value in 3 of 5 consecutive 
measurements < 5%). Their forced expiratory volume in one second (FEV1) had to be 
at least 70% of predicted normal value. Children were required to withhold the use of 
leukotriene receptor antagonists (LTRAs), intranasal steroids, LABAs and ICSs for 24h and 
SABAs for 8h before both exercise challenges. No vigorous exercise was permitted for 4h 
before an exercise challenge.
study design
This was an open-label pilot study. Children and their parents were contacted twice, 4 
and 2 weeks prior to the first visit, to inform them about the importance of medication 
adherence. During the initial visit all children were asked to fill out Juniper’s asthma 
control questionnaire (ACQ) and pediatric asthma quality of life questionnaire (PAQLQ). 
They performed an exercise challenge, with pulmonary function tests before and after 
the challenge, at the local ice rink, Euregio Kunstijsbaan, Enschede. Standard pulmonary 
function test in this study consisted of a duplicated expiratory flow-volume loop.
After the initial visit treatment was reduced from LABA/ICS combination therapy to 
monotherapy with the same dose of the ICS. The second visit was scheduled at the local 
ice rink 3 weeks after the first visit. During the second visit children were again asked to 
fill out both questionnaires and performed a second exercise challenge. This study was 
conducted with permission from the local Medical Ethics Committee.
Questionnaires
The ACQ has seven questions, scoring five symptoms, baseline FEV1 % predicted and 
daily rescue bronchodilator use. Children can respond to these questions on a 7-point 
scale (0 = no impairment, 6 = maximum impairment). Baseline FEV1 % predicted is also 
scored on a 7-point scale. The questions are equally weighted and the ACQ score is 
the mean of the seven questions and therefore between 0 (totally controlled) and 6 
(severely uncontrolled).
The PAQLQ has 23 questions in three domains; symptoms, activity limitation and 
emotional function. Children can respond on a 7-point scale (1 = maximum impairment, 
7 = no impairment). The total PAQLQ score is the mean of all 23 questions and therefore 
between 1 (impaired quality of life) and 7 (no impairment in quality of life). Domain 
scores are the means of the items in those domains.
fraction of exhaled nitric oxide
FeNO was measured before any forced expiratory maneuvers according to current 
guidelines19 at an exhaled flow rate of 50 mL/sec. The single-breath online measure-
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ment method was used to measure FeNO. Children were asked to exhale to residual 
volume and then inhale gas with a low NO concentration through a hand-held nitric 
oxide analyzer (Niox Mino®, Aerocrine, Stockholm, Sweden). Children inhaled to near to 
total lung capacity and immediately exhaled at a constant flow rate.
Pulmonary function test
A MicroLoop MK8 Spirometer (ML3535)®, with Spida5® software, was used to measure 
pulmonary volumes and flow-volume loops. The calibration of this spirometer was 
checked before testing. The expiratory flow-volume loop was recorded by instructing 
the children to perform a maximal expiratory effort from inspiratory vital capacity to 
residual volume. All measurements were performed in duplicate using a standard pro-
tocol.20 Pulmonary function was calculated from the best curve.21
Exercise challenge
Exercise challenge testing was performed by running with nose clipped on a treadmill 
(Reebok®, TR1 premium run) using the standardized ATS protocol.22 A constant tempera-
ture of 10°C and absolute humidity of 4.2 g/kg (relative humidity of 56%) was obtained 
by testing in the local ice rink. Baseline spirometry was performed and the pre-challenge 
FEV1 documented as the best FEV1 of two measurements. The test started with running 
at low speed on the treadmill with an incline of 10%. During the test, heart rate was 
continuously monitored by a radiographic device (Inventum SH 40®). The running speed 
of the treadmill was increased, raising the heart rate to ~90% of the predicted maximum 
((220-age) x 0.9). This speed was maintained for 6 min. After the exercise challenge, flow 
volumes were measured at t = 1, 3, 6, 9, 12, 15 and 20 min. Maximum percent fall in FEV1 
was used for further analysis. A fall of ≥ 15% in FEV1 from baseline was considered a 
positive response.
statistical analysis
Best values of spirometric measurements of FEV1 were used for statistical calculations 
with SPSS® Statistics Version 17.0 for Windows®. Data were split into two groups: children 
with EIB during the initial visit (defined as a ≥ 15% fall in FEV1 after exercise) and chil-
dren without EIB. Further calculations were performed on both groups separately and 
together. The same analysis was performed on children with a ≥ 10% fall in FEV1 after the 
initial exercise challenge.
Baseline percent predicted FEV1 before both challenges were expressed as mean ± SD 
and compared using Student’s paired t-test. Symptom scores on the ACQ and PAQLQ be-
fore both challenges were compared using Wilcoxon’s signed-rank test. Maximum percent 
fall in FEV1 after both exercise challenges were compared using Student’s paired t-test.
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Spearman’s rank order correlation coefficient was calculated for the correlation be-
tween ACQ and PAQLQ scores and % fall in FEV1 after exercise.
rEsulTs
Research population consisted of 20 children. One child was excluded from analysis be-
cause he was not able to perform reproducible spirometry. Data from 19 children were 
used for analysis (Table 1). Among them were 13 boys and 6 girls. Mean age (± SD) was 
11.2 ± 2.8 years. Fifteen children were using the combination preparation fluticasone/sal-
meterol (median dose fluticasone 400µg) before the first visit and stepped down to flutica-
sone monotherapy and 4 children were using the combination preparation budesonide/
formoterol (median dose budesonide 400µg) before the first visit and stepped down to 
budesonide monotherapy. Six children were on a LTRA and six on an intranasal steroid.








% fall in fEv1
laBa/ICs ICs laBa/ICs ICs
1 F 10 FP/SAL 500 + 87 84 5.1 9.5
2 M 8 FP/SAL 300 - 93 101 5.4 3.3
3 M 15 BUD/F 400 + 123 125 17.9 16.5
4 M 15 FP/SAL 200 - 90 92 27.0 4.0
5 M 10 FP/SAL 500 - 95 85 17.8 6.3
6 M 11 FP/SAL 200 - 81 86 26.0 6.6
7 F 8 FP/SAL 200 - 94 111 2.2 9.1
8 F 8 FP/SAL 500 - 96 98 9.0 4.4
9 F 8 BUD/F 600 + 78 74 5.7 12.2
10 M 8 FP/SAL 500 + 72 73 25.2 13.3
11 M 8 FP/SAL 500 - 101 105 6.7 3.7
12 F 9 FP/SAL 200 - 99 99 7.9 2.1
13 M 12 BUD/F 400 - 111 113 20.4 8.6
14 M 12 FP/SAL 300 + 99 97 11.2 6.5
15 F 13 FP/SAL 500 - 101 96 5.1 7.1
16 M 14 FP/SAL 500 - 90 85 33.4 29.0
17 M 8 FP/SAL 250 - 94 97 33.3 8.1
18 M 10 FP/SAL 400 + 70 66 3.3 17.1
19 M 16 BUD/F 400 - 115 111 12.4 3.1
BUD/F = budesonide / formoterol, FP/SAL = fluticasone proprionate / salmeterol, ICS = inhaled corticosteroid, 
LABA = long-acting β2-agonist, LTRA = leukotriene receptor antagonist.
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Baseline FEV1 before the initial exercise challenge had a normal distribution with a 
mean (± SD) of 94.1 ± 13.6% predicted value, which was not significantly different from 
baseline FEV1 3 weeks after the medication reduction (94.6 ± 15.1% predicted value).
Mean maximum heart rate during the first exercise challenge was 87.6 ± 4.2% of 
maximum heart rate, which was not significantly different from mean maximum heart 
rate during the second challenge (87.2 ± 3.9%). SABA use was monitored by the asthma 
control questionnaire (question 6). Before the first exercise challenge (before LABAs 
were stopped) children reported an average use of 3.4 puffs of SABA per week (including 
pre-exercise use). After the medication reduction children reported an average use of 
4.2 puffs per week.
Mean maximum percent fall in FEV1 after the first exercise challenge was 14.5 ± 10.4%. 
Maximum percent fall in FEV1 after the second exercise challenge was significantly lower 
(P = 0.03), with a mean of 9.0 ± 6.5% (Fig. 1 and Fig. 2). In 14 children the response to an 
exercise challenge, measured by the maximum percent fall in FEV1, decreased after the 
medication reduction. In five children the response to an exercise challenge increased.
There were eight children on LABA/ICS combination therapy that experienced EIB; 
defined by a ≥ 15% fall in FEV1 after exercise. This subgroup had a mean maximum per-
cent fall in FEV1 after the first exercise challenge of 25.1 ± 6.2%. Maximum percent fall in 
FEV1 after the second exercise challenge was significantly lower (P < 0.01), with a mean 






















fig. 1. Mean ± SD % fall in FEV1 after exercise challenge after combination therapy and after 3 weeks of 
treatment with ICS monotherapy.
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.
64 Chapter 3
of 11.6 ± 8.1% (Fig. 3 and Fig. 4). In all eight children, maximum percent fall in FEV1 after 
exercise decreased after the medication reduction. In six children, maximum percent fall 
in FEV1 was < 15%, indicating they were no longer experiencing EIB.
There were 11 children on LABA/ICS combination therapy without EIB (fall in FEV1 < 
15%). In this subgroup, there was no change in mean maximum percent fall in FEV1 after 
the medication reduction (Fig. 5) Only one child developed mild EIB (fall in FEV1 17.1%) 
after the medication reduction. Analysis using a cutoff of ≥ 10% fall in FEV1 provided 
similar statistically significant results.
At the initial visit asthma was generally well controlled with a median [range] score on 
the ACQ of 0.86 [3.00]. The children’s quality of life was generally not impaired, with a 
total median [range] score on the PAQLQ at the initial visit of 5.8 [3.6] and a median 
score in the symptoms domain of 6.0 [2.7]. At the second visit median score on the ACQ 
was 0.71 [3.57], which was not significantly different from the initial score. Total and 
symptom scores on the PAQLQ were respectively 6.3 [3.8] and 6.1 [3.7], which were not 
significantly different from the initial scores.
There was a correlation between scores on the ACQ and PAQLQ (Spearman’s rho = 0.43, 
P = 0.01). There was no correlation between scores on the ACQ or PAQLQ and maximum 
percent fall in FEV1 after exercise.
FeNO was measured at both visits in 14 patients. Mean ± SD was 16.6 ± 5.9 ppb after 

















fig. 2. Mean FEV1 after exercise and after 100 µg rescue Salbutamol.
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.






















fig. 3. Individual change in % fall in FEV1 after exercise for those patients with ≥ 15% fall in FEV1 at the first 
exercise challenge (n = 8).
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.























fig. 4. Mean ± SD % fall in FEV1 after exercise challenge after combination therapy and after 3 weeks of 
treatment with ICS monotherapy for those children with a ≥ 15% fall in FEV1 at the first exercise challenge.
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.
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dIsCussIon
In this study, we monitored a medication reduction from LABA/ICS combination therapy 
to monotherapy with the same dose of the ICS in clinically stable asthmatic children. 
Mean maximum percent fall in FEV1 after an exercise challenge was significantly lower (P 
= 0.03) after the medication change. In a subgroup of 8 children with a ≥ 15% fall in FEV1 
after the first exercise challenge, maximum percent fall in FEV1 reduced in all children 
after the medication change (P < 0.01). Of this subgroup, 6 children had a maximum 
percent fall in FEV1 < 15% after the second exercise challenge, indicating they were no 
longer experiencing EIB. This suggests that in asthmatic children on LABA/ICS combina-
tion therapy, the cessation of the LABA can reduce and in most cases abolish EIB.
To our knowledge, the effect of reducing treatment from LABA/ICS combination 
therapy to ICS monotherapy on EIB has not yet been studied. According to international 
guidelines1,2 treatment choices should be guided by asthma control. Once asthma control 
is achieved and maintained for at least 3 months, a step down can be considered. When 
asthma is controlled with LABA/ICS combination therapy, the suggested approach for 
adults is to reduce the ICS by approximately 25–50% every 3 months to the lowest dose 
possible.1,2 An alternative that was recently recommended by the FDA18 is to discontinue 





















fig. 5. Individual change in % fall in FEV1 after exercise for those patients with <15% fall in FEV1 at the first 
exercise challenge (n = 11).
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.
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dose of the ICS is considered more effective than switching to an ICS alone.15-17 The ces-
sation of the LABA could result in a deterioration of asthma control.15-17 However, the 
benefits shown in these studies were largely a measure of the β2-agonist effect, such 
as improved peak expiratory flow and reduced rescue use of SABAs. On the contrary, a 
report by Weinberger and Abu-Hasan23 describes an example of two adolescent patients 
whose EIB improved after the replacement of salmeterol with slow-release theophylline.
We analyzed the effect of stepping down treatment on EIB because EIB occurs in the 
majority of asthmatic children and is considered to have a great impact on their quality 
of life24 (although we found no correlation between the extent of EIB and PAQLQ scores). 
Measuring the airway response to exercise can be used as an indicator of AHR, which 
is indirectly associated with airway inflammation. Titrating treatment guided by AHR 
leads to fewer uncontrolled episodes in adults with asthma25 and prevented a decline in 
lung function in children with asthma.26 This suggests that AHR is an indirect marker of 
asthma control.
A possible limitation of this study is the lack of a control group in whom we did not 
change the medication regimen. In this pilot study, we decided to analyze regular 
medication reductions, based on clinical decisions. However, the lack of a control group 
makes this study susceptible to bias. The variability in fall in FEV1 in standardized exercise 
challenges and regression to the mean may have influenced our results. However, chil-
dren included in this study were clinically stable and their asthma was well controlled, 
as was confirmed by their baseline lung function, low FeNO levels and ACQ scores. To 
exclude a learning bias, only children who had performed an exercise challenge before 
were included. The consistent decrease in fall in FEV1 shown in children with EIB (Fig. 3) 
cannot be solely contributed to regression to the mean, neither can the mean decrease 
in maximum percent fall in FEV1 from 25.1% to 11.6%. In an epidemiological study by 
Haby et al. reproducibility of the % fall in FEV1 to a standardized exercise challenge was 
assessed by the calculation of the single measurement 95% range. A 95% range of ±12% 
was calculated, meaning that there is a 95% probability that the true value for a subject 
is within the range of 12% fall in FEV1 around the single measurement value.27
Exercise challenge responses may be influenced by climatic and environmental fac-
tors such as circulating allergen. To exclude a seasonal bias, this study was performed 
outside the main pollen season. Second visits were planned 3 weeks after the first visit. 
There were no differences between baseline FEV1 % predicted, FeNO levels and scores 
on the ACQ and PAQLQ before both challenges.
To optimize adherence, children and their parents were informed about its impor-
tance 4 weeks prior to the first exercise challenge and again by a telephonic contact 2 
weeks prior to the first exercise challenge. At the first visit to the ice rink, they reported 
an adherence of 86 ± 12%.
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A reversal of the previously developed tolerance due to regular use of LABAs could 
explain the reduction in EIB when LABAs were discontinued. Regular use of LABAs 
leads to downregulation of the β2AR.8 This results in a reduction of the duration of the 
bronchoprotective effect of a LABA against EIB 6,7,9,10 and a prolonged recovery time from 
EIB after rescue therapy with a SABA.11,12 Although corticosteroids increase transcription 
of the β2AR-gene, which could theoretically compensate for the downregulation of the 
β2AR,3 tolerance is not prevented by the concomitant use of ICSs.9,12,28-30
In addition to the development of tolerance to the bronchoprotective and broncho-
dilator effects, a growing body of evidence supports the hypothesis that regular use of 
β2-agonists could increase AHR, especially to allergen.11,13,31-33 The increase in sputum 
inflammatory cells31,34 after regular use of β2-agonists suggests they could paradoxically 
have a pro-inflammatory effect. Regular exposure to LABAs can cause functional desen-
sitization of the β2AR in mast cells35 and airway smooth muscle.36 The complex signaling 
pathway underlying the relationship between AHR and the β2AR is still being explored. 
There appears to be a differentiation between downregulation of the β2AR (causing less 
effective bronchodilation) and enhanced contractile signaling (causing enhanced AHR) 
due to chronic activation of the β2AR.37 Both occur with regular use of β2-agonists.
LABAs have been demonstrated to be useful for many patients whose symptoms 
are not adequately controlled with conventional doses of ICS alone3,4. However, in this 
pilot study, we demonstrated that in clinically stable asthmatic children on LABA/ICS 
combination therapy, the cessation of the LABA can reduce and in most cases abolish 
EIB. Therefore, if EIB can still be demonstrated in children whose asthma is controlled 
with LABA/ICS combination therapy, changing therapy to ICS monotherapy should 
be considered. Further research is required to determine whether this applies to the 
general population or to a specific subgroup of patients.
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The Effect of Stepping Down Combination 










Controversy exists about the safety of long acting β2-agonist (LABA) treatment, in par-
ticular in children. Combination therapy with a LABA and an inhaled corticosteroid (ICS) 
is prescribed to children with moderate asthma and can be stepped down by withdrawal 
of the LABA when asthma is well controlled.
objective
To analyze the effect of stepping down from LABA/ICS combination therapy to mono-
therapy with the same dose of ICS on the airway response to mannitol in asthmatic 
children.
methods
17 children, aged 12-17 years, with clinically stable asthma, receiving combination 
therapy, were analyzed in this observational prospective open-label study. Children 
performed a mannitol challenge at baseline and 30 ± 4 days after their medication was 
stepped down to ICS monotherapy. The changes in the provoking dose of mannitol to 
cause a 15% fall in FEV1 (PD15), response-dose ratio and recovery time following a short-
acting β2-agonist to ≥ 95% of baseline FEV1 were assessed.
results
Mannitol PD15 and response-dose ratio did not significantly change after stepping 
down. The recovery time following a short-acting β2-agonist to ≥ 95% of baseline FEV1 
was significantly shorter (P = 0.01) after the withdrawal of the LABA.
Conclusions
In short-term follow up, stepping down clinically stable asthmatic children from com-
bination therapy to monotherapy with an ICS does not change airway hyperrespon-
siveness (AHR) to mannitol but does shorten recovery time to baseline lung function 
following a rescue short-acting β2-agonist.
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InTroduCTIon
Clinical guidelines recommend to step up asthma therapy when asthma is not well-
controlled on a low to moderate dose of inhaled corticosteroids (ICSs).1,2 In adults the 
addition of a long-acting β2-agonist (LABA) leads to better asthma control than increas-
ing the dose of ICSs.3 In children however, combination therapy did not lead to a sig-
nificant reduction, but rather a trend towards an increased risk of asthma exacerbations 
and hospital admissions.3 These trends raised concern about the safety of combination 
therapy in children and questions on whether and when the LABA should be withdrawn 
when stepping down from combination therapy. The suggested step down approach by 
current guidelines for asthmatic adults is to reduce the ICS to the lowest dose possible, 
while continuing the LABA.1,2 An alternative approach, that was recently suggested by 
the US Food and Drug Administration, is to discontinue the LABA once asthma control is 
achieved and continue the ICS at the same dose.4
In a recent study in asthmatic adults by Reddel et al., both step down approaches 
were compared, and found to result in no significant difference in FEV1, rescue bron-
chodilator use, methacholine PD20, sputum eosinophils and FeNO.5 However, moderate 
exacerbations were less frequent and subjects could be titrated to a lower dose of ICSs in 
subjects on combination therapy.5 Previous studies in asthmatic adults comparing both 
step down approaches found a deterioration of morning peak expiratory flow, daily 
symptoms and bronchodilator use in subjects whose LABA was withdrawn.6-8 The effect 
of withdrawal of the LABA from combination therapy on airway hyperresponsiveness 
(AHR) in children has not been extensively studied.
Regular use of short-acting β2-agonists (SABAs) and LABAs leads to downregulation 
and desensitization of the β2-adrenoreceptor9, which affects AHR in several ways. Firstly, 
it results in a reduced bronchodilator effect of rescue SABA treatment in circumstances 
of acute bronchoconstriction: bronchodilator tolerance. Bronchodilator tolerance devel-
ops after a single dose of a LABA and reaches a maximum after 1 week of regular treat-
ment.10 It leads to a prolonged recovery time after bronchoconstriction and the need 
for extra doses of rescue medication.10-14 Simultaneously, regular use of LABAs leads to 
a reduced protection against AHR provoked by natural or administered stimuli, such as 
methacholine15,16, allergen16 and exercise17. This is called bronchoprotective tolerance. 
Furthermore, Hancox et al. have shown that regular use of SABAs can even enhance AHR 
to exercise.12
In this study, we analyzed the effect of stepping down clinically stable asthmatic 
children from LABA/ICS combination therapy to ICS monotherapy on AHR to mannitol. 





Children with mild to moderate asthma, treated with LABA/ICS combination therapy, 
who underwent a medication reduction according to treatment guidelines,1,2 were 
screened. Twenty four children with mild to moderate, clinically stable asthma for > 3 
months (i.e. no hospital admissions or use of systemic corticosteroids), aged 12-17 years, 
were asked to participate in this study. The study was approved by the Medical Ethics 
Committee, Enschede. All children and parents gave written informed consent.
study design
This was an observational, prospective open-label study. Children and their parents were 
contacted four and two weeks prior to the first visit to emphasize on the importance of 
medication adherence. During the first visit to the outpatient clinic, all children were 
interviewed about medication use and adherence by the lung function assistant. They 
performed a set of tests, including a mannitol challenge, measurement of Fraction of 
exhaled Nitric Oxide (FeNO) and an asthma control test (ACT). After the first visit treat-
ment was stepped down to ICS monotherapy. The second visit was scheduled 30 ± 4 
days after the first visit. During the second visit the same set of tests was performed. 
Primary outcome was change in the provoking dose of mannitol required to cause a 
15% fall in FEV1 (PD15). Secondary outcomes were changes in mannitol response-dose 
ratio, recovery time to ≥ 95% of baseline FEV1 following a rescue SABA, FeNO and scores 
on the ACT.
spirometry
A MicroLoop® MK8 Spirometer (Micromedical, Quayside, United Kingdom) was used to 
measure pulmonary volumes and flow-volume loops. All spirometric measurements 
were performed in duplicate using a standard protocol.18
mannitol challenge
The mannitol challenge was performed according to the standard laboratory protocol, 
using the commercially available mannitol test kit (Aridol®, Pharmaxis, Frenchs Forest, 
Sydney, Australia).19 Children were required to withhold the use of leukotriene antago-
nists, intranasal steroids, LABAs and ICSs for 24h and SABAs for 8h before both mannitol 
challenges. No vigorous exercise was permitted for 8h before a mannitol challenge.
The dose protocol consisted of 0, 5, 10, 20, 40, 80, 160, 160 and 160 mg mannitol. 
Children were asked to exhale completely before taking a calm deep inspiration from 
the device and subsequently hold their breath for 5 s. Children were asked to exhale 
through their mouth to minimize deposition in the nasopharynx. FEV1 was measured 
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60 s after each dose of mannitol. The challenge ended when a ≥ 15% fall in FEV1 from 
baseline or a ≥ 10% fall between subsequent doses occurred, or the cumulative dose 
of 635 mg mannitol had been administered. Mannitol PD15 was calculated by linear 
interpolation. The response-dose ratio was calculated by taking the final percent fall in 
FEV1 recorded and dividing it by the cumulative dose of mannitol administered.
After the challenge, children received a dose of 100 µg Salbutamol and FEV1 was 
measured at t = 1, 3, 5, 10, 15 and 20 min until lung function had returned to ≥ 95% 
of baseline FEV1. If FEV1 had not recovered to ≥ 95% of baseline after 10 min, children 
received a second dose of 100 μg Salbutamol.
fraction of exhaled nitric oxide
The single-breath online measurement method was used to measure FeNO before any 
forced expiratory maneuvers.20 Children were asked to exhale to residual volume and 
then inhale NO-free air through a hand-held nitric oxide analyzer (Niox Mino®, Aerocrine, 
Stockholm, Sweden). Children inhaled to near to total lung capacity and immediately 
exhaled at a constant flow rate of 50 mL/s. FeNO was measured in the expired air by its 
reaction with ozone, which is detected by chemiluminescence.
asthma Control Test
The ACT is a 5 item survey assessing asthma symptoms (daytime and nocturnal), use of 
rescue medications and the effect of asthma on daily functioning. Each item includes 5 
response options corresponding to a 5-point scale. The total score ranges from 5 points 
(uncontrolled asthma) to 25 points (well controlled asthma).
statistical analysis
Statistical analysis was performed with SPSS Statistics® version 17.0 for Windows®. Best 
values of spirometric measurements of FEV1 were used for statistical calculations. 
Geometric means ± 95% confidence intervals (CI) of mannitol PD15 and response-dose 
ratio were calculated using the log-transformed values. Recovery time was expressed as 
mean time to reach FEV1 ≥ 95% of baseline. Recovery curves were analyzed as the total 
area under the curve. FeNO values were analyzed before and after natural log transfor-
mation. Within group changes were analyzed with a paired t-test or Wilcoxon-signed 
rank test, as appropriate. Spearman’s rank correlation coefficient was calculated for the 
correlations between FeNO, scores on the ACT, FEV1, PD15 and response-dose ratio. The 
difference between the number of children positive on both mannitol challenges was 




Twenty children were included, 17 of which completed the study. In 3 children, the first 
mannitol challenge was terminated before they reached a ≥ 15% fall in FEV1. One subject 
was excluded because she was unable to perform reproducible expiratory flow volume 
curves. One subject experienced a frequent and persistent cough after the 5th dose step, 
which interfered with the fixed time schedule and one subject refused to continue after 
the 8th dose step because she didn’t like the taste of mannitol. Patient characteristics are 
presented in Table 1.
Before the first mannitol challenge children reported an average use of 1.8 puffs of 
SABAs per week (including pre-exercise use) and a mean medication adherence of 81 
± 15% during the past 4 weeks. After the medication reduction children reported an 
average use of 1.6 puffs of SABAs per week and an adherence of 82 ± 12%. Changes in all 
outcome parameters are shown in Table 2.






Baseline fEv1 (% pred.) Pd15 mannitol (mg)
laBa/ICs ICs laBa/ICs ICs
1 M 11 FP/SAL 200 - 104 98 >635 268
2 M 13 BUD/F 400 + 75 80 144 217
3 M 14 FP/SAL 100 - 85 89 >635 >635
4 M 13 FP/SAL 250 - 94 101 145 419
5 V 13 BUD/F 200 + 96 83 114 36
6 V 12 BUD/F 400 - 100 100 139 169
7 M 12 BUD/F 200 - 78 73 150 291
8 V 14 FP/SAL 250 - 96 86 >635 256
9 M 14 FP/SAL 200 - 104 81 132 66
10 V 13 FP/SAL 200 - 68 82 49 115
11 M 13 BUD/F 200 + 84 91 236 241
12 V 13 FP/SAL 500 - 98 108 308 467
13 M 17 BUD/F 400 - 69 61 255 58
14 M 13 FP/SAL 200 + 101 97 >635 >635
15 M 13 BUD/F 400 - 76 91 250 221
16 M 13 FP/SAL 200 - 120 122 367 409
17 V 15 FP/SAL 200 + 117 120 >635 >635
BUD/F = budesonide / formoterol, FEV1 = forced expiratory volume in 1 s, FP/SAL = fluticasone proprionate / 
salmeterol, ICS = inhaled corticosteroid, LABA = long acting β2-agonist, LTRA = leukotriene receptor antagonist, 
PD15 = provoking dose to cause a 15% fall in FEV1.
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(± SD) of 92.1 ± 15.6% predicted value, which was not significantly different from base-
line FEV1 before the second challenge (91.9 ± 15.7% predicted value, P = 0.96).
mannitol challenge
Twelve children (70.6%) were positive on the first mannitol challenge, defined by a fall 
in FEV1 ≥ 15% after a cumulative dose of ≤ 635 mg mannitol. Fourteen children (82.4%) 
were positive on the second challenge. The number of children positive on a mannitol 
challenge was not significantly different between both tests (P = 0.50). Geometric mean 
for the PD15 for children positive on the first challenge was 168.9 mg (95% CI: 56.9 - 501.9) 
and for the second challenge 183.7 mg (95% CI: 38.2 – 884.9), which was not significantly 
different (P = 0.91; Fig. 1).
Mean maximum percent fall in FEV1 (± SD) after the first challenge was 15.6 ± 5.4% 
after a mean cumulative dose (± SD) of 347 ± 215 mg mannitol. After the second chal-
lenge FEV1 fell 15.6 ± 4.6% after a cumulative dose of 331 ± 196 mg. Geometric mean of 
the response-dose ratio did not change after the medication reduction (P = 0.81).
Children using leukotriene antagonists did not have a different response to mannitol 
than children not using these medications.
recovery
Mean [Range] recovery time following a SABA was 9.9 min [1 – 20] after the first man-
nitol challenge and 5.7 min [0 – 15] after the second challenge, which was significantly 
shorter (P = 0.01; Fig. 2). Six children needed a second dose of 100 µg Salbutamol after 
the first challenge and only one child after the second challenge. Recovery time after 
mannitol was not age dependent. The total area under the recovery curve (± SD) was 




FEV1 (% pred.) 92.1 ± 15.6 91.9 ± 15.7 0.96
PD15 (mg) 168.9 (56.9, 501.9) 183.7 (38.2, 884.9) 0.91
RDR (% fall in FEV1/ mg) 0.05 (0.01, 0.36) 0.06 (0.01, 0.54) 0.81
Asthma control test 20.2 ± 4.7 20.8 ± 4.7 0.10
FeNO (ppb) 35.5 ± 27.6 36.6 ± 26.5 0.39
Recovery time to ≥ 95% of baseline FEV1 (min) 9.9 ± 6.2 5.7 ± 4.3 0.01
Area under the curve (%.min) 1908.9 ± 66.5 1944.2 ± 51.4 0.04
Data expressed as mean ± standard deviation (SD) or Geometric mean (95% CI). FeNO = fraction of exhaled 
nitric oxide, ICS = inhaled corticosteroid, LABA = long acting β2-agonist, PD15 = provoking dose to cause a 15% 
fall in FEV1, RDR = Response Dose Ratio.
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also significantly larger after the second challenge (1908.9 ± 66.5 %.min vs. 1944.2 ± 51.4 
%.min, P = 0.04).
fraction of exhaled nitric oxide
There was no significant difference in FeNO measured before both challenges (35.5 ± 
27.6 vs. 36.6 ± 26.5 ppb; P = 0.39; Fig. 3). There was no correlation between FeNO and 
mannitol PD15 or response-dose ratio.
asthma Control Test
There was no significant difference between symptom scores on the ACT after the 
medication reduction (20.2 ± 4.7 vs. 20.8 ± 4.7 points, P = 0.10). There was no correlation 
between scores on the ACT and baseline FEV1, FeNO, mannitol PD15 and response-dose 
ratio.
dIsCussIon
In this study, we monitored stepping down from LABA/ICS combination therapy to ICS 
monotherapy in clinically stable asthmatic children. The withdrawal of the LABA did not 
change baseline FEV1, ACT score, FeNO or SABA use. There was no difference in Mannitol 
PD15 and response-dose ratio. However, with LABA/ICS combination therapy there was a 
delayed recovery after the administration of a SABA and more children needed a second 
dose of SABA to recover compared to ICS monotherapy.
fig. 1. Individual changes in Mannitol PD15 
(mg) after regular treatment with LABA/ICS 
combination therapy and 4 weeks after step-
ping down to ICS monotherapy.
ICS = inhaled corticosteroid, LABA = long act-
ing β2-agonist, PD15 = provoking dose to cause 
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To our knowledge, the effect of stepping down treatment from combination therapy 
to ICS monotherapy on AHR to mannitol has not yet been studied in asthmatic adults 
or children. Previous studies in asthmatic adults compared stepping down to ICS mono-
therapy to stepping down to a lower dose of combination therapy.6-8 They found a dete-
rioration of asthma control, as measured by peak expiratory flow, daily symptom scores 
and SABA use in subjects whose LABA was withdrawn. However, the effect on airway 
inflammation, asthma exacerbations, hospitalizations and mortality was not assessed, 
while the main concerns with LABA treatment focus on these outcome measures.4 A 
recent study in adults compared both step down approaches and found no significant 
difference in FEV1, rescue bronchodilator use, methacholine PD20, sputum eosinophils, 
FeNO and annual rate of severe exacerbations.5 However, recently particular concern has 
risen about the risk of LABA treatment among children. A Cochrane review comparing 
step up therapy by adding a LABA to increasing the dose of ICS found that in children 


















































Recovery time (min) after 100μg Salbutamol
100µg
Salbutamol
fig. 2. Percentage of patients with FEV1 recovered to ≥ 95% of baseline after 100μg Salbutamol at resp. 0 
and 10 min after a mannitol challenge.
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, LABA = long acting β2-agonist.
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and hospital admissions.3 The effect of different approaches to step down combination 
therapy in children has not been extensively studied. In a study design similar to this 
study the AHR to exercise (defined as % fall in FEV1) in asthmatic children diminished 
after the withdrawal of the LABA21, suggesting an increased AHR to exercise in children 
on combination therapy.
Several mechanisms could contribute to the increased risk for asthma exacerbations and 
hospitalizations with regular use of LABAs22; such as the development of bronchodila-
tor tolerance, an increased AHR to allergen, interaction with corticosteroid receptors, 
masking of symptoms and altered mucociliary clearance.23 In this study, recovery time 
from bronchoconstriction after rescue therapy with a SABA was significantly longer 
after long-term use of LABA/ICS combination therapy. A prolonged recovery time after 
stepping up treatment with a LABA has been described in both adults and children 
after histamine11, exercise13 and metacholine10,14 challenges. The mechanism by which 
tolerance develops is not fully unraveled, but it is well known that prolonged exposure 
to agonists desensitizes G-protein-coupled receptors, such as the β2-adrenoceptor. The 
principal mechanism of desensitization is cyclic-AMP-dependent and –independent 
phosphorylation of the receptor, which results in a limitation of receptor function. After 
more prolonged exposure to an agonist, an internalization of receptors occurs and the 
total transit time for the recycling of receptors is increased, which results in a net loss of 










































LABA/ICS        4 weeks ICS
fig. 3. Individual changes in Fraction of exhaled Ni-
tric Oxide (ppb) after regular treatment with LABA/
ICS combination therapy and 4 weeks after step-
ping down to ICS monotherapy.
ICS = inhaled corticosteroid, LABA = long acting β2-
agonist.
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receptors which can only be replaced by synthesis of new receptors through transcrip-
tion of the β2-adrenoreceptor gene.9,24
The downregulation and desensitization of the β2-adrenoreceptor result in a decreased 
response to rescue SABA treatment in circumstances of acute bronchoconstriction. The 
process of desensitization differs in different types of cells, which may be explained by a 
variation in the receptor reserve between tissues and a differential resensitization rate. 
Mast cells appear to desensitize more rapidly than smooth muscle cells.9 Therefore, tol-
erance might be more profound against indirect bronchoprovocational stimuli, such as 
mannitol, that act on inflammatory cells (such as mast cells), than against direct stimuli, 
such as methacholine, that act directly on airway smooth muscle cells.25
The response to mannitol in asthmatics is supposed to mimic the airway response 
to exercise, as both increase the osmolarity of the airway surface liquid, triggering 
mediator release from mast cells. In a previous study by our study group the AHR to 
exercise in asthmatic children decreased after combination therapy was stepped down 
to ICS monotherapy.21 We therefore expected a similar reduction in AHR to mannitol, 
which did not occur. We speculate that this discrepancy in results could be explained 
by differences in the physical responses to exercise and mannitol. Mannitol is primar-
ily deposited in the conducting airways, because of its particle size 26, while exercise 
induced hyperpnoea can dehydrate the peripheral airways as well.27 The amount of 
mast cells is greater in smaller airways28, where only a small part of the inhaled mannitol 
powder will penetrate. Therefore, a change in responsiveness in the small airways due 
to desensitization of mast cells is more likely to be detected with an exercise challenge. 
Secondly, the rate of change in osmolarity, which is suggested to be a determinant of 
AHR29, may be important. This rate is likely to be slower with a mannitol challenge which 
is performed according to a stepwise protocol with increasing doses. Thirdly, the fall in 
FEV1 after exercise is usually greater than after mannitol, because a mannitol challenge 
ends when FEV1 falls ≥ 15%. Wraight et al. demonstrated that, in the same patient, the 
effect of tolerance becomes more apparent with increasing degrees of bronchoconstric-
tion.30 Therefore the effect of tolerance might have been more apparent after an exercise 
challenge compared to a mannitol challenge.
Several limitations of this study need to be adressed. Firstly, there was no control group 
in whom we did not change the medication regimen, making this study susceptible 
to bias due to an improved adherence. We measured adherence by interviewing the 
children and found no difference in reported adherence before both challenges. Sec-
ondly, although all children used combination therapy, they were prescribed different 
medication regimens and different doses of ICSs. Five children were using leukotriene 
antagonists (LTRA), which are known to shorten recovery time following mannitol.31 We 
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found no significant difference in recovery time for children on LTRA compared to chil-
dren not on LTRA. Thirdly, we only measured short term effects of the withdrawal of the 
LABA and therefore could not study long term outcomes, such as asthma exacerbations 
and hospitalizations.
A long recovery time and tolerance to a rescue bronchodilator are likely to affect chil-
dren in daily life, as they compromise their athletic performance and participation in 
active play and sports with peers. Failure to respond to rescue bronchodilators could 
offer a possible explanation for the association between LABA use and asthma related 
intubations and mortality. Theoretically, bronchodilator tolerance could be overcome 
by increasing the dose of SABAs, which has happened in the last decades in treatment 
of acute exacerbations. However, Haney and Hancox found that the response to high 
dose nebulised salbutamol was still 15% lower after regular formoterol compared to 
placebo.32
This study shows that in short term follow-up (one month), stepping down clinically 
stable children from LABA/ICS combination therapy to ICS monotherapy did not change 
AHR to mannitol and FeNO and did not alter asthma control as measured by spirom-
etry, SABA use and ACT score. The withdrawal of the LABA led to a significantly shorter 
recovery time following a rescue SABA after a mannitol challenge, suggesting a reversal 
of previously developed bronchodilator tolerance. Future studies should be directed at 
the longer term effects of different step down approaches from combination therapy in 
asthmatic children.
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Beta2-adrenoreceptor agonists (β2-agonists) are extensively used in the treatment of 
childhood asthma. However, there have been concerns regarding their adverse effects 
and safety. In 2005, the FDA commissioned a “Black Box Warning” communicating the 
potential for an increased risk for serious asthma exacerbations or asthma-related death 
with the regular use of LABAs. In a meta-analysis of controlled clinical trials the incidence 
of severe adverse events appeared to be highest in the 4-11 year age group. Several 
mechanisms have been proposed to explain this, such as masking patients’ perception 
of worsening asthma, desensitization and downregulation of the β2-adrenoreceptor, 
pro-inflammatory and pro-asthmatic effects of β2-agonists, pharmacogenetic effects of 
β2-adrenoreceptor polymorphisms and age related differences in pathophysiology of 
asthma.
In this paper, we review β2-receptor pharmacology, discuss the concerns regarding 
treatment with β2-agonists in childhood asthma and exercise induced bronchocon-
striction, and provide suggestions for clinical pediatric practice in the light of current 
literature.
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InTroduCTIon & hIsTorICal BaCKGround
Beta2-adrenoreceptor agonists (β2-agonists) are extensively used in the treatment of child-
hood asthma. Short acting β2-agonists (SABAs) are the first choice as rescue medication 
during acute bronchoconstriction and provide protection against exercise induced bron-
choconstriction (EIB).1 SABAs activate the β2-adrenoreceptor (β2AR) within 5 min and have 
a bronchodilator effect of 4-6h.2 Long acting β2-agonists (LABAs) have a longer (12-24h) 
bronchodilator effect.2 Currently, in clinical guidelines for children, LABAs are recommended 
as one of the step-up options for maintenance treatment in combination with inhaled corti-
costeroids (ICSs) when asthma is not adequately controlled with ICSs alone.3,4
Adrenergic receptor agonists are one of the oldest classes of drugs used in medicine. 
Sympathomimetic agents were already used in Chinese herbal medicine to relieve 
breathing problems as early as 3000 BC.5 Adrenaline was the first “modern” sympatho-
mimetic drug that was used to relieve asthma symptoms. As concerns about possible 
cardiotoxicity and the development of tolerance rose, drugs with a greater selectivity 
for airway smooth muscle were developed. The first non-selective β-receptor agonist, 
isoproterenol (isoprenaline), was developed in the 1940s. Isoproterenol was still associ-
ated with severe side effects such as tachycardia and palpitations through its effects on 
the β1-receptor. The discovery that there were more types of adrenergic receptors led 
to the classification of α- and β-receptors, and subclassification of β1- and β2-receptors. 
This resulted in the development of more selective β2-agonists in the 1960s.
In 1956 the first pressurized metered-dose inhaler was invented6 and aerosol tech-
nology developed rapidly in the subsequent decades. The bronchoprotective effect of 
inhaled β-agonists against EIB in children was demonstrated.7 Inhalation of β2-agonists 
was shown to provide a better effect and fewer cardiovascular side effects than oral or 
intravenous administration.8,9
The short duration of action of SABAs was a problem for patients who needed protec-
tion for a longer period, particularly at night. This led to the development of salmeterol, 
which was marketed in 1990, and the discovery of formoterol soon after. Both drugs 
have a prolonged effect leading to bronchodilation for ≥ 12h. Novel ultra-long-acting 
β2-agonists with a duration of action of approximately 24h have recently been regis-
tered for adults and children > 12 years.10
In the past 20 years, concerns about the safety of LABAs caused an ongoing contro-
versy among drug authorities, scientists and clinicians11,12, as meta-analyses indicate 
a significantly higher risk of serious adverse events, such as life-threatening asthma 
exacerbations13-20, in adults and children regularly taking LABAs. Particular concern has 
risen about the risk of LABAs in childhood asthma.19,21 Approval for LABA/ICS combina-
tion therapy by the US Food and Drug Administration (FDA) for children aged 4-11 years 
was primarily based on extrapolation of efficacy studies performed in adolescents and 
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adults.3 However, in contrast to data in adults, pediatric studies do not show a significant 
superior effect of adding a LABA compared to increasing the dose of ICS on asthma 
control and quality of life, but do show improved lung function and growth.22,23
In this paper, we discuss the concerns regarding treatment with β2-agonists in child-
hood asthma and EIB, review β2-receptor pharmacology, and focus on clinical recom-
mendations for pediatricians in the light of current literature.
PharmaColoGy
The adrenoreceptors are a class of G-protein coupled receptors that are targeted by 
catecholamines. There are two main groups of adrenoreceptors, α- and β-receptors, with 
several subtypes including β1- and β2-receptors. The β2AR predominates in the respiratory 
tract, where it is widely distributed, not only in airway smooth muscle cells (with a density 
of 30.000-40.000 receptors per cell), but also in lung epithelial cells, endothelial cells and 
inflammatory cells that reside in the airways.24 The receptor density increases more distal 
throughout the respiratory tract with highest levels in the central lung and alveolar region.24
Stimulation of the β2AR in airway smooth muscle cells induces a signal transduction 
pathway, resulting in increased intracellular cyclic-3’,5’-adenosine monophosphate 
(cAMP).2 cAMP catalyzes the activation of protein kinase A (PKA), which subsequently 
leads to phosphorylation of key regulatory proteins involved in the control of muscle 
tone. An increase in cAMP inhibits Ca2+ release from intracellular stores, reduces Ca2+ 
entry into the cells, and enhances sequestration of intracellular Ca2+. The G-protein 
also directly interacts with potassium channels present in the airway smooth muscle 
cell membrane, without involving cAMP. Both cAMP-dependent and -independent 
processes finally result in airway smooth muscle relaxation (Fig. 1).
Stimulation of the β2AR in the mast cells leads to mast cell stabilization through an 
increase in intracellular cAMP.25 β2-Agonists inhibit the release of pre-stored histamine 
from mast-cells, and the synthesis of new mediators, such as cysteinyl leukotrienes and 
prostaglandin D2.
Stimulation of the β2AR on epithelial cells leads to an increased beat frequency of cilia 
and may therefore facilitate mucociliary clearance.26 Furthermore, β2-agonists inhibit 
extravasation of plasma proteins in the airway wall, thereby reducing the airway wall 
congestion that contributes to airway obstruction in asthma.26
Prolonged exposure to an agonist desensitizes G-protein-coupled receptors. In homolo-
gous desensitization, within minutes of binding of a ligand to its receptor, G-protein 
receptor kinase is activated. This kinase phosphorylates the carboxyterminal lis of the 
G-protein-coupled receptor, which changes the receptor conformation and leads to 
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decoupling of the receptor from the G-protein, resulting in receptor subsensitivity. In 
heterologous desensitization the receptor is phosphorylated by a non-specific kinase 
that was activated by binding of a ligand to a different G-protein coupled receptor.
β-Arrestin binds to the phosphorylated receptors, after which they are internalized by 
endocytosis. The internalized receptors can be recycled to the cell membrane. However, 
when exposure to the ligand or agonist continues, the total transit time for the recycling 
of receptors increases24 and part of the receptors will be degraded in lysosomes. After 
hours of agonist exposure, there is a net loss of receptors, called downregulation.24 The 
receptors can only be replaced by re-synthesis of new receptors through transcription of 
the β2AR-gene.24,26 However, activation of the β2AR inhibits this transcription. Therefore 
it takes hours to days to overcome downregulation.
Corticosteroids increase β2AR-gene transcription and regulate both the number of 



















fig. 1. Physiological effects of β2-agonists in the airways.
β2AR = β2-adrenoreceptor.
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ConCErns wITh rEGular β2-aGonIsT TrEaTmEnT
No large efficacy and safety studies were performed when SABAs were introduced. Two 
epidemics of asthma related mortality, after the marketing of isoproterenol in the 1960s 
in the United Kingdom27 and fenoterol in the 1970s in New Zealand28, rose concern about 
regular SABA treatment. It was assumed that the relationship between asthma mortality 
and isoproterenol (a non-selective β-agonist) resulted from cardiac toxicity, and it was 
postulated that the dose related effect of fenoterol on asthma mortality29 reflected in-
creased SABA use due to more severe asthma. However, a prospective trial by Sears et al. 
in adolescent and adult asthmatics (aged 15-64y) in 1990 demonstrated worse asthma 
control when fenoterol was used regularly compared to when it was used as rescue, 
as-needed therapy.30 Several placebo controlled studies have since then compared the 
effect of regular treatment with a SABA to as-needed treatment in adults.31 Overall, there 
was little evidence to support regular use of SABAs31 and SABAs are therefore advised to 
use only on an ‘as needed’ basis. Increased use is considered to indicate a deterioration 
of asthma control and the need to step-up treatment.
As SABAs are recommended to be used on an as needed basis, it seems inconsistent to 
recommend regular use of LABAs. Since the introduction of LABAs there have been con-
cerns regarding their adverse effects and safety, leading to large scale studies. Among 
the first studies were the Serevent Nationwide Surveillance Study (SNS)32 and Salmeterol 
Multi-center Asthma Research Trial (SMART).33 The SNS study was a 16-week, double-
blind study in 25,180 subjects aged ≥ 12y that found a statistically insignificant increase 
in the number of asthma-related deaths in patients treated with salmeterol twice daily 
compared to four times daily salbutamol (RR 3.0, 95% CI 0.7–20). The SMART trial was a 
28-week, randomized, placebo-controlled trial in 26,355 subjects aged ≥ 12y that found 
a significantly increased risk for asthma-related death (RR 4.37, 95% CI 1.25–15.3) and 
respiratory related death (RR 2.16, 95% CI 1.06-4.41) in patients treated with salmeterol. 
On subgroup analysis, this increased risk was only found in African-Americans.
SMART was not adequately designed to determine whether or not ICS use affected 
the incidence of asthma or respiratory related deaths, but the vast majority of deaths 
occurred in patients who did not receive ICS.
These observations led to a “Black Box Warning” by the FDA in 2005 communicating 
the potential for an increased risk for serious asthma exacerbations or asthma-related 
death with the regular use of LABAs. Subsequently, over a dozen meta-analyses inves-
tigating the adverse effects of LABAs in adults and children were published, providing 
an equivocal picture.13-20,34-40 Some of these meta analyses demonstrated an increased 
risk of serious adverse events, such as hospitalizations, life-threatening exacerbations 
and asthma-related death with LABA use compared to placebo,13-20 while others did 
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not.34-40 This inconsistency is probably due to differences in background therapy and 
heterogeneity in study design and study populations.
In some meta-analyses, subgroup analyses suggested that combination therapy 
with an ICS protects against asthma-related serious adverse events.19,20,40,41 Two recent 
Cochrane meta-analyses assessed the safety of LABA/ICS combination therapy versus 
ICS monotherapy.36,37 In adults and children on salmeterol with ICS compared to ICS 
monotherapy, there was no significant difference in overall deaths, asthma-related 
deaths or non-fatal serious adverse events.37 However, a trend towards an increase in 
asthma related deaths in adults (OR 3.6, 95% CI 0.79-16.3) and non-fatal serious adverse 
events in children (OR 1.62, 95% CI 0.80-3.28) on formoterol with ICS compared to ICS 
monotherapy was found.36 Because both fatal and non-fatal serious adverse events are 
rare, they concluded that the available evidence from the reviews of randomised trials 
cannot definitively rule out an increased risk.
The FDA performed a meta-analysis of controlled clinical trials comparing the risk of 
LABA use with no LABA use for different age categories.19 They found that the compos-
ite outcome of asthma-related death, -intubation, or -hospitalization had the highest 
incidence in the 4-11y age group (30.4 events per 1000 patient years, 95% CI 5.7–55.1). 
Compared to 4-11y old children not on LABAs the RR was 1.67 (Fig. 2.). These results were 
similar for patients who reported concomitant use of ICS, though adherence to ICS was 
not checked. In the small subgroup of patients who were assigned ICS as study medication 
and whose adherence was checked, there did not seem to be an increased risk.
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fig. 2. Incidence difference (ID) per 1000 patient-years for composite outcome of asthma-related death, 
-hospitalization or -intubation, according to age for LABA versus no-LABA therapy.
LABA = long acting β2-agonist
IncidenceNo LABA = incidence in No LABA group per 1000 patient-years.
Figure adopted from McMahon et al., Pediatrics 201119, with permission.
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In another pediatric meta-analysis in which 82% of patients used ICS, there was no sig-
nificant difference (RR 1.05, 95% CI 0.61-1.83) in asthma-related hospitalizations in 4-11y 
old children on formoterol compared to no LABA.39 A 2012 Cochrane analysis on the 
safety of formoterol and salmeterol in asthmatic children (aged 4 -17y) concluded that 
regular LABA/ICS combination therapy is likely to be less risky than LABA monotherapy.41
The important question that remains is whether the benefits of combination therapy 
in children outweigh the risks. LABA/ICS combination therapy is recommended as a 
third step in asthma treatment for children > 6 years by clinical guidelines.3,4 In adults, 
the addition of a LABA to an ICS improves pulmonary function and symptoms, reduces 
the use of rescue medication and improves quality of life.42-44 In children the evidence 
in favor of LABAs is far less certain, with wide confidence intervals including both supe-
riority and inferiority of LABA/ICS combination therapy compared to the same dose or 
double dose of ICSs alone.23,43,44
It has been postulated that larger trials are necessary to determine the benefits and 
risks of LABA/ICS combination therapy.45 In 2011, the FDA issued a requirement for all 
manufacturers of LABAs to conduct controlled clinical trials to assess the safety of LABA/
ICS combination therapy compared to ICS monotherapy.45 Results from these studies are 
expected in 2017.45
ConCErns wITh β2-aGonIsTs for ExErCIsE InduCEd 
BronChoConsTrICTIon
β2-Agonists are widely used as prophylactic treatment of EIB. A large body of evidence 
supports the use of both SABAs and LABAs shortly before exercise.1 However, regular 
treatment with β2-agonists leads to tolerance to the bronchoprotective effect of β2-
agonists.1 Both the duration of protection as well as the degree of protection decrease. 
This loss of protection against EIB with regular LABA treatment has been observed in 
adults46,47 and children.48-50
Regular treatment with β2-agonists also leads to tolerance to the bronchodilator effect 
of rescue β2-agonists. It has been a long held believe that tolerance to the bronchodila-
tor effect of β2-agonists does not develop5, as early studies found no reduction of the 
bronchodilator effect after regular treatment.51,52 However, these studies measured the 
response to a bronchodilator in subjects with an FEV1 near to normal, leaving little room 
for improvement with a bronchodilator. In a state of bronchoconstriction, such as in EIB, 
more β2ARs are necessary to provide sufficient bronchodilation. Studies in asthmatic 
children49 and adults46,53,54 demonstrated bronchodilator tolerance in EIB with regular 
β2-agonist use, resulting in a reduced response to a rescue SABA, a prolonged recovery 
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time and the need for extra doses of rescue medication. In adults, bronchodilator toler-
ance developed within a week of treatment with formoterol.55 Fortunately, it is also rap-
idly reversed: three days after formoterol was withdrawn, the bronchodilator response 
to salbutamol was similar to pre-treatment.55 No tolerance developed after treatment of 
asthmatic adults with formoterol three times per week.56 In clinical practice, the effect 
of bronchodilator tolerance may therefore be less apparent than in clinical trials due to 
poor compliance of patients. Children who regularly take a ‘drug holiday’ might reverse 
tolerance themselves.
Regular treatment with SABAs has also been described to increase EIB in asthmatic 
adults.54,57 An increase in EIB has not been clearly demonstrated after regular treatment 
with LABA/ICS combination therapy. However, in children with EIB on LABA/ICS combi-
nation therapy, withdrawal of the LABA has been shown to improve EIB.58
An increase in EIB after regular treatment with β2-agonists could result from down-
regulation of the β2AR on mast cells, reducing the protective effect of endogenous 
catecholamines against mediator release by these cells. It could also result from a direct 
osmotic effect of β2-agonists on the airway mucosa. β2-Agonists stimulate the move-
ment of water across the epithelial cells to the airway surface, which could prime the 
submucosa to the additional dehydrating effects of exercise.59 The enhanced need for 
rescue SABAs due to increased EIB and tolerance to their bronchodilator effect could 





























fig. 3. Schematic representation of vicious circle that could occur with frequent β2-agonist use.
β2AR = β2-adrenoreceptor, LABA = long acting β2-agonist, SABA = short acting β2-agonist.
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PossIBlE mEChanIsms of InCrEasEd advErsE EvEnTs wITh rEGular 
β2-aGonIsTs
Several mechanisms have been proposed to explain the increase in adverse events with 
regular β2-agonist treatment.
Masking patients perception of worsening asthma
Since β2-agonists provide good symptom relief, patients may rely on them too much, 
which may prevent them from taking sufficient anti-inflammatory treatment. Regular 
treatment with LABAs does not reduce the inflammatory process in the airways60, but 
because symptoms are reduced patients are unaware of their underlying disease state 
and a deterioration of their asthma could be masked. Furthermore, patients may neglect 
to avoid allergens, as they experience no acute symptoms because of the bronchodila-
tor effect of β2-agonists, causing a more severe late inflammatory response.
Desensitization and downregulation of the β2-adrenoreceptor
The process of desensitization differs from cell to cell. Mast cells and lymphocytes de-
sensitize within 2 min of β2-agonist exposure61, whereas smooth muscle cells are more 
resistant. Therefore, β2-agonists can sometimes still exert their bronchodilator effect on 
airway smooth muscle, without their bronchoprotective effect of stabilizing mast cells. 
A loss of bronchoprotection could make children more vulnerable to asthma exacerba-
tions in response to allergen, exercise or non specific stimuli.
Furthermore, it has been described that bronchodilator tolerance becomes more 
apparent with increasing bronchoconstriction62, such as in an exacerbation. Tolerance 
to emergency SABA treatment during an exacerbation could lead to life-threatening 
situations.
Theoretically, corticosteroid induced transcription of the β2AR-gene compensates for 
receptor downregulation.63 Both systemic corticosteroids64 and a single high dose of ICS 
(1600 μg budesonide)65 have been shown to reverse bronchodilator tolerance. However, 
in clinical studies tolerance to the bronchoprotective effects of β2-agonists developed 
despite concomitant treatment with conventional doses of ICSs.48-50,53
Pro-inflammatory and pro-asthmatic effects of β2-agonists
In vitro, LABAs appear to have both anti-inflammatory as well as pro-inflammatory ef-
fects. LABAs stabilize mast cells, inhibit plasma exudation, and reduce the adhesion of 
neutrophils and eosinophils to endothelial cells.63 Furthermore, LABAs potentiate the 
anti-inflammatory effects of ICSs.63
Regular use of β2-agonists may also paradoxically have a pro-inflammatory effect.66-69 
β2-Agonists induce a shift in peripheral blood mononuclear cells cytokines toward a Th2-
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lymphocyte response.66,67 Regular use of β2-agonists can increase sputum inflammatory 
cells.68,69 Clinically, these observations do not appear to be relevant, as a meta-analysis 
investigating the effect of LABAs on inflammation in adults and children concluded they 
did not have a clinically important anti- or pro-inflammatory effect.60
Sustained exposure to β2-agonists induced ‘pro-asthmatic’ changes in airway smooth 
muscle contractility70 and augmented the effects of bronchoconstrictive mediators71 
and pro-contractile signaling pathways.72 In a ‘proof of principle’ study it was demon-
strated that 9 weeks treatment with a β-blocker improved BHR to metacholine.73 These 
studies indicate that there may be a β2AR-mediated signaling pathway that evokes BHR 
and thereby worsens asthma control.74
Pharmacogenetic effect of β2-adrenoreceptor polymorphisms
β2AR-gene polymorphisms result in changes in the amino acid sequence of the β2AR, 
leading to alterations of its properties. It was hypothesized that rare variants of the β2AR 
gene could account for the rare incidence of asthma-related life threatening events in 
patients receiving regular β2-agonists. The Thr164Ile polymorphism results in a de-
creased β2AR ligand binding in vitro75 and was associated with severe exacerbations 
requiring hospitalizations and systemic corticosteroids in African Americans treated 
with a LABA.76
Two single-nucleotide polymorphisms in specific coding regions, glycine for arginine 
at codon 16 and glutamic acid for glutamine at codon 27, have been more extensively 
studied since they are relatively prevalent in Caucasian populations. The Arg16Gly poly-
morphism has been shown to interfere with treatment responses to β2-agonists. In 
vitro, receptors with the homozygous Arg16 genotype show enhanced susceptibility for 
homologous desensitization and receptor downregulation77, which could account for 
an increase in β2-agonist tolerance in Arg16 homozygotes.
Both retrospective and prospective analyses of data in adults have demonstrated 
adverse effects of the Arg16 homozygous genotype on asthma symptoms78, BHR79 
and exacerbations80 after receiving a SABA as regular therapy. In the BARGE trial the 
response to 16-weeks regular albuterol was compared to placebo plus ipratropium 
rescue treatment in asthmatic adults in a prospective, genotype-stratified, cross-over 
design.78 In this study, Arg16 homozygotes did not experience an improvement in PEFR 
and demonstrated a deterioration of symptom control during albuterol treatment, in 
contrast to Gly16 homozygotes.
Studies searching for the effect of β2AR genotype on the response to treatment with 
LABAs have shown conflicting results which appear to be dependent on the age of the 
study group.
In adults, a large retrospective study in 2250 patients (aged ≥12y) showed no asso-
ciation between LABA treatment and clinical outcomes after stratification by Arg16Gly 
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genotype.81 In the LARGE trial the response to 18-weeks twice daily salmeterol (added to 
ICS) was compared to placebo in a prospective, genotype-stratified, cross-over design.82 
In this study, both Arg16 and Gly16 homozygotes experienced an improvement in lung 
function, but only Gly16 homozygotes were protected against BHR provoked by meta-
choline.82 This loss of bronchoprotection to methacholine after 1-2 weeks of regular 
LABA use in Arg16 homozygotes was previously described in a retrospective analysis of 
data from adult asthmatics.83 However, a prospective trial found no association between 
Arg16Gly genotype and loss of bronchoprotection to EIB after 2 weeks treatment with 
salmeterol.84
In children, an increased risk for exacerbations in Arg16 homozygotes in a cohort of 
1182 patients (aged 3-22y) on daily salmeterol was reported.85 An increase in oral corti-
costeroid use and emergency department visits was found in 597 Arg16 homozygotes 
(aged 4-12y) on LABA/ICS combination therapy, compared to Gly16 homozygotes.86 
A prospective randomized controlled study in asthmatic children aged 5-18y showed 
that in Arg16 homozygotes adding montelukast compared to salmeterol to inhaled 
fluticasone significantly improved asthma symptoms, asthma related school absence 
and quality of life (Fig. 4).87
Age related differences in asthma phenotypes
Children appear to have an increased risk of exacerbations associated with regular LABA 
treatment compared to older age groups (Fig. 2).19 This could result from differences in 
the pathophysiology of asthma between adults and children.88,89
Airway smooth muscle in children might have a shortened response and relaxation 
time.90 BHR to methacholine has a higher reactivity in younger children, in both healthy 
individuals91 and asthmatics.92 Asthmatic children with EIB reach maximal post-exercise 
bronchoconstriction faster than adults.90,93 In epidemiologic studies, asthmatic children 
have a higher incidence of exacerbations than adults.94 This increased responsiveness of 
the airway smooth muscle might wane with ageing, as the airways remodel and become 
more rigid.
Children have relatively unimpaired FEV1 values.95 However, in children FEV1 is not 
correlated to measures of obstruction in the peripheral airways.96 The peripheral airways 
are a major site of the disease process. The density of β2ARs on airway smooth muscle is 
highest in the peripheral airways. The density of mast cells and activated eosinophils is 
also increased in the peripheral airways.95,97 Therefore, undertreatment of the peripheral 
airways in children with relatively normal FEV1 values may make them more susceptible 
to exacerbations and effects of tolerance to β2-agonists.
Possibly adult asthmatics are less vulnerable to the negative effects of β2-agonists 
due to more airway wall rigidity, caused by remodeling of the bronchoconstrictive ap-
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paratus, or due to less atopy, a lower number of inflammatory cells or receptors, or a 
different affinity of β2ARs to their agonists.
ConClusIons & suGGEsTIons for ClInICIans
Despite the fact that β2-agonists are the most effective bronchodilators currently used, 
their place in the treatment of childhood asthma and EIB needs to be carefully reconsid-
ered, taking into account possible genetic and environmental influences. For as-needed 
therapy, SABAs remain the first choice. However, based on the available evidence from 
clinical trials, it can reasonably be concluded that daily use of SABAs and/or LABAs in the 
absence of ICS can have adverse effects on asthma control. At the moment, there is no 
consensus on how to balance benefits and risks of β2-agonist treatment, especially in 
children under the age of 12, due to a paucity of randomized clinical data for children.98 


































































fig. 4. Changes in asthma-related outcomes 
in Arg16 homozygous children treated with 
fluticasone plus oral montelukast (ML) or sal-
metorol / fluticasone plus placebo montelukast 
(SM). Visits were every 3 months.
- Top panel: change in asthma-related school 
absences.
- Middle panel: change in use of salbutamol 
reliever.
- Bottom panel: change in total pediatric asth-
ma quality of life questionnaire score after 12 
months treatment.
Error bars are 95% CI. P-values are shown for the 
comparison between groups after 12 months. 
Figure adopted from Lipworth et al.87, with per-
mission.
102 Chapter 5
tions on the safety and efficacy of LABA/ICS combination therapy. Based on current 
evidence and guidelines we would like to suggest the following:
1. abstain from laBa mono-therapy in children and use laBa/ICs combination 
therapy only in a single inhaler device
As recommended by the FDA45 and clinical guidelines3,4 we should refrain from LABA 
monotherapy, as it does not treat the underlying inflammation60, could mask a dete-
rioration of asthma control and is associated with an increased risk of serious adverse 
events. Combination therapy should be used as a single inhaler to prevent periods of 
LABA monotherapy due to poor compliance to ICSs.
2. laBa/ICs combination therapy should be used with caution in children aged 
4-11 years
In children aged 4-11y, few studies have been performed to compare step-up options 
when asthma is not well controlled on low-dose ICSs. In contrast to data in adult stud-
ies, studies performed in children do not show a significant superior effect of adding a 
LABA compared to the same dose43,99 or a double dose44,100 of ICSs on asthma control, 
quality of life, BHR and risk of asthma exacerbations, but it does improve lung function. 
Concomitant use of ICSs possibly mitigates the risk of asthma-related serious adverse 
events19, yet the number of pediatric studies is limited and these studies should be inter-
preted with caution. We suggest to reserve LABA/ICS combination therapy for children 
aged 4-11y whose asthma is inadequately controlled on a higher dose of ICSs alone, or 
ICS combined with a leukotriene receptor antagonist.
3. Consider to step-up controller therapy in children with daily use of saBas for 
EIB
Although clinical guidelines recommend to step-up anti-inflammatory therapy when 
SABAs are needed more than twice per week, in clinical practice this usually excludes 
pre-exercise use. As daily exercise is recommended for all children, including those with 
asthma, many children use β2-agonists pre-exercise on a daily basis. In children with 
EIB, daily use of SABAs may lead to an increased maximum fall in FEV1 after exercise54,57, 
a protracted recovery from EIB and tolerance to rescue SABAs. This can compromise 
athletic performance and participation in active play and sports. Clinicians should 
consider to step-up controller therapy, such as optimizing the dose of the ICS or adding 
a leukotriene receptor antagonist, when SABAs are used more than twice weekly, includ-
ing pre-exercise use.
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Allergic rhinitis and exercise induced bronchoconstriction (EIB) are common in asthmatic 
children. The aim of this study was to investigate whether treatment of allergic rhinitis 
with an intranasal corticosteroid protects against EIB in asthmatic children.
methods
This was a double-blind, randomized, placebo-controlled, parallel group study. Subjects 
aged 12-17 years, with mild-to-moderate asthma, intermittent allergic rhinitis and ≥ 
10% fall in FEV1 at a screening exercise challenge were randomized to 22 ± 3 days treat-
ment with intranasal fluticasone furoate or placebo. The primary outcome was change 
in exercise induced fall in FEV1. Secondary outcomes were changes in the area under 
the curve (AUC), asthma control questionnaire (ACQ), pediatric asthma quality of life 
questionnaire (PAQLQ) and exhaled nitric oxide (FeNO).
results
Twenty-five children completed the study. Mean exercise induced fall in FEV1 (± SD) 
decreased significantly (95% CI: 0.7 to 18.2%, P = 0.04) in the fluticasone furoate group 
from 28.4 ± 15.8% to 19.0 ± 13.8%, compared to the placebo group (27.4 ± 16.0% to 27.4 
± 19.2%). The change in AUC was not significantly different between treatment groups. 
However, within the fluticasone furoate group the AUC decreased significantly (P = 
0.01). Although total PAQLQ score did not improve, the activity limitation domain score 
improved significantly within the fluticasone furoate group (P = 0.03). No significant 
changes were observed in FeNO and ACQ.
Conclusion
Treatment of allergic rhinitis in asthmatic children with an intranasal corticosteroid 
reduces EIB and tends to improve quality of life.
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InTroduCTIon
Asthma is a chronic disorder of the lower airways, characterized by inflammation and 
bronchial hyperresponsiveness (BHR), leading to recurrent episodes of wheezing, chest 
tightness, shortness of breath and coughing.1 Childhood asthma is often allergy in-
duced.2 Allergy frequently induces inflammation in the upper airways as well, resulting 
in episodes with symptoms of allergic rhinitis (AR). Although AR is very common in asth-
matic children, it often remains unrecognized and undertreated.2,3 AR and asthma are 
recognized as manifestations of a single “united airways” syndrome2,4 and a combined 
treatment strategy therefore seems appropriate.
Intranasal corticosteroids (INCS) provide a safe and effective treatment of AR. Treat-
ment of AR with INCS tends to improve asthma symptom scores and measures of lung 
function.5 The effect of treatment with INCS on BHR is controversial. The effect of INCS on 
BHR to direct stimuli, such as methacholine and histamine, has been studied in a large 
number of studies.6-13 Some have shown that INCS reduce BHR in adult patients with sea-
sonal or perennial AR and asthma.6-9 Others, however, could not confirm this effect.10-13 
The effect of INCS on BHR to indirect stimuli, such as exercise, has been studied in only 
one study, which was inconclusive.14 Direct stimuli act directly on airway smooth muscle 
cells, without involving inflammatory pathways. Indirect stimuli act on inflammatory 
cells, such as mast cells, which release mediators interacting with smooth muscle cells. 
Indirect stimuli are therefore more specific for asthma, as they employ inflammatory 
cells resident in the asthmatic airway wall.15
Exercise is used as an indirect bronchial provocation test to diagnose and monitor 
exercise induced bronchoconstriction (EIB) in children. EIB is defined as an acute, revers-
ible bronchial obstruction induced by physical exercise and is a disabling characteristic 
of asthma, affecting 80-90% of asthmatic children.16 Exercise induced hyperpnoea lead-
ing to evaporative water loss and an increase in osmolarity of the airway surface liquid is 
considered an essential determinant to provoke EIB. A shift of water from the epithelial 
cells to the airway surface induces the release of mediators from inflammatory cells that 
cause bronchoconstriction. The severity of EIB is augmented by exercise in cold and dry 
air. In this study, we investigated the effect of intranasal fluticasone furoate on BHR to 
exercise in cold air in asthmatic children with intermittent AR.
maTErIals and mEThods
subjects
Children were recruited from the outpatient clinic of the pediatric department of the 
Medisch Spectrum Twente, Enschede. Thirty-two children aged 12-17 years, with 
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mild-to-moderate asthma, doctor diagnosed intermittent AR and allergy (defined as a 
positive specific immunoglobulin E test to ≥ 1 inhalation allergen) were included after a 
screening exercise challenge. Children were included if they had an exercise induced fall 
in FEV1 ≥ 10%.17 Other inclusion criteria were the ability to perform reproducible pulmo-
nary function tests (i.e., variation of percentage of the predicted value of FEV1 in 3 of 5 
consecutive measurements < 5%) and clinically stable (i.e., no hospital admissions or use 
of systemic corticosteroids 4 weeks prior to the study), partly or well controlled asthma 
(as measured by the asthma control questionnaire). Exclusion criteria were pulmonary 
or cardiac co-morbidity and use of intranasal corticosteroids 4 weeks prior to the study. 
Both steroid-naïve, as well as children on anti-inflammatory treatment were included. 
Children were not allowed to use short-acting β2-agonists within 8h and long-acting β2-
agonists within 36h prior to testing. Children were excluded if their baseline FEV1 before 
and after treatment with INCS differed >12%. The study was approved by the Medical 
Ethics Committee, Enschede. All children and parents gave written informed consent. 
The study was registered online in the ISRCTN register under number ISRCTN90761040.
study design
The study had a double-blind, randomized, placebo-controlled, parallel group design. 
The study was conducted out of the main grass pollen season, from October 2009 to 
January 2010 and subjects were (based on a pre-test interview) asymptomatic for AR. 
Subjects were allocated fluticasone furoate 27.5 µg/dose or matching placebo nasal 
spray. Subjects were instructed to administer the nasal spray once daily; the first week 2 
puffs into each nostril, and 1 puff into each nostril afterwards, as per guideline. Subjects 
were treated for 22 ± 3 days. Before and after treatment, subjects underwent an exercise 
challenge and filled out the asthma control questionnaire18 (ACQ) and the paediatric 
asthma quality of life questionnaire (PAQLQ). Prior to both exercise challenges, exhaled 
nitric oxide (FeNO) was measured.
The primary end point was the change in exercise induced fall in FEV1 after treatment. 
Secondary end points were changes in the area under the FEV1 curve, asthma control 
score (ACQ), quality of life (PAQLQ) and FeNO.
randomization and allocation concealment
Randomization was performed using a computer-generated randomization list, which 
was maintained by an independent pharmacy. All study medications were packaged 
and labeled by an independent pharmacy (European Packaging Centre, Heerenveen, 
the Netherlands). Treatment allocation was concealed from the investigators and par-
ticipants. Placebo nasal spray was identical in appearance and labeling to fluticasone 
furoate nasal spray, 27.5 µg per dose. Both were supplied by Glaxo Smith Kline (GSK 
Pharmaceuticals, Zeist, the Netherlands). Adherence to medication was determined by 
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weighing study medication before and after the treatment period. The total number of 
administered puffs of nasal spray was calculated by the loss in weight divided by the 
weight of one puff. Adherence was calculated as a percentage of prescribed puffs that 
were used.
spirometry
Pulmonary function tests were performed before (baseline) and after exercise using 
a standardized protocol according to international guidelines.19 A Microloop® MK8 
Spirometer (Micromedical, Quayside, United Kingdom) with Spida5® software was used 
to measure flow-volume loops. The calibration of the spirometer was checked before 
testing. The expiratory flow-volume loop was recorded by one trained assistant in dupli-
cate by instructing the children to perform a maximal expiratory effort from inspiratory 
vital capacity to residual volume. Best spirometry values were used for analysis. Baseline 
values of FEV1 were expressed as percentage of the predicted value.20
Exercise challenge
Exercise challenges were performed by running with nose clipped on a treadmill (Hori-
zon® fitness Ti22, Cottage Grove, Wisconsin, United States) with an incline of 10% using 
the standardized ATS protocol.17 Exercise challenges were performed in the local skating 
rink, where air temperature is kept constant at 9.5-10.0°C and relative humidity at 56% 
(absolute humidity 4.2 g/kg). During exercise, heart rate was continuously monitored 
by a radiographic device (Inventum SH 40®, Veenendaal, the Netherlands). The running 
speed of the treadmill was increased, raising the heart rate to approximately 90% of the 
predicted maximum (220-age). This speed was maintained for a total duration of 6 min. 
Spirometry was performed before exercise (baseline value) and 1, 3, 6, 9, 12, 15, 20, 25 
and 30 min after exercise. Thirty minutes after exercise, or at request, children received 
100 µg salbutamol, after which spirometry was repeated until FEV1 was recovered to 
>95% of baseline. Recovery to baseline FEV1 was measured as the total area under the 
curve from 0 to 30 min post-exercise (AUC0-30min).
fraction of exhaled nitric oxide
FeNO was measured before any forced expiratory maneuvers according to current 
guidelines, using the single-breath online measurement method.21 Children were asked 
to exhale to residual volume and then inhale through a hand-held nitric oxide analyzer 
(Niox Mino®, Aerocrine, Stockholm, Sweden). Children inhaled gas with a low NO con-
centration to near to total lung capacity and immediately exhaled at a constant flow rate 




The ACQ has 7 questions, scoring 5 symptoms, baseline FEV1 % predicted and daily 
rescue bronchodilator use.18 Children can respond to these questions on a 7-point scale. 
Baseline FEV1 % predicted is also scored on a 7-point scale. The questions are equally 
weighted. The ACQ score is calculated as the mean of the 7 questions and ranges be-
tween 0 (totally controlled) and 6 (severely uncontrolled).
The PAQLQ has 23 questions in 3 domains; symptoms, activity limitation and emotional 
function.22 Children can respond on a 7-point scale. The total PAQLQ score is calculated 
as the mean of all 23 questions and domain scores are calculated as the means of the 
items in those domains. Scores range from 1 (maximal impairment in quality of life) to 7 
(no impairment in quality of life).
statistical analysis
Exercise induced fall in FEV1 was expressed as percentage fall from baseline. Continu-
ous variables were tested for normality with a Shapiro-Wilk test. Differences between 
groups were analyzed with a chi-square test (for proportions), independent samples 
t-test (for normally distributed variables) or Wilcoxon-rank sum test (for variables with 
a skewed distribution). Within group changes were analyzed with a paired t-test or 
Wilcoxon-signed rank test, as appropriate. FeNO was analyzed before and after natural 
log transformation. SPSS® 17.0 for Windows® was used for statistical analysis. The sample 
size estimated to detect a 10% change in fall in FEV1 (with a 2-sided significance level of 
5% and 95% power), was set at 10 subjects for each treatment group, on the assumption 
that variability was similar to that observed in previous studies by our study group.
rEsulTs
subjects
Thirty-two children were randomized (17 placebo group, 15 fluticasone furoate group), 
of which 25 completed the study. Five children were excluded because of exclusion 
criteria (3 in the placebo group and 2 in the fluticasone furoate group) and 2 children 
dropped out (one in each treatment group). Patient characteristics are presented in 
Table 1. None of the variables presented in Table 1 was significantly different between 
treatment groups (all P values > 0.10). An overview of changes in all outcome parameters 
is shown in Table 2.
In both treatment groups, 8 children were using inhaled corticosteroids (ICS), with 
a mean ± SD dose of 356 ± 124 µg/day in the placebo group and 320 ± 145 µg/day in 
the fluticasone furoate group (P = 0.30). Mean ± SD adherence was 82.5 ± 20.5% in the 
placebo group and 84.3 ± 24.4% in the fluticasone furoate group (P = 0.85). All children 
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used > 60% of prescribed study medication, except for one patient in the fluticasone 
furoate group who had used only 32% of the prescribed medication.
Exercise induced bronchoconstriction
Mean exercise induced fall in FEV1 (± SD) decreased significantly in the fluticasone fu-
roate group from 28.4 ± 15.8% to 19.0 ± 13.8%, compared to the placebo group (27.4 ± 
16.0% to 27.4 ± 19.2%). The mean difference in decrease in exercise induced fall in FEV1 
between the two groups was 9.5% (95% CI: 0.7 to 18.2 %, P = 0.04); Fig. 1. The exercise 
induced fall in FEV1 decreased in all children in the fluticasone furoate group, except 
for the patient who had used 32% of study medication. Intranasal fluticasone furoate 
provided 33% protection against EIB compared to placebo.
area under the curve
There was a non-significant difference in decrease in the AUC0-30min between placebo and 
treatment groups (95% CI: -41 to 366%.min; P = 0.11). Within the fluticasone furoate group, 
AUC0-30min decreased significantly from 620 ± 363%.min to 404 ± 249%.min (mean decrease 
216%.min; 95% CI: 54 to 378%.min; P = 0.01). Recovery curves are shown in Fig. 2.
spirometry
Baseline FEV1 before the first exercise challenge was 88.5 ± 8.6% predicted in the flutica-
sone furoate group and 88.0 ± 13.2% predicted in the placebo group (P = 0.91). Baseline 
FEV1 after treatment was not significantly different in the fluticasone furoate group (88.2 
Table 1. Patient characteristics (n = 25)
Placebo (n=13) flucticasone furoate (n=12)
Age (years) 14.6 ± 2.1 13.8 ± 1.8
Male (%) 38.5 66.7
Duration asthma (years) 11.1 ± 3.9 12.0 ± 3.1
Height (m) 1.67 ± 0.06 1.66 ± 0.12
Weight (kg) 55.9 ± 11.0 57.6 ± 11.7
LABA (%) 53.8 33.3
ICS (%) 61.5 66.7
Leukotriene antagonist (%) 30.8 16.7
Antihistamine (%) 23.1 16.7
Sensitization to any inhalant allergen (%) 100.0 100.0
House dust mite allergy (%) 84.6 75.0
Pollen allergy (%) 61.5 75.0
Animal dander allergy (%) 61.5 50.0
Data expressed as mean ± standard deviation (SD) or percentage of patients. ICS = inhaled corticosteroid, LABA 
= long acting β2-agonist.
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Table 2. Outcome parameters before and after treatment
Placebo fluticasone furoate 95% CI P-value
FEV1 % predicted
baseline 88.0 ± 13.2 88.5 ± 8.6
after treatment 86.6 ± 13.4 88.2 ± 12.5
change -1.4 ± 3.8 -0.3 ± 5.6 -2.9 to 5.0 0.59
Exercise induced fall in FEV1 (%)
baseline 27.4 ± 16.0 28.4 ± 15.8
after treatment 27.4 ± 19.2 19.0 ± 13.8
change 0.0 ± 0.5 -9.5 ± 10.0 -18.2 to -0.7 0.04
AUC0-30min (%.min)
baseline 592 ± 361 620 ± 363
after treatment 538 ± 394 404 ± 249
change -53 ± 237 -216 ± 255 -366 to 41 0.11
ACQ
baseline 1.1 ± 0.6 1.2 ± 0.8
after treatment 1.1 ± 0.6 1.2 ± 0.7
change 0.0 ± 0.6 0.0 ± 0.8 -0.5 to 0.5 0.84
PAQLQ -total-
baseline 6.0 ± 0.8 6.0 ± 0.8
after treatment 5.9 ± 1.0 6.2 ± 0.7
change 0.0 ± 0.5 0.2 ± 0.5 -0.2 to 0.7 0.28
PAQLQ -symptoms-
baseline 5.8 ± 1.0 5.7 ± 1.0
after treatment 5.7 ± 1.0 5.7 ± 1.0
change -0.1 ± 0.6 0.0 ± 0.7 -0.4 to 0.6 0.72
PAQLQ -activity limitation-
baseline 5.5 ± 1.2 5.6 ± 1.0
after treatment 5.5 ± 1.4 6.0 ± 0.9
change -0.1 ± 0.7 0.4 ± 0.5 -0.1 to 0.9 0.11
PAQLQ -emotional function-
baseline 6.5 ± 0.6 6.5 ± 0.6
after treatment 6.5 ± 0.8 6.8 ± 0.3
change 0.0 ± 0.5 0.3 ± 0.6 -0.1 to 0.7 0.17
FeNO (ppb)
baseline 36.8 ± 26.2 47.0 ± 50.0
after treatment 30.6 ± 25.2 36.5 ± 37.0
change -6.2 ± 17.3 -10.4 ± 32.6 -25.6 to 17.1 0.68
Data expressed as mean ± standard deviation (SD). ACQ = asthma control questionnaire, AUC0-30min = total area 
under the curve from 0-30 min post-exercise, CI = confidence interval, FeNO = fraction of exhaled nitric oxide, 
FEV1 = forced expiratory volume in 1 s, PAQLQ = pediatric asthma quality of life questionnaire, ppb = parts per 
billion.
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± 12.5% pred., P = 0.84) or the placebo group (86.6 ± 13.4% pred., P = 0.22). Change in 
baseline FEV1 did not differ between treatment groups (P = 0.59).
Quality of life and asthma Control
There was no significant difference in total PAQLQ scores or domain scores between the 
two study groups (all P values > 0.10). However, mean activity limitation score increased 
0.4 units (95% CI: 0.0 to 0.7; P = 0.03) in the fluticasone furoate group, whilst no change 
was observed in the placebo group (95% CI: -0.5 to 0.4; P = 0.71). No change was observed 
in other PAQLQ domains, however, in the fluticasone furoate group a trend towards an 
increase in quality of life in emotional function was seen (95% CI: -0.1 to 0.7; P = 0.08).
There was no change in mean ACQ scores after treatment with fluticasone furoate or 
placebo. There was no difference in change in ACQ scores between treatment groups 
(95% CI: -0.5 to 0.5; P = 0.84).
fraction of exhaled nitric oxide
Baseline FeNO was 36.8 ± 26.2 ppb in the placebo group and 47.0 ± 50.0 ppb in the flutica-
sone furoate group, which was not significantly different (95% CI: -42.8 to 22.5; P = 0.53). In 
the fluticasone furoate group, FeNO decreased 10.4 ± 32.6 ppb after treatment, which was 
not significantly different (95% CI: -17.1 to 25.6; P = 0.68) from the decrease in FeNO in the 
placebo group (6.2 ± 17.3 ppb). There was also no significant difference in the decrease in 
FeNO between treatment groups after natural log transformation (P = 0.93).
Children on ICS had a non-significant lower baseline FeNO compared to steroid-naïve 


































fig. 1. Exercise induced 
fall in FEV1 (%) before 
and after treatment 
with placebo or flutica-
sone furoate.
Data expressed as indi-
vidual fall in FEV1 and 
mean fall in FEV1.
FEV1 = forced expiratory 
volume in 1s.
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non-significant greater decrease in FeNO than children on ICS with fluticasone furoate 
(28.8 ± 55.8 ppb vs. 1.25 ± 7.0 ppb; 95% CI: -15.0 to 70.0; P = 0.18). However, steroid naïve 
children also had a greater decrease in FeNO compared to children on ICS with placebo 
(17.4 ± 24.7 ppb vs. -0.9 ± 4.1 ppb; 95% CI: -0.8 to 37.4; P = 0.06) and there was no dif-
ference in decrease in FeNO between treatment groups (95% CI: -76.4 to 53.7; P = 0.69).
adverse events
There were no significant differences in the prevalence of reported adverse events 
between the two groups (P = 0.79). All reported adverse events were mild. Two children 
complained of epistaxis (1 in each group). Six children reported flu like symptoms (3 in 
each group) and respiratory tract infections were reported in 4 (2 in each group). One 


















































fig. 2. Mean fall in FEV1 at 
each time point after exercise.
(A) Before and after treatment 
with placebo.
(B) Before and after treatment 
with fluticasone furoate.
Patients received 100 µg sal-
butamol at t = 30 min.
FEV1 = forced expiratory volume 
in 1s.
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dIsCussIon
The results of this study demonstrate that treatment with an INCS (fluticasone furoate) 
significantly reduces exercise induced fall in FEV1 in children with mild to moderate asth-
ma, intermittent AR and EIB. In addition, there was a significant within group decrease 
in AUC0-30min and a trend towards an improvement in the activity limitation domain of 
quality of life in the fluticasone furoate group.
To our knowledge, this study is the first to investigate the effect of an INCS on EIB in 
cold air in asthmatic children. Henriksen and Wenzel investigated the effect of intranasal 
budesonide on EIB in room temperature in allergic asthmatic children with chronic nasal 
obstruction and found a trend towards a reduction in EIB after 4 weeks treatment.14 
There were important differences between the study by Henriksen and our study. Firstly, 
we included children with intermittent symptoms of AR whereas Henriksen selected 
children with a persistently blocked nose and mouth breathing. Secondly, we used cold, 
dry air, which amplifies EIB17 and may explain the greater difference between groups in 
our study. Furthermore, Henriksen used a different device to deliver INCS, a pressurized 
aerosol and a different, but equipotent INCS, i.e., budesonide.
This study, using an indirect bronchial provocation test, showed a clinically significant 
attenuation of BHR to exercise by INCS that is similar to the attenuation provided by a low 
dose of inhaled corticosteroids.23 Studies assessing the effect of INCS on BHR to direct 
bronchial provocation tests, such as methacholine and histamine, were inconclusive.6-13 
Some studies demonstrated an attenuation of the increase in BHR during seasonal al-
lergy exposure.8,9 Studies that did find a decrease in BHR to direct stimuli had a longer 
duration of treatment with INCS and showed a small, statistically significant, though 
not clinically relevant improvement.6,7 We hypothesized that the short-term effects 
of INCS on the lower airways may be better demonstrated with an indirect bronchial 
provocation test. The response to an indirect stimulus reflects the actual inflammatory 
state of the airways and the presence and activity of inflammatory cells.24 BHR to a direct 
stimulus is more closely related to airway smooth muscle function and airway caliber15 
and is therefore a reflection of functional and anatomic airway remodeling as a result of 
chronic inflammation.
Several methodological issues of our study design need to be addressed. Firstly, in our 
study duration of treatment (22 ± 3 days) was rather short compared to other studies, 
treating for 4-6 weeks.7-9,14 We hypothesized that this treatment period was long enough 
as BHR to indirect stimuli responds more rapidly to anti-inflammatory treatment than 
BHR to direct stimuli.25 Furthermore, fluticasone furoate is a modern, potent corticoste-
roid, with an onset of action against nasal symptoms within the first 24h of treatment.26 
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Fluticasone furoate reaches its maximal effect on nasal symptoms after 2-3 weeks of 
treatment.26
The size of our study population was small, yet we found a clinically relevant im-
provement in EIB. However, a larger study population might have provided statistically 
significant changes in secondary outcome measures that showed a trend in our study.
Our study population was non-homogeneous in relation to asthma severity, upper 
airway symptoms and atopic sensitization. The study was intended as a ‘proof of prin-
ciple’ study and we chose to include a cross section of the mainstream of asthmatic 
children in a general pediatric outpatient clinic. The improvement in EIB was seen in all 
children in the fluticasone furoate group, both with mild or more severe EIB, partly or 
well controlled asthma and with or without concomitant treatment with ICS, except for 
one child who had used only 32% of study medication.
As we did not perform additional tests to objectify symptoms of AR on inclusion 
we cannot clearly distinguish whether our patients had asymptomatic upper airway 
inflammation or undiagnosed perennial AR. It is therefore uncertain from this study if 
INCS would be more effective against EIB in subgroups of patients with more severe or 
persistent AR.
The effect of INCS on asthma control in asthmatic children, as measured with an ACQ, has 
not been described before. In our study, no change in ACQ was observed after treatment 
with fluticasone furoate, which is in agreement with results of Nathan et al. who found 
no improvement on asthma symptoms scores and rescue albuterol use with INCS in 
asthmatic adults on ICS.27 In our study the ACQ score was already low at baseline leaving 
little room for improvement. Several other studies did show a beneficial effect of INCS 
on asthma symptom scores6,10 and the asthma control test28 in adults, suggesting an 
improvement in asthma control. However, the effect of INCS on symptoms of AR could 
confound asthma symptoms scores, as symptoms of AR and asthma overlap.
The PAQLQ showed a within group reduction in activity limitation after treatment with 
INCS, which could be a result of the reduction in EIB. Although this result was statistically 
significant, its mean increase was 0.4 units, which is just below the clinically relevant 
difference of 0.5 units.22 Nair et al. found no additional improvement in asthma qual-
ity of life score (AQLQ) in adults treated with both intranasal and inhaled fluticasone 
compared to treatment with inhaled fluticasone alone.12
In this study, we found no significant reduction in FeNO after treatment with intranasal 
fluticasone furoate. However, steroid-naïve children tended to have a greater decrease 
in FeNO after treatment with fluticasone furoate than children on ICS. As in our study, 
Pedroletti et al. described unchanged levels of FeNO after treatment of asthmatic chil-
dren on ICSs with mild to moderate AR with intranasal mometasone furoate.29 A study 
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in steroid-naïve asthmatic adults did find a significant decrease in FeNO after treatment 
of AR with triamcinolone. 30
The results of this study confirm the existence of an important physiologic relation be-
tween the upper and lower airways. Several mechanisms have previously been proposed 
as putative underlying mechanisms, such as the existence of a neural nasobronchial 
reflex and/or systemic inflammatory response from upper to lower airways.4,31 An im-
provement of nasal breathing can reduce epithelial injury and chronic inflammation of 
the lower airways, as the nose warms, humidifies and filters the inspired air.4,14 Improved 
nasal breathing during the exercise challenges cannot explain the protective effect 
of fluticasone furoate on EIB, as patients wore a nose clip during both challenges. A 
systemic effect of nasal corticosteroids is also unlikely, since nasal and gastro-intestinal 
absorption of fluticasone furoate after intra-nasal administration is low.32 Furthermore, 
a protective effect due to intrapulmonary deposition of fluticasone furoate also seems 
unlikely, as less than 2% of nasal medication reaches the lower airways.7
In conclusion, this study shows that anti-inflammatory treatment of AR improves EIB 
in children with mild to moderate asthma and intermittent AR. Although AR is very 
common in asthmatic children, it often remains unrecognized and undertreated.2,3 This 
study shows that in the general pediatric outpatient clinic, many asthmatic children 
could benefit from intranasal anti-inflammatory treatment. Therefore, in children with 
EIB, clinicians should actively inquire about symptoms of AR. In the presence of such 
symptoms, even when only intermittently, INCS can improve EIB, which may improve 
quality of life. Studies in larger populations are required to corroborate our findings and 
to look further into the mechanism by which upper airway inflammation affects lower 
airway inflammation.
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Exercise induced bronchoconstriction (EIB) can be prevented by a single dose of monte-
lukast (MLK). This effect is variable, similar to the variable responsiveness observed after 
daily treatment with MLK. We hypothesized that the effect of a single MLK-dose (5 or 10 
mg) on EIB could predict the clinical effectiveness of longer term once daily treatment.
methods
This was a prospective, open-label study. Twenty-four asthmatic adolescents (12-17 y) 
suboptimally controlled by low dose inhaled corticosteroids, with ≥10% post-exercise 
fall in FEV1, were included. They performed an exercise test at baseline, 20h after a single 
MLK-dose and 40-44h after the last dose of 4 weeks once daily treatment. The correla-
tions between the effect of a single dose and 4 weeks treatment on area under the curve 
(AUC) and maximum % fall in FEV1 were calculated.
results
AUC0-20min, decreased significantly after a single MLK-dose (P = 0.001, CI 64.9 – 218.2), 
but not after 4 weeks of treatment (P = 0.080, CI -12.2 – 200.4). There was a moderate 
correlation between the effect of a single MLK-dose and 4 weeks treatment on AUC0-
20min, r = 0.49 (P = 0.011), and maximum % fall in FEV1, r = 0.40 (P = 0.035). The positive 
and negative predictive value of ≥ 25% reduction in AUC0-20min after a single dose were 
respectively 84.6% and 50.0% (P = 0.146).
Conclusion
The protection provided by a single MLK-dose against EIB only modestly predicts the 
effect of regular treatment against EIB in adolescent asthmatics on low dose inhaled cor-
ticosteroids. If used on a daily base, MLK offered clinically significant protection against 
EIB in the large majority (80%) of children suboptimally controlled by low dose ICS.
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InTroduCTIon
Asthma is a heterogeneous disease, which is reflected in the variability of individual 
patients’ responses to medications. It has been shown that symptomatic asthmatic 
children on low dose inhaled corticosteroids (ICS) show a considerable variability in 
response to the currently available step-up options: i.e., doubling the dose of ICS, add-
ing a long-acting β2-agonist (LABA) or adding a leukotriene receptor antagonist (LTRA).1 
There is little evidence to guide clinicians to the most effective step-up option.
Adding an LTRA to ICS to reinforce anti-inflammatory treatment is one of the step-up 
options in children with persistent asthma symptoms.2 Cysteinyl leukotrienes (CysLTs) 
are pro-inflammatory mediators causing potent and long-lasting airway narrowing. In 
exercise induced bronchoconstriction (EIB), CysLTs are released from activated mast cells 
as a result of airway drying and cooling.3 Compared to placebo, daily treatment with 
the LTRA montelukast (MLK) significantly attenuated EIB, measured by post-exercise 
maximum % fall in FEV1 and area under the FEV1 curve (AUC), in adults4 and in children4-8 
uncontrolled by low dose ICS. In adult asthmatics, a single MLK-dose (10 mg) has been 
shown to provide a rapid (1h post-dosing)9,10 protection against post-exercise maximum 
% fall in FEV1 compared to placebo. Other placebo controlled studies in both adults11,12 
and children (aged 4-14y)13 showed a sustained protection 24h after a single MLK-dose 
(4, 5 or 10 mg). In these studies, the reduction in both maximum % fall in FEV1 and 
AUC0-60min was similar at 2h and 24h post-dosing.11-13
However, MLK does not protect against EIB in all children and 20-40% of children are 
considered non-responders both after a single dose13,14 and longer-term daily treat-
ment.4,6,8,15,16
It is not clear if a single MLK-dose response against EIB relates to the clinical effective-
ness following longer-term daily MLK-treatment within the same child. If both treatment 
responses are mediated through the same pathway, a single dose response should pre-
dict the longer-term clinical effectiveness of step-up therapy with MLK. In the present 
study, we investigated the relationship between a single dose response to MLK (5 or 10 
mg) against EIB and the clinical effectiveness after 4 weeks once daily MLK-treatment 
against EIB in children with mild to moderate persistent asthma suboptimally controlled 
by low dose ICS.
mEThods
subjects
Children were recruited from the pediatric outpatient clinic of the Medisch Spectrum 
Twente, Enschede, the Netherlands. Children with a clinical history of persistent asthma 
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and EIB (confirmed by a previous exercise challenge), partly or fully uncontrolled by low 
stable doses of ICS alone (daily dose of 100 – 400 μg of beclomethasone dipropionate or 
equipotent) based on guideline derived symptom scores2, were screened. Fifty-one chil-
dren, aged 12-17 years, were screened by a standardized treadmill exercise challenge17 
before starting treatment with MLK (5 or 10 mg depending on age). Children were 
included if a fall in FEV1 ≥10% from baseline occurred within 20 min post-exercise.17,18 
Other inclusion criteria comprised the ability to perform reproducible pulmonary func-
tion tests (i.e., variation of percentage of the predicted value of FEV1 in 3 of 5 consecutive 
measurements < 5%) and baseline FEV1 ≥ 70% of predicted.
Exclusion criteria included viral upper airway infections, other lower airway or cardiac 
co-morbidities or hospitalization due to an asthma exacerbation in the month before 
inclusion. Furthermore, children were excluded for use of systemic corticosteroids, anti-
histamines, LTRA or anticholinergics in two weeks prior to the study or other medication 
changes during the treatment period. Children were not allowed to use short-acting 
bronchodilators within 8h or long-acting bronchodilators within 24h prior to testing or 
to perform vigorous exercise within 8h prior to testing.
The study was approved by the Medical Ethics Committee, Medisch Spectrum Twente, 
Enschede. All children gave written assent and their parents gave written informed 
consent. The study was registered online in the NTR register as NTR2059.
study design
The study had a prospective, open-label design. During baseline visit, children per-
formed an asthma control questionnaire (ACQ) and pediatric asthma quality of life 
questionnaire (PAQLQ) and were interviewed about their asthma symptoms, (rescue) 
medication use, allergies, smoking and other environmental factors. Children performed 
an exercise challenge with lung function measurements pre- and repeatedly up to 30 
min post-challenge.
One week after the baseline visit, children were started on a therapeutic MLK-dose (5 
or 10 mg QD, depending on their age) before bedtime. Twenty hours after the first dose 
(through of dosing interval) a second exercise challenge was performed. After 30 ± 4 
days of treatment, a third exercise challenge was performed. Children received the last 
MLK-dose 40-44h prior to the third exercise challenge to ensure that the ‘longer-term’ 
anti-inflammatory effect was measured and not the more acute antagonistic effect of a 
single dose. Children were asked to bring their medication strip to the third visit to allow 
compliance check.
spirometry
Pulmonary function tests were performed 5 min pre- and repeatedly post-exercise using 
a standardized protocol according to international guidelines.19 A calibrated Microloop® 
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MK8 Spirometer (Micromedical, Quayside, United Kingdom) with Spida5® software was 
used to measure pulmonary volumes and flow-volume loops. All measurements were 
performed in duplicate and technically best values were included in the analysis. All 
spirometry values were expressed as percentage of the predicted value.
Exercise challenge
Exercise challenges were performed by running with nose clipped on a treadmill (Hori-
zon® fitness Ti22, Cottage Grove, Wisconsin, United States) with an incline of 10% using a 
standardized ATS protocol.17 Exercise challenges in children have a good short term re-
peatability (mean difference in fall in FEV1 -0.4%, 95% CI ± 12%).20 All exercise challenges 
were performed in the afternoon (between 1.30 and 5 p.m.). During exercise, children 
inhaled dry air with a temperature of 20 – 25 degrees Celcius and a humidity of 16 ppm. 
Heart rate was continuously monitored by a radiographic device (Polar Sport Tester®, 
Kempele, Finland) and the running speed of the treadmill was increased to raise the 
heart rate to approximately 90% of the predicted maximum. This speed was maintained 
for a total duration of 6 min. Spirometry was performed before exercise (baseline value) 
and 1, 3, 6, 9, 12, 15 and 20 min after exercise. Twenty minutes after exercise, or earlier 
at request, children received 100 µg salbutamol and spirometry was performed at t = 
21, 23, 25 and 30 min until FEV1 had returned to ≥ 95% of baseline value. If FEV1 had not 
recovered to ≥ 95% of baseline after 30 min, children received a second dose of 100 μg 
salbutamol.
Questionnaires
The ACQ and PAQLQ questionnaires were performed at the screening and third visit to 
the outpatient clinic by the research assistant. The ACQ is used to assess asthma control 
and consists of 7 questions, scoring symptoms, daily rescue bronchodilator use and 
baseline FEV1 % predicted.21 Children can respond to these questions on a 7-point scale. 
Baseline FEV1 % predicted is scored by the lung function assistant. The questions weigh 
equally and the ACQ score is the mean and ranges between 0 (totally controlled) and 6 
(severely uncontrolled).
The PAQLQ is used to measure quality of life and consists of 23 questions in 3 domains; 
symptoms, activity limitation and emotional function.22 Children can respond on a 
7-point scale. The total PAQLQ score is the mean of all 23 questions and domain scores 
are the means of the items in those domains, ranging from 1 (impaired quality of life) to 
7 (no impairment in quality of life).
statistical analysis
Data consisted of 3 sets of pre-exercise and post-exercise FEV1 values at pre-defined 
time points. Exercise induced bronchoconstriction was expressed as total area under 
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the curve from 0 to 20 min post-exercise (AUC0-20min), calculated by a trapezoid rule, and 
post-exercise % fall in FEV1 from baseline at each time point. The time to recovery to ≥ 
95% of baseline FEV1 was retained for analysis, and the percentage of children not recov-
ered after 20 min was calculated. Children who received a dose of salbutamol before 20 
min post-exercise were excluded from this analysis. If FEV1 did not decrease below 95% 
of baseline, the time to recovery was assigned a value of zero.
As CysLTs produce a potent and longlasting bronchoconstrictor effect on airway 
smooth muscle, MLK was anticipated to mainly attenuate the duration of bronchocon-
striction, measured by the AUC.3 This was previously confirmed in several large adult 
studies demonstrating a greater reduction in post-exercise AUC than in the maximum 
post-exercise % fall in FEV1 after regular treatment with MLK.23-25 Hence, the primary end 
point was the correlation (reported as the intraclass correlation coefficient) between the 
change in AUC0-20min after a single MLK-dose and after 4 weeks MLK-treatment. Second-
ary end points were the correlation between change in maximum % fall in FEV1 after 
a single MLK-dose and 4 weeks MLK-treatment and percentage protection against EIB 
(defined as % reduction in AUC0-20min and maximum% fall in FEV1 ) provided by a single 
MLK-dose and 4 weeks MLK-treatment. Changes between screening, second and third 
visits in all outcome variables were analyzed with Students’ paired t-test (for normally 
distributed variables, i.e., FEV1 values and % fall in FEV1) or Wilcoxon-signed rank test (for 
variables with a skewed distribution, i.e., ACQ and PAQLQ).
Children with < 25% reduction in AUC0-20min after MLK were considered non-responders. 
A cross-tabulation was made of responders and non-responders to a single MLK-dose 
and 4 weeks MLK-treatment. Fisher’s exact test was used to calculate the positive and 
negative predictive value of a single dose response.
SPSS® 20.0 for Windows® was used for statistical analysis. A P-value of < 0.05 was 
considered statistically significant. The sample size estimated to detect a difference of 
-0.60 between the null hypothesis correlation of 0,00 and the alternative hypothesis 
correlation of 0.60 using a two-sided hypothesis test with a significance level of 5% and 
80% power, was 19 subjects.
rEsulTs
Fifty-one children were screened by a standardized treadmill exercise challenge. 
Twenty-seven children had a < 10% post-exercise fall in FEV1 and were excluded. 
Twenty-four eligible children were included of whom twenty-one completed the study. 
Patient baseline characteristics are presented in Table 1. One girl was excluded because 
she underwent another medication change during the treatment period and two other 
children dropped out for reasons unrelated to MLK-treatment or the study protocol.
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Three children reported adverse events during the treatment period with MLK. Two of 
them complained of headache during the first days of treatment, and one child reported 
an increase in pre-existing symptoms of dizziness. All adverse events were mild and self-
limiting.
All children included in this study were clinically suboptimally controlled on low dose 
ICS (stable dose for at least 6 weeks) and used short-acting β2-agonists on an as-needed 
basis, with a self-reported mean (± SD) use of 1.9 (± 1.8) puffs per week before the base-
line exercise challenge and 1.6 (± 1.6) puffs per week after 4 weeks of treatment with 
MLK. FEV1 after a single MLK-dose and after 4 weeks treatment were not significantly 
different from FEV1 before the baseline exercise challenge. All outcome variables are 
summarized in Table 2.
Exercise induced bronchoconstriction
Exercise induced bronchoconstriction, expressed as the AUC0-20min, decreased significant-
ly after a single MLK-dose (P = 0.001, CI 64.9 – 218.2), but not after 4 weeks of treatment 
(P = 0.080, CI -12.2 – 200.4). There was a moderate correlation between the response to 
a single MLK-dose and 4 weeks MLK-treatment on exercise-induced AUC0-20min, r = 0.49 
(P = 0.011) (Fig. 2A).
Table 1. Baseline characteristics of study population (n = 24)
Characteristic
Male 45.8%
Age (yr) 14.4 ± 1.6
Weight (kg) 55.8 ± 13.0
Height (cm) 167 ± 12.6
BMI (kg/m2) 19.8 ± 3.1
Baseline FEV1 (% pred.) 92.9 ± 12.4
Allergic 86%
RAST animal dander positive 54%
RAST house dust mite positive 75%
RAST tree pollen positive 46%
RAST grass pollen positive 46%
nasal corticosteroid use 50%
LABA use 13%
ICS use 100%
ICS daily dose (µg) 200 (100 – 400)
Data expressed as mean ±SD, median (range) or percentage of total patients. BMI = body mass index, RAST = 
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Exercise-induced maximum % fall in FEV1 decreased significantly after a single MLK-
dose (P = 0.002, CI 2.4 – 9.2), but not after 4 weeks of MLK-treatment (P = 0.16, CI -1.9 – 
10.9). There was however no significant difference in maximum % fall in FEV1 between a 
single MLK-dose and 4 weeks of MLK-treatment. Mean % fall in FEV1 (± SEM) at each time 
point post-exercise is shown in Fig. 1 for all three exercise challenges. There was a weak 
correlation between the response to a single MLK-dose and to 4 weeks MLK-treatment 
on exercise induced maximum % fall in FEV1, r = 0.40 (P = 0.035) (Fig. 2B).
A single dose of MLK and 4 weeks MLK-treatment respectively provided 45.7% vs. 
30.4% reduction in AUC0-20min and 24.0% vs. 18.5% reduction in maximum % fall in FEV1. 
When children with ≥ 25% reduction in AUC0-20min were considered responders to MLK, 
13 out of 21 (62%) could be considered responders after a single MLK-dose and 15 out of 
21 (71%) after 4 weeks of MLK-treatment. Table 3 shows a cross-tabulation of responders 
and non-responders based on reduction in AUC0-20min. In this study, the positive predic-
tive value of a single MLK-dose response was 84.6% and the negative predictive value 
50.0% (P = 0.146).
Complete data sets for the evaluation of recovery were available for 18 children, as 3 
children received a rescue gift of salbutamol before 20 min post-exercise (1 child after 
the baseline exercise challenge, 2 children after the second challenge and 2 children after 























fig. 1. Mean % fall in FEV1 (± SEM) at each time point post-exercise after a baseline exercise challenge,20h 
after a single MLK-dose and 40-44h after the last dose of a 4 week course of MLK once daily.










































Change in max. % fall in FEV1B
fig. 2. Change in AUC0-20min (panel A) and maximum % fall in FEV1 (panel B) between a baseline exercise 
challenge test (ECT) and an ECT after a single MLK-dose and between a baseline ECT and an ECT after 4 
weeks MLK-treatment.
AUC0-20min = area under the curve, FEV1 = forced expiratory volume in 1s, MLK = montelukast
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to ≥ 95% of baseline within 20 min; after a single MLK-dose and 4 weeks MLK-treatment 
resp. 68% and 72% of children recovered within 20 min. However, these differences were 
not statistically significant.
Quality of life and asthma Control
At the baseline visit children had a mean ACQ score of 1.07 ± 0.83 units. Based on their 
ACQ, 10 out of 21 children (48%) could be considered partly or fully uncontrolled (ACQ 
score ≥ 0.75), although all children were suboptimally controlled based on guideline de-
rived symptom scores2. After 4 weeks MLK-treatment there was no change in mean ACQ 
scores (P = 0.53, CI -0.25 – 0.46) and 8 out of 21 children (38%) could still be considered 
partly or fully uncontrolled.
At baseline, quality of life was slightly impaired with a mean PAQLQ score of 6.04 ± 0.98 
units. After 4 weeks MLK-treatment there was no significant difference in total PAQLQ 
score (P = 0.13, CI -0.71 – 0.09). However, there was a small, but significant improvement 
in the PAQLQ activity limitation domain score (P = 0.040, CI -0.93 to -0.02).
dIsCussIon
In this study we found a moderate correlation between the protective effect against EIB 
of a single MLK-dose and 4 weeks of MLK-treatment, expressed as post-exercise AUC0-
20min and maximum % fall in FEV1. A single MLK-dose provided a greater reduction in 
AUC0-20min post-exercise (45.7%) than 4 weeks of MLK-treatment (30.4%). A minority of 
the children (19.0%) failed to show protection against EIB after either a single MLK-dose 
or 4 weeks of MLK-treatment.
This was the first study that separated the single dose and longer term response 
to MLK by assessing EIB 20-24h after a single MLK-dose, and 40-44h after 4 weeks 
MLK-treatment, to measure their relationship. Previous studies both in adults11,12 and 
children13 showed a similar attenuation in EIB performed at the through interval (24h) 
after a single MLK-dose. Bronsky et al.26 observed in adult asthmatics that this protective 
effect expired 32-36h after two once daily doses of MLK (2, 10 or 50 mg). However, Kim et 
Table 3. Cross-tabulation of the response to montelukast
response after single dose
response after 4 weeks treatment Total
Responder Non-responder
Responder 11 2 13
Non-responder 4 4 8
Total 15 6 21
A responder is defined as ≥ 25% reduction in AUC0-20min compared to baseline AUC0-20min.
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al.16 found a prolonged protective MLK-effect against EIB in asthmatic children, i.e. 48h 
after the last dose of 8 weeks daily treatment, suggestive of anti-inflammatory proper-
ties of regular MLK-treatment. In an animal model of allergic asthma, it was shown that 
4 weeks treatment with MLK has anti-inflammatory effects on the airway wall and lung 
parenchym.27 In all other previous pediatric studies describing longer-term protection 
against EIB, children performed an exercise challenge at the end of the dosing interval 
(i.e., 20-24h post-dosing)5-7, which is expected to reflect the composite response to 
both the more acute, functional antagonistic and the long(er)-term, anti-inflammatory 
properties of MLK. By measuring EIB 40-44h after the last dose of 4 weeks of regular 
MLK-treatment we allowed assessment of the anti-inflammatory MLK-effect only.
Our data can be affected by several factors. Firstly, the timing of the exercise challenges 
may have influenced our data. Based on pharmacological data showing a plasma half 
life of MLK of 2.7-5.5h, measuring the effect of a single MLK-dose 20-24h after dosing 
may underestimate the acute antagonistic effect of MLK. However, previous studies in 
both adults11,12 and children (aged 4-14y)13 showed that the reduction in both maximum 
% fall in FEV1 and AUC0-60min was similar at 2h and 24h after a single MLK-dose.11-13
The 40-44h time interval between the last dose of MLK and the exercise challenge 
can explain why we found a smaller reduction in AUC (30.5%) and maximum % fall in 
FEV1 (18.5%) after 4 weeks of MLK-treatment. Previous pediatric studies reported 63.8% 
reduction in AUC6 and 44.8 - 56.5% reduction in maximum % fall in FEV15-7, but measured 
the effect 10-24h after the last dose. However, the small effect of MLK on EIB after 4 
weeks was consistent with the lack of effect on ACQ and PAQLQ scores. The treatment 
period of 4 weeks might have been rather short to evaluate the anti-inflammatory ef-
fects of MLK, but was similar to other pediatric studies describing the effect of regular 
daily MLK on EIB.5-7
A second possible confounder is the lack of a placebo arm. This study was designed 
to correlate the single dose response to MLK and the response to regular daily MLK-
treatment. Both have been shown to be effective against EIB in asthmatic children in 
previous placebo controlled studies.4-8,13 As the children included in this study were 
partly or fully uncontrolled by low dose ICS alone, we decided not to withhold proper 
add-on treatment any longer than necessary.
A third factor that may have influenced our results is that based on ACQ scores both 
well controlled, as well as fully uncontrolled children were included. However, based on 
clinical symptoms, all children were partly or fully uncontrolled according to interna-
tional guidelines. Furthermore, all children had ≥ 10% fall in FEV1 at baseline, which is 
a sign of uncontrolled asthma. Subgroup analysis comparing children with ACQ scores 
<0.75 vs. ≥0.75 did not show any significant differences.
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Furthermore, children took MLK at home, unsupervised by hospital staff. We explicitly 
instructed the children and their parents about the timing of the medication gifts, and 
checked their compliance by checking their medication strip during the study and fol-
lowing study completion. Asthmatic children in our outpatient clinic are reviewed for 
their adherence and inhalation technique every three months.
Interestingly, in our study a single dose provided a greater mean protection against EIB 
than 4 weeks treatment. However, as some children reached a significant attenuation 
of EIB only after 4 weeks of treatment, or showed greater protection against EIB after 4 
weeks of MLK-treatment, the absolute number of responders was greater after 4 weeks 
of treatment. Meanwhile, some patients only responded to a single MLK-dose and not 
to 4 weeks treatment. We speculate that this heterogeneity in response to a single MLK-
dose and 4 weeks of MLK-treatment reflects the variable progression of airway inflam-
mation and remodeling in children with asthma. When inflammation is relatively mild 
and EIB is mainly the result of transient increased airway smooth muscle tone due to 
mediator release, a single dose of MLK is effective and inflammation is easily reversible 
within 4 weeks treatment. However, when inflammation is more progressed and airway 
remodeling more pronounced, 4 weeks daily treatment is probably insufficient. In these 
patients, EIB might bounce back after the single dose effect of MLK has waned.
In real life, children using step-up treatment with MLK on a daily base will benefit from 
both the single dose antagonistic effect and the anti-inflammatory effect of regular treat-
ment. In our study, only 4 (19%) of children could be considered true non-responders 
with no response to either a single dose or 4 weeks treatment. Previous studies found 
similar or higher percentages of non-responders (ranging from 17.9% - 43%)5,6,8,16,23-25 
based on the reduction in % fall in FEV1 after regular treatment with MLK. However, these 
studies used a variety of different cut-off values to differentiate between responders and 
non-responders. Some studies considered patients with ≥ 50%5 reduction in maximum 
% fall in FEV1 responders; others considered all patients with < 10%6, < 20%8,16,24,25 or 
< 30%23 fall in FEV1 responders. We chose to define MLK-responders based on AUC, as 
large studies both in adults23-25 and children6 have shown that following exercise chal-
lenge, MLK has a greater impact on AUC than on maximum % fall in FEV1. For children 
practicing sports, the AUC, representing both the severity and duration of EIB, is at least 
as important as the maximum % fall in FEV1.
Montelukast has been shown to provide similar or better protection against EIB after 
4 weeks treatment compared to other step-up options. Long-acting β2-agonists initially 
provide significant protection against EIB, but as tolerance develops, the bronchopro-
tective effect of long-acting β2-agonists wanes after 4 weeks treatment.4,7,28 Doubling 
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the dose of ICS did not result in significant differences in EIB after 3 weeks treatment29,30, 
and quadrupling the dose of ICS resulted in only 26.1 - 34.8% reduction in AUC30.
In conclusion, in the present study we found that the protection provided by a single 
dose of MLK against EIB only modestly predicts the effect of regular MLK-treatment 
against EIB. The single dose response to MLK was stronger than the response to 4 weeks 
regular treatment, implying that a high adherence is essential to profit from the full pro-
tective effect of MLK against EIB. If used on a daily base, MLK offered clinically significant 
protection against EIB in the large majority (80%) of children suboptimally controlled by 
low dose ICS.
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IndIrECT BronChIal ProvoCaTIon TEsTs
In chapter 1 we describe the current approach to diagnosing, monitoring and treat-
ing childhood asthma. We discuss several clinical dilemmas of this approach that are 
debated in current literature. We postulate that indirect bronchial provocation tests 
(BPTs) can be used to monitor BHR and airway inflammation. In the following chapters 
of this thesis we used exercise challenge tests (ECTs) and mannitol tests for short term 
monitoring of asthmatic children.
The idea that indirect BPTs can be used to monitor airway inflammation is not new. In 
2003 the European Respiratory Society task force on indirect airway challenges already 
concluded: ‘Indirect challenges may reflect acute changes in airway inflammation more 
closely and be clinically relevant markers to assess the clinical course of asthma.’1 A re-
view by Cockcroft and Davis compared the use of direct and indirect BPTs in the clinical 
assessment of asthma2 and concluded that indirect BPTs should be the challenges of 
choice for evaluating and monitoring asthma treatment.
BHR to an indirect stimulus has advantages over other parameters used to monitor the 
response to anti-inflammatory treatment.
Symptoms and lung function are accessible parameters to monitor treatment, but 
poorly correlate to the underlying disease severity in asthmatic children.3,4 Question-
naires to assess asthma control, such as the Asthma Control Test (ACT), do not correlate 
with measures of airway inflammation in the follow-up of asthmatic children.5,6
Invasive techniques, such as analysis of induced sputum, broncho-alveolar lavage and 
lung biopsies can be used to assess airway inflammation. In adults, tailoring treatment 
to sputum eosinophils reduces asthma exacerbations.7 In children, invasive tests are not 
suitable for routine use. Safety issues, technical demands and costs of sputum induction 
and analysis limit the use in clinical practice.
Analysis of Fraction of exhaled Nitric Oxide (FeNO) is relatively easy to perform in chil-
dren. However, various other factors can influence FeNO levels, such as atopy, allergic 
rhinitis (AR), exercise, age, and viral respiratory tract infections.8,9 A 2012 pediatric (mean 
age 10-14y) meta-analysis concluded that tailoring the dose of inhaled corticosteroids 
(ICSs) to FeNO compared to symptoms and lung function cannot be recommended for 
clinical practice, as it leads to increased use of ICSs without meaningful changes in clini-
cal outcomes.9
BHR to direct stimuli reflects chronic inflammation and responds slowly to anti-
inflammatory treatment. In adults, tailoring treatment to direct BHR for 2 years leads 
to fewer exacerbations, better lung function and a greater reduction in basement 
membrane thickness compared to tailoring treatment to symptoms and lung function 
alone.10 A similar study in asthmatic children (aged 6-16y) treated with ICSs over 2 years 
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showed no benefit in number of exacerbations, but a better pre-bronchodilator FEV1, 
in children whose treatment was tailored to direct BHR compared to symptoms alone.11 
This could result from differences in the pathophysiology of asthma between adults 
and children.12,13 Direct BHR reflects chronic inflammation leading to functional and 
anatomic airway remodeling1,2, which may play a larger role in adults.
BHR to indirect stimuli is closely associated with current airway inflammation. In adults, 
there is a significant relationship between sputum eosinophilia and the sensitivity to 
indirect, but not direct, BPTs.15,16 In adolescents and adults, the percentage of sputum 
eosinophils correlates with the severity of EIB17 and sensitivity to mannitol.16 In children 
(aged 8-14y), BHR to hypertonic saline is strongly associated with the presence of mast 
cells in sputum.18
A response to an indirect BPT could identify patients who are likely to benefit from ICSs, 
as it reflects the presence of inflammatory cells that are targets for ICS treatment.19 The 
regular use of ICSs can attenuate airway sensitivity and reactivity to indirect stimuli.20-22 
In adults, the increase in BHR to mannitol during down-titration of the dose of ICSs was 
predictive of an asthma exacerbation.23
Airway sensitivity and reactivity to adenosine monophosphate (AMP; an osmotic 
indirect BPT) correlated significantly with guideline derived asthma control in adults.24 
Abolishing the response to indirect stimuli, as a marker of asthma control, may be a 
treatment goal.25 Tailoring treatment with ICSs to BHR to mannitol was demonstrated 
to improve quality of life in asthmatic adults in a primary care setting.26 In a larger study 
in adults with mild-to-moderate asthma, tailoring ICS treatment to BHR to mannitol 
for a year led to reductions in number of mild exacerbations, FeNO, eosinophilic cat-
ionic protein, symptoms and rescue β2-agonist use, compared to tailoring treatment to 
symptoms and lung function.27
In summary, indirect BPTs are clinically relevant parameters to assess and monitor airway 
inflammation and the short term response to anti-inflammatory treatment in asthmatic 
children.
Further research is necessary to assess the complex relationship between BHR and 
airway inflammation. Unraveling the exact pathophysiologic mechanisms of BHR to 
different stimuli would lead to a better understanding of childhood asthma and pos-
sible targets for therapy. Larger, randomized placebo controlled studies are necessary to 
evaluate how indirect BPTs can be used to monitor long-term changes in airway inflam-
mation. The effect of tailoring treatment to indirect BHR should be studied for longer 
treatment periods and in different subgroups of patients.
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mannITol ProvoCaTIon TEsT
In chapter 2 we studied the clinical utility of the mannitol test to identify asthmatic 
children with exercise induced bronchoconstriction (EIB). In this study, 33 asthmatic 
children, aged 9-18 years, with a history of EIB, performed both mannitol and exercise 
tests. Data were composed of a cross tabulation comparing the reaction on an exer-
cise test to a mannitol test. Correlations between post-exercise % fall in FEV1 and RDR 
(response-dose ratio) and PD15 (provoking dose to cause a 15% fall in FEV1) of mannitol 
were calculated. Twenty-five children completed both tests. Pearson’s correlation be-
tween log-transformed RDR for mannitol and post-exercise % fall in FEV1 was rp = 0.666 
(P < 0.001). There was no significant relationship between the log PD15 of mannitol and 
post-exercise % fall in FEV1. Positive and negative predictive values of the mannitol test 
for EIB were respectively 69% and 92%. We concluded that a mannitol test is a suitable 
alternative for an exercise challenge test (ECT) to assess EIB in asthmatic children.
In 2011, Stickland et al. performed a systematic meta-analysis to determine the sen-
sitivity and specificity of the mannitol test to diagnose EIB.38 They concluded that the 
sensitivity and specificity ranged from 58–96% and 65–78% respectively.38 Since then, 
several other studies have been performed to assess the concordance between BHR to 
mannitol and exercise and/or eucapnic voluntary hyperpnoea (which is considered a 
sensitive test for EIB, especially in athletes).39 The results of these and previous studies 
are summarized in Table 1.
These studies demonstrate a variable sensitivity and specificity of mannitol, depend-
ing on the research population. Especially in elite athletes, sensitivity of mannitol ap-
peared low.34-37 However, the pathophysiology of EIB differs between asthmatic children 
and adult athletes. In childhood asthma, EIB is a consequence of the inflammatory 
substrate present in the airway wall. In adult athletes, EIB results from repetitive thermal, 
osmotic and mechanical stress due to extensive training, causing injury to the airway 
epithelium.40,41 Only one other study was performed in asthmatic children (aged 6-16y) 
and found similar positive and negative predictive values of the mannitol test for EIB 
compared to our study. 32
Although a mannitol test can be used as an alternative for an ECT, there are some differ-
ences between the physical responses to exercise and mannitol (Table 2.)
Firstly, exercise induces a variety of other physiologic changes, such as the release 
of steroids and catecholamines and an increase in minute ventilation, cardiac output 
and oxygen uptake. Some of these mechanisms protect the airway from narrowing and 
compensate for the ventilation-perfusion (VA/Q) imbalance caused by bronchoconstric-
tion.42 These compensatory mechanisms do not occur during a mannitol test.42
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Secondly, mannitol is primarily deposited in the large central airways, because of its 
particle size.43 The amount of mast cells is greater in the peripheral airways44,45, where 
only a small part of the inhaled mannitol powder will penetrate. When exercise is more 
vigorous and/or longer, producing a higher ventilation rate, or when the inspired air is 
colder and/or dryer, the smaller airways beyond the 10th generation are recruited in the 
humidifying process.46 Therefore, a change in inflammation of the small airways is more 
likely to be detected with an ECT.
Thirdly, the osmotic stimulus provoked by mannitol is different because it is caused 
by active withdrawal of water from the airway epithelium instead of evaporative water 
loss. The rate of change in osmolarity, which is suggested to be a determinant of BHR47, 
is faster and greater with an ECT.
A mannitol test is faster and easier to perform than an ECT, and does not require 
specifically trained personnel or specialized equipment. Mannitol tests showed good 
Table 2. Characteristics and differences of exercise challenge and mannitol tests
Exercise challenge test mannitol test
safety
Burden for patient -vigorous exercise
-time consuming
-side effect: coughing48
Safety during test -risks of running at high speed
-(uncontrolled) large fall in FEV1
-approved for safety & efficacy48
-dose-response protocol avoids large fall in 
FEV148
Recovery rapid (< 10 min after SABA) rapid (< 10 min after SABA)49
Technical
Equipment -space occupying ergometer
-dry air source, cold air environment
-office based test kit
Personnel trained personnel easy standard procedure
Duration 45 - 50 min 20 - 30 min48
Costs high moderate
Repeatability variation ± 12 % in children50 variation ± 1.1 doubling dose in children51
diagnostic value for asthma
Stimulus natural stimulus; real life test osmotic stimulus; surrogate test
Specificity high (90%) high (95%)52
Sensitivity moderate (65%); depends on study 
population and air conditions
moderate (40 - 75%)52; depends on study 
population
monitoring value for asthma
Treatment effect improves with ICS treatment20 improves with ICS treatment21,22
Asthma control can be used to monitor asthma 
control
can be used to monitor asthma control23,27
FEV1 = forced expiratory volume in 1s, ICS = inhaled corticosteroid, SABA = short acting β2-agonist
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repeatability in asthmatic children (aged 6-16y).51,53 Its safety was demonstrated in 592 
asthmatic and non-asthmatic subjects, including 126 children (aged 6-18y).48 In this 
study, only 14/592 subjects experienced > 30% fall in FEV148, as the test can be stopped 
before major falls in FEV1 occur. The mannitol test is also feasible in younger children, 
aged 3-7 years.54
A limitation of the mannitol test is the occurrence of a dry cough, which almost all 
patients experience. This cough can interfere with the fixed time schedule. The test 
should be performed quickly (next dose within 60s after spirometry). Prolonging the 
time between the inhalation of subsequent doses of mannitol could lead to a milder os-
motic stimulus and give falsely negative results. Severe coughing, leading to disruption 
of the test, occurs in 1.3% of tested subjects.52 Mannitol provoked coughing can occur 
immediately after inhalation due to the impaction of powder on the oropharynx30,53 or 
later due to deposition of powder in the lower respiratory tract, stimulating nerve fibers 
by hyperosmolarity.55,56 Mannitol induced coughing is related to the increased sensitiv-
ity of the asthmatic airways, making it useful in the diagnosis of asthma.57
In summary, mannitol has a high specificity and moderate sensitivity to diagnose EIB 
in asthmatic children; but there are some differences in the physiological responses to 
exercise and mannitol. As mannitol is a practical, fast and safe test, it has the potential 
to become an office based test to monitor treatment alterations in asthmatic children 
with EIB.
Future research studying the differences in physical responses to mannitol and 
exercise could present new information on the pathophysiology of EIB. The effects of 
tailoring treatment to BHR to mannitol in children with asthma and EIB should be further 
explored.
β2-aGonIsTs
In chapter 3 and 4 we investigated the effect of the development of tolerance to 
long-acting β2-agonists (LABAs) on BHR to indirect BPTs. We analyzed clinically stable 
asthmatic children who were stepped down from LABA/ICS combination therapy to 
monotherapy with the same dose of the ICS. As regular use of β2-agonists can increase 
BHR to indirect stimuli, we hypothesized that this step down could do the opposite.
In chapter 3 we analyzed the effect of stepping down combination therapy to mono-
therapy with an ICS on EIB in clinically stable asthmatic children with a history of mild to 
moderate EIB. Nineteen children, aged 8-16 years, were analyzed in this open-label pilot 
study. Children performed a baseline ECT after a 4 week run-in period on combination 
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therapy and 3 weeks after the medication was stepped down. Maximum % fall in FEV1 
was significantly lower after 3 weeks of ICS monotherapy (P = 0.03).
Eight children had a ≥ 15% fall in FEV1 after exercise at the initial ECT. The cutoff value 
to diagnose EIB on an ECT is controversial. A fall of ≥ 10% is considered abnormal; a fall of 
≥ 15% appears to be more diagnostic of EIB, particularly if exercise has been performed 
in the field. Haby et al.50 found that 1.96 SD above the mean fall in FEV1 when testing 
8-11 year old healthy children in the field was 15.3%. Because the environmental cir-
cumstances in which the test was performed in our study were more similar to outdoor 
circumstances than to laboratory settings, a cut-off value of 15% was used.
In the subgroup of patients with EIB, maximum % fall in FEV1 was significantly lower 
(P < 0.01) after the medication was stepped down and in 6 children it decreased to < 
15%. We concluded that in clinically stable asthmatic children with mild to moderate 
EIB despite LABA/ICS combination therapy, the cessation of the LABA can reduce and in 
most cases even abolish EIB.
In chapter 4 we performed a similar study design, analyzing the effect of stepping down 
combination therapy to ICS monotherapy on BHR to a mannitol test. Seventeen chil-
dren, aged 12-17 years, with clinically stable asthma and a history of mild to moderate 
EIB were analyzed in this prospective open-label study. Children performed a mannitol 
test after a 4 week run-in period on combination therapy and 30 ± 4 days after their 
medication was stepped down. The changes in mannitol PD15, RDR and recovery time 
following a short-acting β2-agonist (SABA) to ≥ 95% of baseline FEV1 were calculated. 
Mannitol PD15 and RDR did not change after stepping down. The recovery time following 
a SABA was significantly shorter (P = 0.01) after the cessation of the LABA. We concluded 
that in clinically stable asthmatic children with mild to moderate EIB despite LABA/ICS 
combination therapy, the cessation of the LABA does not change BHR to mannitol, but 
does shorten recovery time to baseline lung function following a rescue SABA.
Due to concerns about the safety of LABA use, the US Food and Drug Administration 
(FDA) advised that in asthmatic children on combination therapy, LABAs should be 
withdrawn once asthma control is achieved.59 A recent meta-analysis reviewed the 
effect of stepping down to ICS monotherapy compared to continuation of LABA/ICS 
combination therapy in asthmatic adults.60 They concluded that the LABA step-down 
regimen resulted in worse asthma control and quality of life.60 However, they did not 
assess the effect on BHR, and no pediatric studies were included.
The results from our studies are consistent with findings from studies that stepped up 
treatment with a LABA. Regular treatment with β2-agonists leads to downregulation 
and desensitization of the β2-adrenoreceptor (β2AR), resulting in a reduced protection 
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against BHR61-66 and a prolonged recovery time after rescue therapy with a SABA.61,64,65 
Because this process occurs faster in mast cells than smooth muscle cells, the effects of 
tolerance are more pronounced when measured with an indirect BPT compared to a 
direct BPT.67-70 As BHR to exercise decreased after the cessation of the LABA, and BHR to 
mannitol did not, we speculate that EIB gives a better reflection of inflammation in the 
peripheral airways, where more mast cells reside45 and the amount of β2ARs on smooth 
muscle is highest.58
Downregulation of β2ARs on the mast cell increases its susceptibility to degranulate, 
as was shown by increased levels of mast cell mediators following an allergen challenge 
in adults treated with a SABA.71 This could lead to more instable asthma and an increase 
in BHR.
The number of β2ARs on leukocytes in asthmatic children (aged 11-16y) has a negative 
correlation with BHR to exercise.72 Regular treatment of steroid-naïve asthmatic adults 
with a SABA increases BHR to exercise73,74 and hypertonic saline.75 This has not been 
studied after regular treatment with LABA monotherapy. However, in studies compar-
ing a step-up to LABA/ICS combination therapy to the same dose of ICS monotherapy, 
asthmatic children (aged 6-18y) showed a significantly lower improvement in BHR to 
methacholine76 and a non-significantly lower improvement in BHR to exercise63 on 
LABA/ICS combination therapy. This suggests that LABAs may attenuate the beneficial 
effects of ICSs on BHR.
In daily life, the effect of LABA tolerance may be less apparent than in clinical trials 
due to poor compliance. The effects of tolerance have been shown to be reversed within 
three days after a LABA is discontinued.77 Therefore, patients who regularly take a ‘drug 
holiday’ might not experience the adverse effects of LABA tolerance.
The clinical relevance of β2AR downregulation and β2-agonist associated increased 
BHR to indirect stimuli is still debated. In chapter 5 we review current literature on 
the benefits and safety of β2-agonists in childhood asthma. We hypothesize that the 
combination of increased BHR and a reduced response to rescue bronchodilators could 
account for the association between serious asthma related adverse events and regular 
β2-agonist use.
Asthmatic patients with specific genotypes might be more susceptible to this. β2AR-
gene polymorphisms result in changes in the amino acid sequence of the β2AR, leading 
to alterations of its properties, possibly representing a risk factor for adverse responses 
to β2-agonist therapy.
The rare Thr164Ile polymorphism results in a decreased β2AR ligand binding in vitro78 
and was associated with severe exacerbations requiring hospitalizations and systemic 
corticosteroids in African American adults treated with a LABA.79
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The more extensively studied Arg16Gly polymorphism, which is prevalent in 12-
15%80,81 of the Caucasian population, has also been shown to interfere with treatment 
responses to β2-agonists. In vitro, receptors with the homozygous Arg16 genotype 
show enhanced susceptibility for homologous desensitization and receptor downregu-
lation.82
Retrospective analyses of data from trials in adults on ICSs have demonstrated adverse 
effects of the Arg16 homozygous variant on BHR83 and exacerbations84 after receiving 
a SABA as regular therapy. In a genotype stratified prospective trial in steroid-naïve 
asthmatic adults the response to 16 weeks regular albuterol was compared to placebo 
plus ipratropium rescue treatment.85 In this study, Arg16 homozygotes did not demon-
strated a deterioration of symptom control during albuterol treatment, in contrast to 
Gly16 homozygotes.
Studies searching for the effect of the Arg16 homozygous genotype on the response 
to treatment with LABAs have shown conflicting results, which appear to be dependent 
on the age of the study group.
In children, an increased risk for exacerbations in Arg16 homozygotes in a cohort of 
1182 patients on ICSs (aged 3-22y) with daily use of salmeterol was reported.86 Another 
study described an increase in oral corticosteroid use and emergency department visits 
in the past year in 597 Arg16 homozygotes (aged 4-12y) on LABA/ICS combination 
therapy compared to Gly16 homozygotes.87 A prospective randomized controlled trial in 
asthmatic children (aged 5-18y) showed that in Arg16 homozygotes adding montelukast 
compared to salmeterol to inhaled fluticasone significantly improved asthma symptoms 
and quality of life.88 This study suggests that in children the Arg16Gly genotype could 
help to determine the appropriate step-up or step-down regimen.
In summary, regular treatment with β2-agonists leads to a loss of bronchoprotection 
and a reduced bronchodilator response to rescue SABAs. Downregulation of β2ARs 
on the mast cell could lead to more instable asthma, increased BHR and a higher risk 
of exacerbations. Therefore, if asthmatic children on LABA/ICS combination therapy 
experience EIB, a withdrawal of the LABA or a switch to another step 3 option should be 
considered. If asthmatic children with EIB need SABAs more than twice weekly, includ-
ing pre-exercise use, a step-up in controller therapy should be considered.
Future trials should study the effects of different LABA treatment regimens, with con-
comitant ICSs, on BHR and other outcome measures of inflammation, asthma control 
and quality of life. More research in children < 12 years is necessary to provide evidence 
based recommendations on the safety and efficacy of LABA/ICS combination therapy in 
general, and in different genetic subgroups.
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InTranasal CorTICosTEroIds
In chapter 6 we studied the effect of intranasal anti-inflammatory treatment on lower 
airway inflammation and BHR. In this study, children aged 12-17 years, with mild-to-
moderate asthma, intermittent AR and ≥ 10% fall in FEV1 at a screening ECT were 
randomized (double-blind) to 22 ± 3 days treatment with nasal fluticasone furoate or 
placebo. The primary outcome was change in exercise induced fall in FEV1. Secondary 
outcomes were changes in scores on the asthma control questionnaire, pediatric asthma 
quality of life questionnaire and FeNO.
Twenty-five children completed the study. Exercise induced fall in FEV1 decreased 
significantly in the fluticasone furoate group compared to the placebo group (P = 0.04). 
Although total quality of life score did not improve after nasal fluticasone furoate treat-
ment, the activity limitation domain score improved significantly within the fluticasone 
furoate group (P = 0.03). No significant changes were observed in FeNO and asthma 
control questionnaire scores. We concluded that treatment with an intranasal cortico-
steroid reduces EIB in children with mild-to-moderate asthma.
Preceding studies on the effect of INCS on measures of BHR and lower airway inflam-
mation have shown conflicting results.89,90 The 2010 Allergic Rhinitis and its Impact on 
Asthma (ARIA) guidelines concluded there was no clear benefit from the use of INCS for 
asthma.91 However, since 2010 several new studies have been published and a meta-
analysis of both adult and pediatric studies concluded that INCS significantly improve 
FEV1, symptom scores, rescue medication use and BHR to methacholine and histamine 
compared to placebo in steroid-naïve patients.92 There was no significant change in 
asthma outcomes with the addition of INCS to ICSs.92 This may reflect the fact that most 
patients on ICSs already have good baseline asthma control with less room for improve-
ment with additional INCS. In our study, we included children with a ≥ 10% fall in FEV1 
post-exercise, which is a sign of partially uncontrolled asthma. This may explain why we 
did demonstrate an improvement in EIB with INCS even in children on ICSs.
Although the effect of INCS on BHR to direct BPTs was statistically significant in the 
2013 meta-analysis, it was only small (improvement in PC20 of 0.43 doubling doses; 95% 
CI 0.16 – 0.69) and not clinically relevant.92 An indirect BPT might be more suitable to 
measure the short-term effects of INCS on the lower airways. The effect of INCS on BHR 
to indirect stimuli was only studied in one other study.93 Henriksen et al. investigated 
the effect of intranasal budesonide on EIB in room temperature in steroid-naïve al-
lergic asthmatic children (mean age 11.6y) with chronic nasal obstruction and found 
a non-significant trend towards a reduction in EIB after 4 weeks treatment.93 The main 
differences compared to our study were the inclusion criteria and the condition of the 
inhaled air during the ECT. We included children with intermittent symptoms of AR 
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whereas Henriksen selected children with a persistently blocked nose. Furthermore, we 
used cold, dry air, which amplifies EIB, and may explain the greater difference between 
groups in our study.
Results of our study support the existence of an important physiologic relation between 
upper and lower airway inflammation.
It could be argued that treatment effects result from deposition of INCS into the 
lungs. However, studies assessing drug delivery of intranasal sprays in adults observed 
no significant deposition of medication into the lower airways.94,95 An effect of INCS 
through systemic absorption is also unlikely, since absorption of fluticasone furoate 
after intranasal administration is low.96
It was suggested that post nasal drip may lead to aspiration of nasal secretions, 
spreading inflammatory and infectious cells and mediators to the lower airways. This 
concept was studied in adults by Bardin et al., who concluded that there was no seeding 
of the lower airways by nasal secretions.97
Improved nasal breathing may reduce chronic irritation of the lower airways as the 
nose warms, humidifies and filters the inspired air. In contrast, nasal blockage leads to 
exposure of the bronchial mucosa to cold, dry air. This has an acute effect on EIB in daily 
life, as it amplifies evaporative water loss from the airway surface liquid, but it has no 
effect on EIB in laboratory testing, as patients wear a nose clip during an ECT. Chronic 
exposure of the bronchial mucosa to cold, dry and unfiltered air increases the deposition 
of allergen to the lower airways, leading to increased lower airway inflammation and 
BHR.
Nasal provocation with allergen leads to increased trafficking of eosinophils and pro-
genitor cells from the bone marrow to peripheral blood98,99 and thereby increases the 
blood levels of eosinophils and inflammatory mediators.100 These could spread to the 
lower airways through the systemic circulation. It has been shown in adolescents and 
adults that INCS can reduce the number of circulating eosinophils in peripheral blood101 
and surrogate markers of inflammation, such as pulmonary FeNO.102 In our study, we 
found no significant reduction in FeNO after treatment with intranasal fluticasone 
furoate, but steroid-naïve children tended to have a greater decrease in FeNO than ICS 
treated children. Previously, Pedroletti et al. described unchanged levels of FeNO in 
asthmatic children (mean age 13y) with mild to moderate AR treated with INCS added to 
ICSs.103 Conversely, Sandrini et al. found a significant decrease in FeNO in steroid-naïve 
asthmatic adults after treatment of AR with intranasal triamcinolone.102 This may reflect 
a difference in the severity of allergic inflammation due to ICS use.
In summary, in children with concomitant asthma and AR, treatment of the upper air-
ways with an INCS can improve EIB and asthma outcomes, especially in steroid-naïve 
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children. This effect is most likely due to a combination of improved nasal breathing and 
a decreased number of circulating inflammatory cells and mediators.
Further research studying the cells and mediators involved in the pathophysiologic 
connection between the upper and lower airways could increase our understanding 
of both asthma and AR. Larger studies in adults and children, with different asthma 
severity and control status and intermittent vs. persistent AR are required to develop 
evidence-based integrated treatment strategies.
PharmaColoGIC PhEnoTyPInG
Asthma is a heterogeneous disease, which is also exemplified in the variability of in-
dividual patients’ responses to medications. Guideline recommendations for treatment 
are primarily based on evidence from trials comparing mean responses between medi-
cation regimens. However, there is a considerable inter-individual variability in response 
to medications. There is currently a lack of evidence to guide clinicians in selecting the 
medication most likely to achieve a favorable response in an individual patient.
In the past decade, the Childhood Asthma Research and Education (CARE) Network 
examined the variability in response to step 2 treatment options (i.e., initial controller 
therapy with an ICS or LTRA) to assess phenotypic factors indicative of a specific favor-
able response.104 They found that children (aged 6-17y) who responded better to ICSs 
had higher baseline FeNO, blood eosinophils, serum Eosinophil Cationic Protein and IgE 
and lower FEV1 and methacholine PC20.105-107 A parental history of asthma and prior ICS 
use also predicted a favorable response to ICSs.107 Those who responded better to MLK 
were significantly younger and had a shorter duration of asthma and a higher urinary 
leukotriene E4 (uLTE4)105 and uLTE4 / FeNO ratio.108 These results suggest that an eo-
sinophilic inflammatory phenotype is associated with a better ICS response, and a high 
CysLT inflammatory phenotype is associated with a better LTRA response.
Subsequently, differential response to step 3 treatment (i.e., step-up therapy in 
children uncontrolled on low dose ICSs) was analyzed by the CARE network in the Best 
Add-On Giving Effective Response (BADGER) study.109 By using a composite outcome 
measure of exacerbations, asthma control days and FEV1, 44.1% of asthmatic children 
(aged 6-17y) responded best to add-on LABA, 26.7% to medium dose ICS (250μg fluti-
casone twice daily) and 29.2% to add-on LTRA. In a multivariate analysis with data from 
this study, higher uLTE4 levels were associated with a favorable response to LTRA over 
LABA step-up therapy and higher impulse oscillometry reactance area with a favorable 
response of LABA over ICS step-up therapy.110 There were no apparent baseline predic-
tors of differential responses comparing ICS with LTRA step-up therapy.110
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Phenotypic variables that predict a favorable response to treatment are dependent on 
the definition of response that is used, for example an improvement in lung function 
or asthma control, or the prevention of exacerbations.111 As a single dose of MLK and 
regular daily treatment with MLK both attenuate EIB, we hypothesized that we could 
pharmacologically phenotype children who would be protected against EIB by MLK by 
measuring the response to a single dose on EIB.
In chapter 7, we describe a prospective open-label study, in which 24 adolescents 
on low dose ICSs, aged 12-17 years, with a history of persistent asthma and ≥ 10% 
post-exercise fall in FEV1, were treated with MLK once daily for 30 ± 4 days. Children 
performed an ECT 3 times: at baseline, 20h after the first dose and 40-44h after the last 
dose of 4 weeks treatment. The relationship between the effect of a single MLK-dose and 
4 weeks treatment on EIB was analyzed. The positive and negative predictive values of ≥ 
25% reduction in area under the curve for 20 min post-exercise (AUC0-20min) after a single 
dose were calculated.
Twenty-one children completed the study. There was a moderate correlation between 
the effect of a single MLK-dose and the effect of 4 weeks treatment on AUC0-20min, r = 0.49 
(P = 0.011). The AUC0-20min decreased significantly after a single MLK-dose (P = 0.001), but 
not after 4 weeks treatment (P = 0.080). The positive and negative predictive values of ≥ 
25% reduction in AUC0-20min after a single dose were resp. 84.6% and 50.0% (P = 0.146). 
We concluded that the effect of a single MLK-dose on EIB only modestly predicts the 
effect of 4 weeks treatment on EIB in adolescent asthmatics on low dose ICSs. The single 
dose response to MLK was stronger than the response to 4 weeks regular treatment, 
implying that a high adherence is essential to profit from the full protective effect of MLK 
against EIB. If used on a daily base, MLK offered clinically significant protection against 
EIB in the large majority (80%) of children uncontrolled by low dose ICS.
Instead of phenotyping patients responsive to different treatment regimens, pharmaco-
genetic studies analyze how different genotypes predict individual responses to phar-
macological therapies.112 Genetic variation can influence the drug response through 
pharmacodynamic mechanisms (for example variation in the receptor pathway) of 
pharmacokinetic mechanisms. As described in a previous paragraph, polymorphisms 
of the β2AR can influence the response to LABA treatment. Similarly, polymorphisms 
of the glucocorticoid pathway and CysLT pathway can influence responses to ICSs and 
LTRAs.113
In summary, our results suggest that pharmacologic phenotyping of children by 
measuring the single dose effect on an indirect BPT is not useful for MLK. Studies that 
assessed phenotypic factors indicative of a favorable response to different step 2 and 
step 3 treatment options showed no consistent pattern of baseline predictors. Phar-
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macogenetic studies may have the potential to identify genetic polymorphisms that 
predict a favorable response to treatments.
In future research, larger prospective genotype-stratified studies are required to 
further explore the impact of genetic variations on therapeutic responses. Furthermore, 
additional factors influencing variability in treatment response, such as gene-gene 
interactions and environmental effects (such as smoking) should be identified.
TrEaTmEnT of ExErCIsE InduCEd BronChoConsTrICTIon
The presence of EIB in asthmatic children is a sign of partially uncontrolled asthma. 
Physical activity is the most important trigger for asthma symptoms and EIB has a great 
impact on a child’s quality of life. Therefore, protection against EIB should be a priority 
for pediatricians treating asthmatic children.
Non-pharmaceutical treatment options include warming up114, maneuvers to pre-
warm and humidify the air during exercise, improving cardiovascular condition and 
losing weight.115 Furthermore, co-morbid conditions should be treated. For example, al-
lergic asthmatic children with concomitant AR can be treated with an INCS, as described 
in chapter 6.
Pharmaceutical management of EIB follows guidelines of asthma management in gen-
eral. However, treatment directed at the prevention of EIB may lead to other step-up or 
step-down decisions than treatment directed at other outcome measures.
The first step in the treatment of EIB is the prophylactic use of SABAs shortly before 
exercise.116 A large body of evidence supports the use of SABAs and it was calculated 
that post-exercise maximum fall in FEV1 was reduced with 18.99% (95% CI 16.60 – 21.38) 
by administration of a single dose of SABA.117 However, daily use of SABAs leads to toler-
ance and an increase in EIB.73,74 If a SABA is needed more than twice a week (even if only 
before exercise), controller therapy is recommended.
Alternative prophylactic treatment options include LABAs, LTRAs and ICSs. A single 
dose of a LABA reduces post-exercise maximum fall in FEV1 with 15.60% (95% CI 12.92 
– 18.29).117 A single dose of MLK was reported to reduce maximum fall in FEV1 4.65 to 
17.0% within hours (Table 3). In our study presented in chapter 7, MLK provided 5.8% 
(95% CI 2.4 – 9.2) reduction in maximum fall in FEV1 20h after a single dose.
A single dose of an ICS has also been shown to attenuate maximum post-exercise fall 
in FEV1.118-120 The 2012 ATS clinical practice guideline on EIB calculated that the single 
dose effect of ICSs is only small (mean difference in maximum fall in FEV1 4.68%, 95% CI 
-7.01 – 16.37) and pre-exercise ICS use is therefore not recommended. However, in two 
studies the effect of a high dose of 1 mg Fluticasone Proprionate in asthmatic children 
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(aged 8-16y) was reported, and this dose attenuated the maximum fall in FEV1 with resp. 
9.5% (95% CI -1.8 – 20.8)119 and 9.9% (95% CI 0.9 – 18.8)120
Controller treatment options include ICSs, LABAs and LTRAs. The first step is usually a 
low dose ICS. Daily treatment with ICSs for >4 weeks has been shown to reduce maxi-
mum post-exercise fall in FEV1 with 10.98% (95% CI 7.11 - 14.86%).116 Daily treatment 
with MLK provides similar protection against EIB, as it reduces maximum post-exercise 
fall in FEV1 with 10.70% (95% CI 7.15 - 14.25%).116
In our study presented in chapter 7, MLK as add-on therapy to ICSs provided only 4.8% 
(95% CI -1.9 – 10.9) reduction in maximum fall in FEV1 after 4 weeks treatment. However, 
we performed the ECT 40-44h after the last dose of MLK, whereas previous pediatric 
studies performed an ECT 10-24h after the last dose.61,63,121 As the acute antagonistic 
effect of MLK wanes within 36h, a high compliance is essential to profit from the full 
protective effect against EIB.
LABAs are less effective for long-term treatment of EIB, as their bronchoprotective 
effect decreases with daily use.117 As described in chapter 3 and 4, many children even 
profit from the discontinuation of LABA treatment. Studies directly comparing the 
protective effects of regular daily treatment with LABAs and LTRAs against EIB, with or 
without concomitant ICSs, consistently favor LTRAs (Table 4).
Doubling the dose of ICSs does not result in significant differences in the airway 
response to exercise after 3 weeks treatment132,133, but quadrupling the dose of ICSs 
resulted in 26.1 - 34.8% protection in AUC133. However, high dose ICSs may cause more 
side effects than LTRAs.
Table 3. Overview of randomized controlled trials comparing the effect of a single dose montelukast versus 
placebo on post-exercise maximum % fall in FEV1






95% CI % 
protectionn age
Coreno 2000122 10 29 ± 3 MLK 10 mg 1-12h 17 n/r 65.4
Peroni 2002123 19 7-13 MLK 5 mg 2-24h 8.9 3.6-14.2 47.6
Pearlman 2006124 51 15-45 MLK 10 mg 2-24h 11.5 0.3-14.7 51.6
Peroni 2011125 69 6-14 MLK 5 mg 1-8h 9.9 n/r 34.7
Philip 2007126 47 15-44 MLK 10 mg 2-24h 8.7 n/r 39.9
Philip 2007127 (2) 53 15-41 MLK 10 mg 2h 5.8 2.7-8.9 33.1
Rundell 2005128 9 19 ± 1 MLK 10 mg 6-8h 10.3 n/r 64.8
Rundell 2005129 (2) 11 23 ± 7 MLK 10 mg 6h 11.8 n/r 52.7
Mastalerz 2002130 19 19-54 MLK 10 mg 1h 12.3 n/r 54.7
Wasfi 2011131 66 4-14 MLK 4 / 5 mg 2-24h 4.65 0.75-8.55 23.3
CI = confidence interval, MLK = montelukast, n/r = not reported
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In summary (Table 5), treatment of asthmatic children directed at the prevention of EIB 
may lead to other decisions than treatment directed at other outcome measures.
Based on the currently available evidence, we suggest the following steps for treat-
ment of EIB in children:
All children: Non-pharmaceutical treatment (improve cardiovascular condition, lose 
weight). Consider treatment of co-morbid conditions, such as AR with INCS. Check 
inhalation technique and compliance.
1. Pre-exercise prophylactic SABA. Step up if SABA is needed more than twice per week.
2. Start daily low dose ICS.
 Alternative option: monotherapy with daily LTRA. This provides similar protection 
against EIB, but has less effect on other outcome parameters of asthma.
3. Add daily LTRA.
 Alternative option: double dose of ICSs. There are no studies comparing the effect of 
double dose ICS vs. LTRA on EIB, but a double dose of ICSs has a better effect on other 
outcome parameters of asthma.
4. Refer to expert.
Table 4. Overview of studies comparing the effect of treatment with a LABA vs. a LTRA on post-exercise 
maximum % fall in FEV1
study subjects Intervention ICs duration absolute 
reduction % 
fall fEv1

























































Bud = budesonide, CI = confidence interval, Flu = fluticasone, Form = formoterol, ICS = inhaled corticosteroid, 
MLK = montelukast, NS = non-significant, Salm = salmeterol
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Table 5. Effects of different medications used in the treatment of EIB





ICS = inhaled corticosteroid, LABA = long acting β2-agonist, LTRA = leukotriene receptor antagonist, SABA = 
short acting β2-agonist 
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Astma is een chronische ziekte van de onderste luchtwegen, gekenmerkt door inflam-
matie en bronchiale hyperreactiviteit (BHR).1 Astma is na allergische rhinitis (AR) de 
meest voorkomende chronische ziekte bij kinderen en adolescenten in Nederland en 
vormt een substantiële belasting voor het kind, zijn familie en de gezondheidszorg. In 
hoofdstuk 1 beschrijven we de huidige aanpak in het diagnosticeren, monitoren en be-
handelen van kinderen met astma. Tevens behandelen we een aantal actuele klinische 
dilemma’s van deze aanpak.
Bronchiale provocatietesten (BPT’s) zijn testen die worden gebruikt om BHR vast te 
stellen in reactie op bepaalde stimuli. Dit kunnen directe stimuli zijn die rechtstreeks 
effect hebben op de effector cellen (zoals gladde spiercellen rond de bronchieën en 
slijmproducerende cellen). Ook kunnen dit indirecte stimuli zijn die effect hebben op de 
aanwezige inflammatoire cellen, die in reactie hierop mediatoren uitscheiden met een 
effect op de effector cellen. Deze zogenaamde indirecte BPT’s zijn sterk geassocieerd 
met actuele inflammatie en zijn daarom geschikt om luchtweginflammatie op korte 
termijn te monitoren.2 In de volgende hoofdstukken gebruiken we indirecte BPT’s om 
het effect van verschillende medicamenteuze interventies op inflammatie en BHR te 
monitoren.
mannITol ProvoCaTIE TEsT
In hoofdstuk 2 beschrijven we een studie waarin we onderzochten of de mannitol test 
gebruikt kan worden om inspanningsastma bij astmatische kinderen aan te tonen. In-
spanningsastma wordt gedefinieerd als een acute, reversibele bronchiale obstructie die 
direct na, en soms al tijdens, inspanning optreedt. Inspanningsastma komt bij 80-90% 
van de astmatische kinderen voor3 en is geassocieerd met een verminderde kwaliteit 
van leven.
Een inspanningstest kan gebruikt worden om inspanningsastma te diagnosticeren 
en monitoren. De inspanningstest is de meest natuurlijke ‘real life’ test, maar heeft ook 
nadelen. Er is voor de test dure apparatuur, speciaal opgeleid personeel en een bron 
van droge, en bij voorkeur ook koude, lucht nodig. Kinderen worden blootgesteld aan 
een relatief zware fysieke inspanning en oncontroleerbare daling in hun longfunctie. 
Daarom werden er andere BPT’s ontwikkeld waarmee inspanningsastma aangetoond 
kan worden. Één van deze BPT’s is de mannitoltest.4 Mannitol heeft een osmotisch effect 
op de luchtwegmucosa waardoor de dehydratie die tijdens inspanning optreedt wordt 
nagebootst. Ten gevolge van de toename van osmolariteit van de luchtwegmucosa 
komen mediatoren vrij die bronchoconstrictie veroorzaken.
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In onze studie hebben 33 astmatische kinderen van 9-18 jaar, met een voorgeschiede-
nis van inspanningsastma, een mannitoltest en een inspanningstest ondergaan. Er werd 
een kruistabel gemaakt waarin de reactie op de mannitoltest vergeleken werd met die 
op de inspanningstest. Ook werden de correlaties tussen de procentuele daling in FEV1 
na inspanning en mannitol RDR (response-dose ratio) en PD15 (dosis die 15% daling in 
FEV1 veroorzaakt) berekend. Vijfentwintig kinderen volbrachten beide testen. Pearson’s 
correlatie coëfficient voor de correlatie tussen log-getransformeerde mannitol RDR en % 
daling in FEV1 na inspanning was rp = 0.666 (P < 0.001). Er was geen significante correlatie 
tussen de log-getransformeerde PD15 van mannitol en % daling in FEV1 na inspanning. 
De positief en negatief voorspellende waarde van de mannitoltest voor inspannings-
astma waren respectievelijk 69% en 92%. We concludeerden dat een mannitoltest een 
geschikt alternatief is voor een inspanningstest. Gezien de hoge negatief voorspellende 
waarde is de test vooral geschikt om inspanningsastma uit te sluiten.
De observatie dat kinderen die combinatietherapie met een inhalatiecorticosteroïd 
(ICS) en een lang werkende β2-agonist (LABA) gebruikten een significant hogere kans (P 
< 0.05) hadden op een positieve respons op de mannitol test, leidde tot de in hoofdstuk 
3 en 4 beschreven studies.
β2-aGonIsTEn
In de studies beschreven in hoofdstuk 3 en 4 hebben we het effect van tolerantie 
voor LABA’s op luchtweginflammatie en BHR onderzocht. We hebben klinisch stabiele 
astmatische kinderen met milde tot matige inspanningsastma geanalyseerd tijdens het 
afbouwen van hun medicatie van LABA/ICS combinatietherapie naar monotherapie met 
een zelfde dosis ICS.
Klinische richtlijnen adviseren om medicatie af te bouwen wanneer gedurende ten 
minste 3 maanden astma controle bereikt is.1 Combinatietherapie met een ICS en een 
LABA wordt vaak voorgeschreven als de derde stap in de behandeling. Wanneer astma 
controle bereikt is met combinatietherapie is één van de opties de LABA te stoppen en 
het ICS met dezelfde dosis te continueren. Het effect van deze methode op BHR en lucht-
weginflammatie was niet onderzocht bij astmatische kinderen. Aangezien beschreven 
is dat regelmatig gebruik van een β2-agonist kan leiden tot een toename van BHR op 
indirecte stimuli,5,6 was onze hypothese dat BHR voor indirecte BPT’s zou verminderen 
door het afbouwen van combinatietherapie naar monotherapie met een ICS.
In hoofdstuk 3 onderzochten we het effect van het afbouwen van combinatie-therapie 
naar monotherapie met een ICS op inspanningsastma bij astmatische kinderen. Negen-
tien kinderen van 8-16 jaar werden geanalyseerd in deze prospectieve open-label studie. 
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Kinderen ondergingen een inspanningstest na 4 weken run-in periode op combinatie-
therapie en 3 weken na het afbouwen naar ICS monotherapie. De maximale % daling 
in FEV1 na inspanning was significant lager na 3 weken monotherapie met een ICS (P = 
0.03). Acht kinderen hadden bij de eerste inspanningstest ≥ 15% daling in FEV1. Vijftien 
procent daling is de afkapwaarde voor het stellen van de diagnose inspanningsastma 
wanneer de inspanningstest in koude lucht wordt uitgevoerd.7 In deze groep was de 
maximale % daling in FEV1 na inspanning significant lager (P < 0.01) na het afbouwen 
van de medicatie, en bij 6 kinderen zelfs < 15%, wat erop duidt dat zij geen inspannings-
astma meer hadden. We concludeerden dat bij klinisch stabiele astmatische kinderen 
met inspanningsastma ondanks gebruik van combinatietherapie, inspanningsastma 
kan verminderen, en vaak zelfs verdwijnen, na het stoppen van de LABA.
In hoofdstuk 4 onderzochten we het effect van het afbouwen van combinatie-therapie 
naar monotherapie met een ICS op BHR na een mannitoltest. Zeventien kinderen van 
12-17 jaar, met klinisch stabiel astma en milde tot matige inspanningastma, werden 
geanalyseerd in deze prospectieve open-label studie. Kinderen ondergingen een man-
nitoltest na 4 weken run-in periode op combinatietherapie en 30 ± 4 dagen na afbou-
wen naar ICS monotherapie. Mannitol PD15 en RDR veranderden niet na het afbouwen 
van de medicatie. De tijdsduur tot herstel naar ≥ 95% van de uitgangs FEV1 na een 
kortwerkende β2-agonist (SABA) was significant korter (P = 0.01) na het stoppen van de 
LABA. We concludeerden dat bij klinisch stabiele astmatische kinderen, met milde tot 
matige inspanningsastma ondanks gebruik van combinatietherapie, BHR na mannitol 
niet vermindert, maar de hersteltijd na een SABA wel verkort wordt, na het stoppen van 
de LABA.
In hoofdstuk 5 geven we een overzicht van de huidige literatuur over de veiligheid 
en effectiviteit van β2-agonisten voor astmatische kinderen. In het afgelopen decen-
nium zijn er zorgen gekomen over de veiligheid van deze middelen nadat een aantal 
meta-analyses beschreven dat er met gebruik van LABA’s een verhoogd risico is op 
ziekenhuisopnames, levensbedreigende astma exacerbaties en astma gerelateerd over-
lijden.8-10 In één van deze meta-analyses, verricht door de Amerikaanse Food and Drug 
Administration (FDA), werd gevonden dat de incidentie van deze ernstige bijwerkingen 
het hoogst is bij kinderen tussen de 4-11 jaar.10
Verschillende mechanismen zouden dit verhoogde risico kunnen verklaren. Het 
kan dat patiënten door regelmatig gebruik van bronchodilaterende medicatie het 
niet op tijd door hebben wanneer hun astma controle achteruit gaat. Tevens leidt 
regelmatig gebruik van SABA’s en LABA’s tot downregulatie en desensitisatie van de 
β2-adrenoreceptor (β2AR), resulterend in een verminderd bronchodilatoir effect en 
een verminderde bescherming tegen broncho-constrictieve stimuli.11 Daarnaast zijn er 
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aanwijzingen dat β2-agonisten een paradoxaal pro-inflammatoir effect kunnen hebben. 
Verder is er mogelijk een invloed van leeftijd en polymorfismen van het β2AR-gen op de 
associatie tussen β2-agonisten en ernstige astma-gerelateerde incidenten.
Eerdere studies verricht met BPT’s hebben laten zien dat ICS slechts ten dele bescher-
men tegen downregulatie en desensitisatie van de β2AR. Het is onduidelijk wat het 
risico op ernstige astma-gerelateerde incidenten van LABA/ICS combinatietherapie is 
bij kinderen van 4-11 jaar. Daarom concluderen we dat meer onderzoek naar de veilig-
heid en effectiviteit van LABA’s bij 4-11 jaar oude kinderen geindiceerd is, alvorens er 
evidence-based adviezen kunnen worden gegeven over het gebruik van combinatie-
therapie in deze leeftijdsgroep.
InTranasalE CorTICosTEroïdEn
In hoofdstuk 6 beschrijven we het effect van intranasale anti-inflammatoire behande-
ling op inflammatie van de onderste luchtwegen en BHR. In de huidige internationale 
richtlijnen voor de behandeling van astma is anti-inflammatoire behandeling van de 
bovenste luchtwegen niet opgenomen. AR is echter aanwezig bij meer dan 80% van de 
kinderen met astma12, hoewel het vaak niet herkend wordt door de kinderen, hun ouders 
en behandelaars. Kinderen met astma en AR krijgen vaker astma exacerbaties, bezoeken 
vaker hun arts en de spoedeisende hulp en worden vaker opgenomen in het ziekenhuis 
dan astmatische kinderen zonder AR.13,14 Een geïntegreerde anti-inflammatoire behan-
deling is daarom belangrijk.
In deze studie werden kinderen van 12-17 jaar, met mild tot matig ernstig astma, in-
termitterende AR en ≥ 10 % daling in FEV1 bij een inspanningstest, dubbel-blind geran-
domiseerd voor 22 ± 3 dagen behandeling met nasale fluticasone furoate of placebo. De 
primaire uitkomstmaat was het verschil in % daling in FEV1 na inspanning. Secundaire 
uitkomstmaten waren de verschillen in scores op de astma controle vragenlijst, de pedi-
atrische astma kwaliteit van leven vragenlijst en stikstofoxide in de uitgeademde lucht 
(FeNO). Vijfentwintig kinderen doorliepen het gehele onderzoeksprotocol. De maximale 
% daling in FEV1 na inspanning was significant lager in de fluticasone furoate groep 
in vergelijking met de placebo groep (P = 0.04). Hoewel de totale kwaliteit van leven 
score niet verbeterde na nasale behandeling met fluticasone furoate in vergelijking met 
placebo, verbeterde de score in het domein van activiteitsbeperking wel significant in 
de fluticasone furoate groep (P = 0.03). Er waren geen significante verschillen in FeNO 
en score op de astma controle vragenlijst. We concludeerden dat behandeling met een 
intranasaal corticosteroïd inspanningsastma vermindert en kwaliteit van leven kan 




In hoofdstuk 7 hebben we onderzocht of de respons op een eenmalig dosis montelukast 
(MLK) het klinische effect van 4 weken behandeling met MLK kan voorspellen bij adoles-
centen met astma die een lage dosis ICS gebruiken.
Symptomatische kinderen die een lage dosis ICS gebruiken laten een variabele res-
pons zien op de 3 mogelijke step-up opties: het toevoegen van een LABA of leukotriene 
antagonist (LTRA) of het verdubbelen van de dosis ICS.15 Een diagnostische test die 
clinici kan wijzen in de richting van de meest geschikte step-up optie voor een indivi-
duele patiënt zou daarom nuttig zijn. MLK beschermt tegen inspanningsastma na een 
eenmalige dosis en na langer dagelijks gebruik. Omdat de respons na een eenmalige 
dosis MLK een zelfde variabiliteit vertoont als na langere behandeling, poneerden we de 
hypothese dat het effect van een eenmalige dosis op inspanningsastma het effect van 
langere dagelijkse behandeling met MLK kan voorspellen.
In deze prospectieve, open-label studie, behandelden we 24 adolescenten van 12-
17 jaar met een voorgeschiedenis van persisterend astma, waarvoor zij lage dosis ICS 
gebruikten, en ≥ 10% daling in FEV1 na inspanning, gedurende 30 ± 4 dagen met MLK 
eenmaal daags. Zij ondergingen driemaal een inspanningstest: voor starten van de 
behandeling, 20u na de eerste dosis en 40-44u na de laatste dosis. De relatie tussen 
het effect van een eenmalige dosis MLK en 4 weken behandeling op inspanningsastma 
werd geanalyseerd. De correlatie tussen het effect van een eenmalige dosis en 4 weken 
behandeling op de Area Under de Curve 20 min na inspanning (AUC0-20min) werd bere-
kend. Tevens werden de positief en negatief voorspellende waarden van ≥ 25% reductie 
in AUC0-20min na een eenmalige dosis berekend.
Eenentwintig kinderen voltooiden de studie. Er was een matige correlatie tussen 
het effect van een eenmalige dosis MLK en het effect van 4 weken behandeling op de 
AUC0-20min, r = 0.49 (P = 0.011). De AUC0-20min daalde significant na een eenmalige dosis 
MLK (P = 0.001), maar niet na 4 weken behandeling (P = 0.080). De positief en negatief 
voorspellende waarde van ≥ 25% reductie in AUC0-20min waren resp. 84.6% en 50.0% (P = 
0.146). We concludeerden dat het effect van een eenmalige dosis MLK op inspannings-
astma slechts matig het effect van langere behandeling met MLK op inspanningsastma 
voorspelt in adolescenten met astma die een lage dosis ICS gebruiken. De respons op 
een eenmalige dosis MLK was sterker dan de respons na 4 weken behandeling, wat sug-
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